<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacy (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacy (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmacy</journal-id><journal-title-group><journal-title>Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2226-4787</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998006</article-id><article-id pub-id-type="pmc">PMC11859396</article-id>
<article-id pub-id-type="doi">10.3390/pharmacy13010007</article-id><article-id pub-id-type="publisher-id">pharmacy-13-00007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Predescu</surname><given-names>Iasmina-Alexandra</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00007" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3619-2484</contrib-id><name><surname>J&#x000ee;jie</surname><given-names>Alex-Robert</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00007" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>P&#x00103;tra&#x0015f;cu</surname><given-names>Dalia</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00007" ref-type="aff">2</xref><xref rid="c1-pharmacy-13-00007" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Pasc</surname><given-names>Aida-Luisa-Vanessa</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Piro&#x0015f;</surname><given-names>Elisaveta-Ligia</given-names></name><xref rid="af3-pharmacy-13-00007" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Trandafirescu</surname><given-names>Cristina</given-names></name><xref rid="af4-pharmacy-13-00007" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2083-0581</contrib-id><name><surname>Oancea</surname><given-names>Cristian</given-names></name><xref rid="af5-pharmacy-13-00007" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Dehelean</surname><given-names>Cristina Adriana</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00007" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2631-7028</contrib-id><name><surname>Moac&#x00103;</surname><given-names>Elena-Alina</given-names></name><xref rid="af1-pharmacy-13-00007" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00007" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Schommer</surname><given-names>Jon</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmacy-13-00007"><label>1</label>Discipline of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, &#x0201c;Victor Babe&#x0015f;&#x0201d; University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania; <email>iasmina-alexandra.predescu@umft.ro</email> (I.-A.P.); <email>alex-robert.jijie@umft.ro</email> (A.-R.J.); <email>aida-luisa.pasc@student.umft.ro</email> (A.-L.-V.P.); <email>cadehelean@umft.ro</email> (C.A.D.); <email>alina.moaca@umft.ro</email> (E.-A.M.)</aff><aff id="af2-pharmacy-13-00007"><label>2</label>Research Center for Pharmaco-Toxicological Evaluation, &#x0201c;Victor Babes&#x0201d; University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania</aff><aff id="af3-pharmacy-13-00007"><label>3</label>Faculty of Medicine, &#x0201c;Vasile Goldi&#x0015f;&#x0201d; Western University of Arad, 86 Liviu Rebreanu Street, 310048 Arad, Romania; <email>piros.ligia@uvvg.ro</email></aff><aff id="af4-pharmacy-13-00007"><label>4</label>Discipline of Pharmaceutical Chemistry, Faculty of Pharmacy, &#x0201c;Victor Babes&#x0201d; University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania; <email>trandafirescu.cristina@umft.ro</email></aff><aff id="af5-pharmacy-13-00007"><label>5</label>Discipline of Pneumology, Faculty of Medicine, &#x0201c;Victor Babe&#x0015f;&#x0201d; University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania; <email>oancea@umft.ro</email></aff><author-notes><corresp id="c1-pharmacy-13-00007"><label>*</label>Correspondence: <email>patrascu.dalia@umft.ro</email>; Tel.: +40-744-886-534</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>1</issue><elocation-id>7</elocation-id><history><date date-type="received"><day>09</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The complexities surrounding the use of medications, substance abuse, and the recreational use of plants are multifaceted and warrant a comprehensive examination. This review highlights the complexities surrounding the consumption of chemical substances in excess or for non-medical purposes, obtained through legal prescriptions, over-the-counter purchases, or illicit means, with an emphasis on the predictive role of stressors and individual-level variables in the development of substance use disorders, as well as the influence of the regulatory environment on patterns of consumption. Additionally, the alarming escalation in the mortality rate associated with illicit drug and opioid overdoses is also underscored. The recreational use of prescription medications can lead to significant health risks, particularly when combined with other substances; therefore, the need for interventions and preventive measures to address substance abuse among various populations is imperative. Furthermore, novel insights on substance abuse addiction, exploring the neurobiological mechanisms underlying addiction, and discussing treatment approaches and interventions are elucidated. Advancements in technology for detecting substance abuse are also highlighted, displaying innovative tools for more effective identification and monitoring. In conclusion, the complexities of medications, substance abuse, and the recreational use of plants reveal a landscape marked by overlapping motivations and health implications. The distinction between medical and recreational use is critical for understanding user behavior and addressing public health concerns.</p></abstract><kwd-group><kwd>substance abuse</kwd><kwd>medication abuse</kwd><kwd>recreational plants</kwd><kwd>narcotic plants</kwd><kwd>substance use disorders</kwd><kwd>psychoactive substances</kwd><kwd>addiction</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmacy-13-00007"><title>1. Introduction</title><p>Substance abuse is a significant issue with far-reaching consequences, such as damage to all organs and especially brain development in adolescents. It contributes to rising mortality rates, an increase in crimes committed while acquiring drugs, low employment rates, higher risks of poverty, and damaged relationships with family, friends, and loved ones [<xref rid="B1-pharmacy-13-00007" ref-type="bibr">1</xref>,<xref rid="B2-pharmacy-13-00007" ref-type="bibr">2</xref>].</p><p>Defined as the misuse of psychoactive substances for non-medicinal purposes, substance abuse poses a considerable medical problem [<xref rid="B1-pharmacy-13-00007" ref-type="bibr">1</xref>]. Studies have shown that stressors and individual-level variables play a predictive role in the development of substance use disorders [<xref rid="B3-pharmacy-13-00007" ref-type="bibr">3</xref>].</p><p>Medication and substance abuse entails the consumption of chemical substances in excessive amounts or for non-medical purposes, whether obtained through legal prescriptions, over-the-counter purchases, or illicit means. The recreational use of substances is often linked to the regulatory environment surrounding their availability, influencing patterns of consumption [<xref rid="B4-pharmacy-13-00007" ref-type="bibr">4</xref>,<xref rid="B5-pharmacy-13-00007" ref-type="bibr">5</xref>]. Addiction, a hallmark of substance abuse, is typified by the loss of control over substance intake and disregard for adverse outcomes, constituting a medical disorder characterized by the compulsive pursuit of psychoactive agents, indicative of a neuropsychiatric condition [<xref rid="B6-pharmacy-13-00007" ref-type="bibr">6</xref>,<xref rid="B7-pharmacy-13-00007" ref-type="bibr">7</xref>].</p><p>Substance abuse presents a significant global challenge. Recent decades have witnessed a notable surge in the availability of drugs, prompting widespread concern among the populace and posing a substantial risk to public health [<xref rid="B8-pharmacy-13-00007" ref-type="bibr">8</xref>]. The substances implicated in this issue encompass a range, including cocaine, cannabis, tobacco, and opioids such as heroin, codeine, and morphine. These substances fall into two broad categories: legal and illegal. Cocaine and heroin are classified as illicit substances, while cannabis straddles both categories due to variations in its legal status across different nations. Tobacco enjoys legal approval for consumption worldwide, and opioid medications are legally sanctioned for managing chronic pain conditions [<xref rid="B9-pharmacy-13-00007" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-13-00007" ref-type="bibr">10</xref>].</p><p>The use of medications and substances, particularly those derived from plants for recreational and narcotic purposes, is a topic of significant concern and interest in both medical and societal contexts. One of the most known plants throughout history for use in both medicinal and recreational purposes is <italic toggle="yes">Cannabis sativa</italic> [<xref rid="B11-pharmacy-13-00007" ref-type="bibr">11</xref>]. The psychoactive properties of Cannabis, particularly the cannabinoid THC, have made it the subject of extensive research [<xref rid="B12-pharmacy-13-00007" ref-type="bibr">12</xref>]. The diverse array of phytochemicals present in Cannabis, including cannabinoids, terpenes, and phenolic compounds, have been studied for their potential medicinal benefits [<xref rid="B13-pharmacy-13-00007" ref-type="bibr">13</xref>]. Additionally, the genetic structure of Cannabis has been explored to understand the differences between drug types like marijuana and hemp [<xref rid="B12-pharmacy-13-00007" ref-type="bibr">12</xref>].</p><p>The mortality rate associated with illicit drug and opioid overdoses has exhibited a steady escalation over the past two decades. Consequently, in 2021, there was an estimated surge of over 90% in fatalities as opposed to the statistics from 1999. Furthermore, empirical evidence underscores that individuals of the male sex constitute a predominant proportion of overdose incidents [<xref rid="B14-pharmacy-13-00007" ref-type="bibr">14</xref>].</p><p>Substance abuse, encompassing the misuse of legal and illicit substances, is a global issue that affects various populations [<xref rid="B15-pharmacy-13-00007" ref-type="bibr">15</xref>]. Studies have shown that substances like alcohol, tobacco, and illegal drugs are commonly abused among the population, highlighting the need for interventions and preventive measures [<xref rid="B16-pharmacy-13-00007" ref-type="bibr">16</xref>]. Understanding the motivations behind substance abuse, whether for recreational purposes or to cope with stress, is crucial for developing effective interventions [<xref rid="B17-pharmacy-13-00007" ref-type="bibr">17</xref>]. Motives for the medical misuse of prescription opioids among adolescents have been linked to an increased risk of substance abuse, emphasizing the complex interplay between medical prescription practices and substance misuse [<xref rid="B18-pharmacy-13-00007" ref-type="bibr">18</xref>]. The misuse and abuse of substances like benzodiazepines, often in combination with other drugs like opioids and alcohol, pose significant challenges in terms of addiction and treatment [<xref rid="B19-pharmacy-13-00007" ref-type="bibr">19</xref>].</p><p>An escalation in substance abuse was noted, with approximately 1.7 million individuals in the United States affected by addiction or disorders related to opioid substances by 2017. In Norway, a decline in these figures was observed. Yet, the reduction in fatalities was predominantly associated with the misuse of prescription painkillers rather than heroin (illicit drugs), underscoring the persistent societal challenges posed by opioids [<xref rid="B20-pharmacy-13-00007" ref-type="bibr">20</xref>]. Cocaine misuse, in contrast, resulted in a higher number of overdose fatalities, with emergency departments recording 70,237 overdose-related deaths in 2017 [<xref rid="B21-pharmacy-13-00007" ref-type="bibr">21</xref>]. Despite being the third most abused substance globally, cannabis is often underestimated by consumers who believe they do not develop addictive behaviors or withdrawal symptoms post-consumption [<xref rid="B22-pharmacy-13-00007" ref-type="bibr">22</xref>]. Tobacco, acknowledged for its harmful effects, was consumed by approximately 18% of the global population in 2013, with projections indicating a continued rise in consumption rates by 2030 [<xref rid="B23-pharmacy-13-00007" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00007" ref-type="bibr">24</xref>]. Smoking has become a prevalent practice among both adults and youth, with statistics revealing that 80.2% of high school students have experimented with tobacco products, and 11.5% of adults were regular smokers in 2021 [<xref rid="B25-pharmacy-13-00007" ref-type="bibr">25</xref>]. Furthermore, a significant proportion of adolescent smokers initiated tobacco use at a young age, between 10 and 12 years old [<xref rid="B26-pharmacy-13-00007" ref-type="bibr">26</xref>].</p><p>In the context of substance abuse prevention, education plays a vital role in equipping medical professionals with the knowledge and skills to address substance-related disorders in their practice. Courses related to drug abuse prevention in medical curricula are essential for raising awareness and promoting effective interventions [<xref rid="B27-pharmacy-13-00007" ref-type="bibr">27</xref>]. Novel interventions in the realm of substance abuse and addiction have been sanctioned to mitigate usage. In pain management, the emphasis lies on administering opioids at a minimally effective dose [<xref rid="B28-pharmacy-13-00007" ref-type="bibr">28</xref>]. Innovations in tobacco and nicotine products focus on developing less deleterious alternatives to diminish the morbidity and mortality associated with cigarettes [<xref rid="B29-pharmacy-13-00007" ref-type="bibr">29</xref>]. Regulatory measures such as taxation increments and public consumption restrictions are pivotal in curtailing the sale and utilization of these substances [<xref rid="B30-pharmacy-13-00007" ref-type="bibr">30</xref>,<xref rid="B31-pharmacy-13-00007" ref-type="bibr">31</xref>]. Specialized initiatives are being implemented to deter illicit substance use. Diverse therapeutic modalities play a pivotal role in cessation efforts and preventing relapse [<xref rid="B31-pharmacy-13-00007" ref-type="bibr">31</xref>,<xref rid="B32-pharmacy-13-00007" ref-type="bibr">32</xref>].</p><p>The purpose of the review is to provide updated information and novel perspectives on the use of various plants for recreational and narcotic purposes. The scope of the review encompasses an examination of the pharmacological properties, potential risks, and societal implications associated with the consumption of these plants. By synthesizing current research findings, the review aims to contribute to a better understanding of the complex relationship between medication, substance abuse, and the use of plants for recreational and narcotic purposes.</p></sec><sec id="sec2-pharmacy-13-00007"><title>2. History of Medication, Substance Abuse, and Plants for Recreational and Narcotic Purposes</title><sec id="sec2dot1-pharmacy-13-00007"><title>2.1. Early Use of Plants for Recreational and Narcotic Purposes</title><p>The utilization of psychoactive plants for ceremonial and recreational purposes has been a common practice throughout history. Some African Helichrysum species, although containing non-narcotic compounds, have been used for ritual inebriating fumigations [<xref rid="B33-pharmacy-13-00007" ref-type="bibr">33</xref>]. The Mandrake plant, known for its effects and compounds, has been associated with healing, inducing madness, and even causing death [<xref rid="B34-pharmacy-13-00007" ref-type="bibr">34</xref>]. The early relationship between humans and psychoactive plants, whether for medicinal, ritualistic, or recreational purposes, highlights the long-standing history of plant usage for altering states of consciousness [<xref rid="B35-pharmacy-13-00007" ref-type="bibr">35</xref>].</p><p>Various cultures have acknowledged specific plants&#x02019; sacred attributes, employing them for recreational and therapeutic purposes. For example, Indigenous communities have traditionally embraced coca leaves for their stimulating effects, with documented instances of leaf-chewing dating back to 3000 years ago [<xref rid="B6-pharmacy-13-00007" ref-type="bibr">6</xref>]. In the 19th century, cocaine was extracted from these leaves and utilized as a stimulant in beverages and analgesic solutions. Presently, cocaine is available in the forms of cocaine hydrochloride or free base, typically as a white powder for intravenous, intranasal, or oral consumption or as a solid mass for smoking, commonly referred to as &#x0201c;crack cocaine&#x0201d; [<xref rid="B36-pharmacy-13-00007" ref-type="bibr">36</xref>].</p><p>The Sumerians utilized the sap of the poppy plant for therapeutic purposes [<xref rid="B6-pharmacy-13-00007" ref-type="bibr">6</xref>]. Opium&#x02019;s medicinal properties were recognized before the identification of morphine. In antiquity, the Egyptians harnessed opium&#x02019;s analgesic and mood-enhancing effects [<xref rid="B37-pharmacy-13-00007" ref-type="bibr">37</xref>]. The isolation of morphine from the opium poppy in 1803 significantly influenced pain management. The discovery of morphine and codeine spurred advancements in synthesizing opioid alkaloids for pain relief [<xref rid="B38-pharmacy-13-00007" ref-type="bibr">38</xref>]. Heroin, derived from morphine through acetylation, initially transformed pain management practices and was widely manufactured for its efficacy in treating respiratory ailments. However, its addictive properties were soon uncovered, leading to its classification as a substance of abuse [<xref rid="B39-pharmacy-13-00007" ref-type="bibr">39</xref>].</p><p>Recent paleobotanical research indicates that cannabis has been utilized for approximately 11,700 years, with archaeological evidence pinpointing its presence in the Altai Mountains region of Central Asia. Initially harnessed for practical purposes such as rope and net production, cannabis also served as a dietary staple and a source of oil from its seeds. The serendipitous discovery of its psychoactive properties led to its widespread cultivation and dissemination globally [<xref rid="B40-pharmacy-13-00007" ref-type="bibr">40</xref>]. Scientific investigations have revealed the therapeutic potential of cannabis in alleviating conditions like headaches, rheumatic pains, insomnia, constipation, and venereal diseases [<xref rid="B41-pharmacy-13-00007" ref-type="bibr">41</xref>]. The evolution of cannabis consumption has progressed alongside the development of THC-containing products, with smoking being the traditional method. Modern consumption methods include manual rolling, using filtering devices like bongs, vaping, and ingesting THC through edibles such as brownies and teas [<xref rid="B42-pharmacy-13-00007" ref-type="bibr">42</xref>].</p><p>Tobacco, a plant with a long history of recreational use dating back to ancient times, has been integral to ceremonies and rituals within North American tribes for over 2300 years. While its consumption traditionally lacked significant psychoactive effects, the cultivation of tobacco held sacred significance, influencing both the tribe and its initiates. Gender roles also played a role in the cultivation of tobacco, with some cultures restricting women from engaging in this practice. Over time, the method of consuming tobacco evolved from smoking it in specialized &#x0201c;T&#x0201d;-shaped pipes to the development of modern products like cigarettes, cigars, and electronic cigarettes [<xref rid="B43-pharmacy-13-00007" ref-type="bibr">43</xref>]. The emergence of electronic cigarettes in 2007 marked a significant shift in tobacco consumption, utilizing a liquid solution containing nicotine and artificial flavors that is vaporized through heating. This innovation has since progressed to include disposable electronic cigarettes, commonly referred to as vapes, as well as more advanced devices designed for heating tobacco specifically. Additionally, alternative nicotine and tobacco products such as nicotine gum, sprays, and patches have been introduced as part of smoke-free initiatives [<xref rid="B44-pharmacy-13-00007" ref-type="bibr">44</xref>].</p><p>The historical use of plants for recreational and narcotic purposes is a fascinating aspect of human civilization. From cannabis and opium poppy to psychoactive plants like the Mandrake, the relationship between humans and plants for altering consciousness dates back millennia. The diverse phytochemical composition of these plants, including cannabinoids, alkaloids, and terpenes, has contributed to their medicinal, ceremonial, and recreational significance throughout history. Understanding the historical context of plant usage for recreational and narcotic purposes provides valuable insights into the cultural, social, and pharmacological dimensions of these practices.</p></sec><sec id="sec2dot2-pharmacy-13-00007"><title>2.2. Evolution of Law and Regulations</title><p>The evolution of laws and regulations concerning medication, substance abuse, and plants for recreational and narcotic purposes has been a complex and dynamic process influenced by various factors such as societal attitudes, scientific research, and political considerations. The laws and rules for the consumption of substances of abuse vary both regionally and depending on the substance incriminated. In recent years, there has been a notable shift in the legislation governing substances like cannabis, with many jurisdictions relaxing restrictions on cultivation and use for research, medicinal, and even recreational purposes [<xref rid="B12-pharmacy-13-00007" ref-type="bibr">12</xref>]. This change reflects a growing acceptance of the potential therapeutic benefits of substances like marijuana, which has been traditionally used for both recreational and medicinal purposes [<xref rid="B45-pharmacy-13-00007" ref-type="bibr">45</xref>].</p><p>The liberalization of cannabis policies in numerous U.S. states and countries like Spain, Uruguay, and Portugal over the past two decades has been a significant development in drug regulation [<xref rid="B46-pharmacy-13-00007" ref-type="bibr">46</xref>]. This shift toward decriminalization and legalization for medical and recreational use signifies a departure from the previous prohibitionist approach that classified cannabis as a narcotic and banned its use [<xref rid="B47-pharmacy-13-00007" ref-type="bibr">47</xref>]. As geographic regulations and testing guidelines for cannabis products continue to evolve, there is a need for comprehensive frameworks to ensure the safety and quality of these substances [<xref rid="B48-pharmacy-13-00007" ref-type="bibr">48</xref>].</p><p>The recreational use of cannabis has a historical background, dating back to its recognition as a medicinal substance in 1850 when it was included in the American Pharmacopeia. However, due to widespread abuse, cannabis was classified as an illegal drug in 1970, leading to its possession being deemed a misdemeanor [<xref rid="B41-pharmacy-13-00007" ref-type="bibr">41</xref>]. Presently, medical cannabis enjoys legal status in numerous countries across the United States and Europe. The trend toward decriminalization of cannabis use has been on the rise since 2012, primarily driven by the reduction in penalties associated with personal consumption [<xref rid="B49-pharmacy-13-00007" ref-type="bibr">49</xref>]. Notably, the legalization of recreational cannabis has been implemented in various countries, including Canada and 15 states within the United States, as well as in European nations such as Germany, Spain, and the Netherlands [<xref rid="B50-pharmacy-13-00007" ref-type="bibr">50</xref>].</p><p>The 20th century marked the inception of significant growth in the cigarette industry. In response to mounting anti-smoking movements, cigarette manufacturing faced prohibition and stringent oversight in 15 states initially. Subsequently, several states enacted more stringent regulations concerning tobacco marketing and smoking in public spaces. Major tobacco corporations devised strategies aimed at refuting the harmful effects of cigarettes. The official acknowledgment of the correlation between smoking and lung cancer in 1964 precipitated the enactment of the Federal Cigarette Labeling and Advertising Act of 1965 [<xref rid="B51-pharmacy-13-00007" ref-type="bibr">51</xref>]. This legislation mandated that cigarette manufacturers provide consumers with explicit warnings about the hazards associated with smoking. Complementing these efforts, the 2009 Family Smoking Prevention and Tobacco Control Act prohibited the advertisement of cigarettes and cigars through mass media [<xref rid="B52-pharmacy-13-00007" ref-type="bibr">52</xref>]. To mitigate the health repercussions of smoking, tobacco levies are periodically increased [<xref rid="B30-pharmacy-13-00007" ref-type="bibr">30</xref>].</p><p>Opioids, a class of drugs utilized for pain management, straddle the fine line between therapeutic use and potential misuse. The responsibility for the overprescription of opioids primarily falls on healthcare professionals. The Controlled Substances Act of 1970 was enacted to regulate the manufacturing and distribution of opioids, aiming to mitigate instances of abuse [<xref rid="B53-pharmacy-13-00007" ref-type="bibr">53</xref>]. States grappling with escalating rates of opioid abuse and overdose have responded by enacting stringent legislation governing prescription practices. These regulations encompass establishing centralized databases to monitor controlled substance dispensation and imposing restrictions on the prescribing authority of medical practitioners. As of 2019, 38 states had implemented such laws, which also include limitations on prescription quantities, varying based on individual state consumption patterns [<xref rid="B54-pharmacy-13-00007" ref-type="bibr">54</xref>].</p><p>Cocaine, with a well-documented historical trajectory, was initially employed as an anesthetic within the medical field toward the conclusion of the 19th century. Its medicinal application promptly brought to light the peril of addiction among patients. After the adverse occurrences during that era, cocaine was classified as a controlled substance under the Misuse of Drugs Act of 1971 [<xref rid="B55-pharmacy-13-00007" ref-type="bibr">55</xref>]. Despite the implementation of measures aimed at curtailing illicit substance abuse, the United States government introduced novel regulations on the supervision of substance distribution. Presently, four enduring regulations are in effect, specifically targeting the prevention of illicit drug manufacturing, notably focusing on cocaine and heroin [<xref rid="B56-pharmacy-13-00007" ref-type="bibr">56</xref>].</p><p>The evolution of laws and regulations concerning medication, substance abuse, and plants for recreational and narcotic purposes is a multifaceted process influenced by scientific advancements, societal attitudes, and public health considerations. The shift toward liberalizing cannabis policies in various jurisdictions reflects changing perceptions of these substances and their potential benefits. However, challenges such as stigmatization, product differentiation, and ensuring safety and quality remain critical aspects of regulatory frameworks in this evolving landscape.</p></sec><sec id="sec2dot3-pharmacy-13-00007"><title>2.3. Impact of Medication and Substance Abuse on Society</title><p>The impact of medication, substance abuse, and plants for recreational and narcotic purposes on society is a multifaceted issue that encompasses various aspects of human behavior, health, and culture. The abuse of substances like cocaine, derived from plants like <italic toggle="yes">Erythroxylum coca</italic>, has had significant repercussions on society, leading to addiction, health problems, and social issues [<xref rid="B57-pharmacy-13-00007" ref-type="bibr">57</xref>].</p><p>In contemporary society, there is a growing trend, particularly among younger generations, to experiment with hallucinogenic plants for recreational purposes [<xref rid="B58-pharmacy-13-00007" ref-type="bibr">58</xref>]. This trend raises concerns about the accessibility and potential risks associated with the use of these substances. Additionally, the socioeconomic context plays a significant role in shaping patterns of substance abuse, with factors such as tobacco, alcohol, and cannabis use among young adults being influenced by social and economic conditions. Understanding the societal implications of substance abuse requires a comprehensive examination of the interplay between individual behavior, cultural norms, and economic disparities [<xref rid="B59-pharmacy-13-00007" ref-type="bibr">59</xref>].</p><p>Plants have long been utilized for their medicinal properties, with many traditional pharmacopeias incorporating various plant species for therapeutic purposes. The exploitation of plant ingredients for anesthetic preparations, as seen in historical formulations, underscores the diverse roles that plants have played in society, ranging from narcotic effects to adjuvant functions [<xref rid="B60-pharmacy-13-00007" ref-type="bibr">60</xref>]. However, the use of certain plants, such as kratom (<italic toggle="yes">Mitragyna speciosa</italic>), has raised concerns due to their addictive properties and potential adverse effects on individuals and communities. The regulation of plants with narcotic properties reflects the ongoing dilemma authorities face in balancing public health concerns with individual freedoms and cultural practices [<xref rid="B61-pharmacy-13-00007" ref-type="bibr">61</xref>].</p><p>The misuse of substances has been demonstrated in contemporary research to exert a negative influence on both professional and social relationships. Such consumption is linked to a decline in the individual&#x02019;s motivation, resulting in the neglect of routine responsibilities. This behavior may lead to severe repercussions such as unemployment, significant financial implications, a deterioration in interpersonal connections, and a decline in overall quality of life [<xref rid="B62-pharmacy-13-00007" ref-type="bibr">62</xref>].</p><p>The etiology of substance addiction encompasses pathological, familial, genetic, and individual developmental factors. The onset of substance use at a young age correlates with heightened addiction susceptibility. Recent studies identify depression and ADHD as additional risk factors in conjunction with the variables above. Childhood psychological traumas exert a substantial influence on individual development, thereby elevating the vulnerability of this demographic to substance abuse [<xref rid="B63-pharmacy-13-00007" ref-type="bibr">63</xref>].</p><p>Despite the association between marijuana legalization and increased consumption, recent data indicate that the patterns of heightened usage were observable before legalization. In Canada, studies conducted within 2 years pre- and post-legalization present varying viewpoints on the prevalence of cannabis use and the well-being of users. Moreover, it is recommended that more comprehensive post-consumption evaluations be conducted at intervals of 2&#x02013;3 years [<xref rid="B64-pharmacy-13-00007" ref-type="bibr">64</xref>,<xref rid="B65-pharmacy-13-00007" ref-type="bibr">65</xref>]. In contrast to the legalization of cannabis, a survey involving allergists revealed that 30% of physicians do not inquire about patients&#x02019; potential cannabis use, indicating that this topic remains stigmatized within certain segments of the population [<xref rid="B65-pharmacy-13-00007" ref-type="bibr">65</xref>].</p><p>Tobacco, ranking second among substances of abuse, exhibits distinct consumption patterns within the population. Research indicates a higher prevalence of consumption among men, with a tendency toward higher daily intake (exceeding one package per day) compared to women. The habit of smoking is often linked to alcohol use, poor dietary choices, and, in some instances, a sedentary lifestyle [<xref rid="B66-pharmacy-13-00007" ref-type="bibr">66</xref>]. Among adolescents, cigarette consumption is associated with exposure to secondhand smoke, social circles, and disadvantaged socioeconomic backgrounds [<xref rid="B26-pharmacy-13-00007" ref-type="bibr">26</xref>]. Studies have illustrated the profound influence of marketing strategies on consumer behavior. Neuroimaging investigations have revealed that novel cigarette packaging designs stimulate neural pathways associated with reward processing and cognitive regulation. Enhancements in product quality, cigarette design, and packaging aesthetics have been shown to boost sales and user consumption rates. Furthermore, the sensory gratification derived from smoking may stem from the ritualistic nature of the activity [<xref rid="B67-pharmacy-13-00007" ref-type="bibr">67</xref>].</p><p>Chronic pain often drives the widespread consumption of opioids, with the rapid development of tolerance in affected individuals [<xref rid="B68-pharmacy-13-00007" ref-type="bibr">68</xref>]. The progression of pain pathology can result in comorbid conditions such as anxiety and depression among patients. In response to the adverse effects of opioids, such as sedation, individuals may escalate their intake to manage their symptoms [<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>]. Additionally, some patients may underestimate the risks associated with opioids due to their prescription status, leading to misuse or sharing of medication with others. This misconception can contribute to the rapid onset of addiction, culminating in a concerning rise in overdose and mortality rates within society [<xref rid="B70-pharmacy-13-00007" ref-type="bibr">70</xref>].</p><p>The compulsive use of cocaine is categorized as a psychiatric disorder known as cocaine use disorder, impacting a substantial portion of the global population and posing a societal concern [<xref rid="B71-pharmacy-13-00007" ref-type="bibr">71</xref>]. This disorder may present through instances of physical aggression that foster and escalate criminal activities and violence [<xref rid="B72-pharmacy-13-00007" ref-type="bibr">72</xref>]. Regrettably, there is a notable escalation in cocaine trafficking, leading to a rise in consumption rates. Despite endeavors to eliminate the illicit cocaine market, it endures, concurrently perpetuating violence and exerting adverse effects on public health [<xref rid="B73-pharmacy-13-00007" ref-type="bibr">73</xref>].</p></sec></sec><sec id="sec3-pharmacy-13-00007"><title>3. Most Commonly Used Plants for Recreational and Narcotic Purposes Nowadays</title><p>Plants containing psychoactive compounds have a long history of diverse uses, ranging from medicinal and spiritual to recreational purposes, evolving toward more recreational and narcotic applications, notably seen in the legalization of cannabis in multiple jurisdictions [<xref rid="B74-pharmacy-13-00007" ref-type="bibr">74</xref>]. This shift is not limited to cannabis but extends to other plants like opium poppy, ayahuasca, kratom, and peyote, reflecting an increasing trend in their consumption [<xref rid="B75-pharmacy-13-00007" ref-type="bibr">75</xref>]. The availability and accessibility of these plants have been enhanced by technological advancements and globalization, making them more obtainable than ever before. The surge in plant consumption for recreational and narcotic purposes is influenced by factors such as legalization, which impacts pricing, potency, and availability [<xref rid="B74-pharmacy-13-00007" ref-type="bibr">74</xref>]. The potential therapeutic value of these plants, particularly those with hallucinogenic properties, is being increasingly explored for novel psychotropic drug development [<xref rid="B76-pharmacy-13-00007" ref-type="bibr">76</xref>].</p><p>The recreational use of plants, particularly those with psychoactive properties, can be attributed to various reasons that cater to different individual needs and desires. Some individuals engage in the recreational use of plants solely to seek euphoric and perception-altering experiences, aiming to escape from the constraints of reality [<xref rid="B77-pharmacy-13-00007" ref-type="bibr">77</xref>]. This desire for altered states of consciousness is a driving force behind the recreational use of psychoactive plants, as they offer a reprieve from the mundane aspects of everyday life. Additionally, people turn to these plants as a coping mechanism for stress, anxiety, and other mental health issues, believing that the psychoactive compounds present in these plants can provide a momentary escape from their problems, offering a sense of relaxation and relief [<xref rid="B78-pharmacy-13-00007" ref-type="bibr">78</xref>].</p><p>Moreover, another significant reason for the recreational use of plants is the pursuit of self-exploration, with individuals seeking to gain a deeper understanding of themselves and the world around them. Through the consumption of psychoactive herbs, some individuals embark on journeys of introspection and self-discovery, using these plants as tools to explore their consciousness and emotions. Studies have indicated that individuals engaging in self-discovery through psychoactive herbs often report feelings of spiritual connectedness and enhanced psychological well-being. This introspective aspect of plant use highlights a more profound motivation beyond mere recreation, delving into the realms of personal growth and enlightenment [<xref rid="B79-pharmacy-13-00007" ref-type="bibr">79</xref>].</p><p>Certain plants&#x02019; traditional and cultural significance also plays a role in their recreational use. For instance, the South Pacific medicinal plant kava (<italic toggle="yes">Piper methysticum</italic>) has been historically utilized for its relaxant properties. It is now incorporated into modern phytotherapy as a treatment for anxiety [<xref rid="B78-pharmacy-13-00007" ref-type="bibr">78</xref>]. This cultural heritage surrounding the use of specific plants adds a layer of depth to their recreational consumption, intertwining traditional practices with contemporary recreational preferences. Additionally, the recreational use of plants is often intertwined with societal behaviors and norms, shaping human culture in multifaceted ways. The consumption of psychoactive plants can lead to habit formation and elicit various effects such as relaxation, stimulation, pain relief, enhanced memory, and reduced anxiety, reflecting the complex interplay between plant use and cultural practices [<xref rid="B80-pharmacy-13-00007" ref-type="bibr">80</xref>].</p><p>Furthermore, the recreational use of plants is not solely driven by individual motivations but is also influenced by external factors such as accessibility and societal acceptance. The surge in recreational cannabis use among adolescents and adults has prompted a closer examination of the short-term and long-term effects of consuming this plant on both the mind and body [<xref rid="B81-pharmacy-13-00007" ref-type="bibr">81</xref>]. This shift in societal attitudes toward cannabis has led to increased scrutiny and research into its recreational use, highlighting the evolving landscape of plant consumption in contemporary society. Additionally, the availability of specific plants for recreational purposes, such as those used in making recreational teas, underscores the continued relevance of traditional practices in modern recreational settings. Despite changes in plant usage over time, some recreational teas remain popular and are even served in commercial establishments, showcasing the enduring appeal of plant-based recreational experiences [<xref rid="B82-pharmacy-13-00007" ref-type="bibr">82</xref>].</p><p>The use of serotonergic hallucinogens, such as LSD, has been documented for recreational, personal, spiritual, and therapeutic purposes, indicating the multifaceted nature of plant-based psychoactive substances [<xref rid="B83-pharmacy-13-00007" ref-type="bibr">83</xref>]. Similarly, ayahuasca (<italic toggle="yes">Banisteriopsis caapi</italic>), traditionally used for spiritual and medicinal purposes, has seen a shift toward recreational use, particularly in Western societies, underscoring the evolving trends in plant consumption [<xref rid="B84-pharmacy-13-00007" ref-type="bibr">84</xref>]. Kratom (<italic toggle="yes">Mitragyna speciosa</italic>), another plant with psychoactive properties, has gained popularity as a recreational drug globally, reflecting a broader pattern of increased recreational plant use [<xref rid="B85-pharmacy-13-00007" ref-type="bibr">85</xref>]. These shifts in usage patterns raise important questions about the implications of widespread recreational plant consumption and its potential risks.</p><p>Research on ayahuasca (<italic toggle="yes">Banisteriopsis caapi</italic>) has suggested potential therapeutic uses for treating psychiatric disorders and addictions, pointing toward the complex interplay between traditional medicinal practices and modern therapeutic approaches [<xref rid="B86-pharmacy-13-00007" ref-type="bibr">86</xref>]. Additionally, studies on kratom (<italic toggle="yes">Mitragyna speciosa</italic>) have highlighted its interaction with various receptors in the body, leading to a wide range of effects and shedding light on its emergence within the broader context of substance use disorders [<xref rid="B87-pharmacy-13-00007" ref-type="bibr">87</xref>]. The safety and potential benefits of ayahuasca use under certain conditions have been indicated, emphasizing the need for a nuanced understanding of the risks and benefits associated with plant-based psychoactive substances [<xref rid="B88-pharmacy-13-00007" ref-type="bibr">88</xref>]. Moreover, the increasing clinical awareness around kratom use and the assessment of kratom use disorder among United States adults underscore the growing recognition of the impact of these plants on public health [<xref rid="B89-pharmacy-13-00007" ref-type="bibr">89</xref>].</p><p>The global phenomenon of ayahuasca use and the recreational consumption of DMT (<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyltryptamine) and similar alkaloids have raised concerns about uncontrolled use and the potential for severe intoxications, highlighting the need for regulatory measures and public health interventions [<xref rid="B90-pharmacy-13-00007" ref-type="bibr">90</xref>]. The detection and quantification of psychoactive compounds in plant matrices have become essential for monitoring and addressing the recreational abuse of plants like kava, emphasizing the importance of analytical techniques in understanding and regulating plant-based psychoactive substances [<xref rid="B91-pharmacy-13-00007" ref-type="bibr">91</xref>]. Furthermore, the toxicological issues related to kratom usage underscore the complexities surrounding the management of substance abuse disorders and withdrawal effects, necessitating a comprehensive approach to address these challenges [<xref rid="B92-pharmacy-13-00007" ref-type="bibr">92</xref>].</p><p>The evolving landscape of plant consumption for recreational and narcotic purposes presents a complex interplay between traditional uses, modern trends, regulatory frameworks, and public health considerations. Understanding the multifaceted nature of plant-based psychoactive substances, their potential benefits, risks, and societal implications is crucial for developing evidence-based policies and interventions to address the challenges posed by the increasing use of these plants [<xref rid="B93-pharmacy-13-00007" ref-type="bibr">93</xref>]. The recreational use of plants for various purposes, including seeking altered states of consciousness, coping with mental health issues, self-exploration, and cultural practices, reflects the diverse motivations and influences that shape human interactions with psychoactive flora. From traditional herbal remedies to contemporary recreational preferences, the consumption of plants for recreational purposes is a multifaceted phenomenon that intertwines individual desires, cultural heritage, and societal norms. Understanding the reasons behind the recreational use of plants provides insights into human behavior, cultural practices, and the intricate relationships between individuals and the natural world [<xref rid="B94-pharmacy-13-00007" ref-type="bibr">94</xref>,<xref rid="B95-pharmacy-13-00007" ref-type="bibr">95</xref>].</p><p>By synthesizing research findings and empirical evidence, this chapter provides a comprehensive overview of the most used plants for recreational and narcotic purposes, shedding light on their historical significance, contemporary trends, and future implications for public health and regulatory frameworks.</p><p><xref rid="pharmacy-13-00007-f001" ref-type="fig">Figure 1</xref> illustrates the mechanisms of action of plants used for recreational and narcotic purposes. This information enhances our understanding of how they exert their effects and the risks associated with exposure to them.</p><sec id="sec3dot1-pharmacy-13-00007"><title>3.1. Cannabis sativa (Cannabis)</title><sec id="sec3dot1dot1-pharmacy-13-00007"><title>3.1.1. Historical Background</title><p><italic toggle="yes">Cannabis sativa</italic>, commonly known as marijuana, has a long and complex history intertwined with human civilization. It belongs to the Cannabaceae family and is native to Central Asia [<xref rid="B13-pharmacy-13-00007" ref-type="bibr">13</xref>]. It is an annual flowering herb that can be classified into two main species: <italic toggle="yes">Cannabis sativa</italic> var. sativa, which is taller and more fibrous, and <italic toggle="yes">Cannabis sativa</italic> var. indica, which is shorter and more psychoactive [<xref rid="B96-pharmacy-13-00007" ref-type="bibr">96</xref>]. The distinction between these two types of cannabis and the different biological effects associated with them has been a subject of significant interest and research [<xref rid="B97-pharmacy-13-00007" ref-type="bibr">97</xref>]. <italic toggle="yes">Cannabis sativa</italic> has been cultivated for centuries for various purposes, including medicinal, recreational, and industrial uses. The plant&#x02019;s versatility is evident in its applications, ranging from medicine to textile fiber production and even religious rituals [<xref rid="B98-pharmacy-13-00007" ref-type="bibr">98</xref>]. The use of <italic toggle="yes">Cannabis sativa</italic> for recreational and narcotic purposes has been a topic of debate and study for many years. The plant contains a wide array of compounds, with over 500 identified in the Cannabis genus, distributed across 18 chemical classes [<xref rid="B99-pharmacy-13-00007" ref-type="bibr">99</xref>]. Among these compounds, the presence of high concentrations of cannabinoids, such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in Cannabis flowers play crucial roles in the plant&#x02019;s effects on the human body [<xref rid="B100-pharmacy-13-00007" ref-type="bibr">100</xref>].</p></sec><sec id="sec3dot1dot2-pharmacy-13-00007"><title>3.1.2. Drug Policy</title><p>The legalization of <italic toggle="yes">Cannabis sativa</italic> for various purposes, including medical and recreational use, has been a significant trend in recent years. In the United States, the 2014 Farm Bill paved the way for the re-introduction of hemp (<italic toggle="yes">Cannabis sativa</italic> L.) as an industrial crop [<xref rid="B101-pharmacy-13-00007" ref-type="bibr">101</xref>]. Furthermore, the Agriculture Improvement Act of 2018 legalized the cultivation of <italic toggle="yes">Cannabis sativa</italic> with a THC content of no more than 0.3%, opening up new opportunities for the production of hemp-derived products. This shift in legislation reflects changing attitudes toward <italic toggle="yes">Cannabis sativa</italic> and its potential economic and agricultural benefits [<xref rid="B102-pharmacy-13-00007" ref-type="bibr">102</xref>].</p></sec><sec id="sec3dot1dot3-pharmacy-13-00007"><title>3.1.3. Pharmacological Properties and Health Implications</title><p>The pharmacological properties of <italic toggle="yes">Cannabis sativa</italic> have been the subject of extensive research, with studies exploring its effects on various medical conditions. The plant has been used for centuries for recreational purposes and, more recently, in the treatment of patients with neurological or psychiatric disorders [<xref rid="B103-pharmacy-13-00007" ref-type="bibr">103</xref>]. The potential therapeutic uses of <italic toggle="yes">Cannabis sativa</italic> have led to investigations into its efficacy in managing conditions such as chronic pain, postoperative discomfort, and substance-related disorders [<xref rid="B104-pharmacy-13-00007" ref-type="bibr">104</xref>]. The diverse chemical composition of <italic toggle="yes">Cannabis sativa</italic>, including cannabinoids, terpenes, and other compounds, contributes to its pharmacological effects and potential medical applications [<xref rid="B105-pharmacy-13-00007" ref-type="bibr">105</xref>].</p><p>Despite its recreational appeal, the consumption of <italic toggle="yes">Cannabis sativa</italic> is associated with adverse effects, mainly when used in excess or by vulnerable populations. Short-term adverse effects of cannabis use can include psychotic states, cognitive impairments, and dependence, particularly among regular users [<xref rid="B106-pharmacy-13-00007" ref-type="bibr">106</xref>]. Furthermore, the co-use of cannabis with other substances, such as tobacco, can exacerbate dependence and have implications for overall health and well-being. Understanding the risks associated with cannabis consumption is crucial for developing effective public health interventions and harm reduction strategies [<xref rid="B107-pharmacy-13-00007" ref-type="bibr">107</xref>].</p></sec><sec id="sec3dot1dot4-pharmacy-13-00007"><title>3.1.4. Mechanism of Action</title><p>Cannabis acts through the activation of cannabinoid receptors, in particular, the CB1 and CB2 receptors of the endocannabinoid complex system. Interaction with presynaptic CB1 receptors on GABAergic inhibitory neurons in the reward pathway inhibits adenylate cyclase, reducing electrical excitation and neurotransmitter release. This inhibition of GABA release causes a disinhibition of dopaminergic neurons, leading to increased synaptic dopamine levels&#x02014;a mechanism similar to that of opioids. The main active compound in cannabis, THC, is primarily responsible for the plant&#x02019;s psychoactive properties (which produce a euphoric and relaxing state). At the same time, CBD is known for its potential therapeutic benefits [<xref rid="B108-pharmacy-13-00007" ref-type="bibr">108</xref>].</p><p>The narcotic and recreational effects of <italic toggle="yes">Cannabis sativa</italic> are primarily attributed to cannabinoids and terpenoids. These bioactive molecules interact with the endocannabinoid system in the human body, influencing various physiological processes and producing psychoactive effects [<xref rid="B109-pharmacy-13-00007" ref-type="bibr">109</xref>]. Consumers seek marijuana for its recreational effects, as it can induce pleasurable states, enhance sensory perception, distort time perception, and facilitate social interactions. The levels and ratios of these cannabinoids in <italic toggle="yes">Cannabis sativa</italic> determine its potency and effects, making it a subject of interest for both recreational users and researchers exploring its medicinal potential [<xref rid="B110-pharmacy-13-00007" ref-type="bibr">110</xref>].</p></sec><sec id="sec3dot1dot5-pharmacy-13-00007"><title>3.1.5. Future Perspectives on Public Health</title><p>Looking toward the future, the implications of <italic toggle="yes">Cannabis sativa</italic> for public health are multifaceted. The increasing consumption of cannabis for recreational purposes globally raises concerns about the potential impact on mental health and substance use disorders. With approximately 200 million cannabis users worldwide, monitoring trends in consumption, addressing regulatory challenges, and promoting evidence-based education are essential for mitigating potential harms [<xref rid="B111-pharmacy-13-00007" ref-type="bibr">111</xref>]. Additionally, as research on <italic toggle="yes">Cannabis sativa</italic> advances, there is a need to explore its therapeutic potential while ensuring safe and responsible use in the context of evolving legal frameworks [<xref rid="B112-pharmacy-13-00007" ref-type="bibr">112</xref>].</p></sec><sec id="sec3dot1dot6-pharmacy-13-00007"><title>3.1.6. General Conclusion</title><p>Overall, <italic toggle="yes">Cannabis sativa</italic> remains a complex and multifaceted plant with a long history of use for recreational, medicinal, and industrial purposes. Understanding its historical significance, contemporary consumption trends, mechanisms for narcotic and recreational purposes, chemical compounds responsible for effects, adverse effects of consumption, and future implications for public health is essential for informed decision-making and policy development. By synthesizing research findings and staying abreast of emerging trends, stakeholders can navigate the complex landscape of <italic toggle="yes">Cannabis sativa</italic> use with a focus on promoting public health and well-being.</p></sec></sec><sec id="sec3dot2-pharmacy-13-00007"><title>3.2. Erythroxylum coca (Coca Plant)</title><sec id="sec3dot2dot1-pharmacy-13-00007"><title>3.2.1. Historical Background</title><p><italic toggle="yes">Erythroxylum coca</italic>, commonly known as the coca plant, has a long history of traditional use by indigenous South American tribes for various purposes, including stimulant, anesthetic, religious, and recreational uses [<xref rid="B113-pharmacy-13-00007" ref-type="bibr">113</xref>]. Belonging to the Erythroxylaceae family, this plant has been cultivated for thousands of years, with evidence of its use dating back at least 8000 years ago [<xref rid="B114-pharmacy-13-00007" ref-type="bibr">114</xref>]. The plant has been cultivated for its leaves, which contain the alkaloid cocaine, a potent stimulant and narcotic substance [<xref rid="B115-pharmacy-13-00007" ref-type="bibr">115</xref>]. The coca plant was one of the first domesticated plant species, providing nutritional, medicinal, and digestive properties to ancient civilizations through the practice of chewing its leaves [<xref rid="B116-pharmacy-13-00007" ref-type="bibr">116</xref>]. The use of coca for medicinal purposes, particularly in treating altitude sickness, has been a centuries-old tradition among the native peoples of South America [<xref rid="B115-pharmacy-13-00007" ref-type="bibr">115</xref>].</p></sec><sec id="sec3dot2dot2-pharmacy-13-00007"><title>3.2.2. Drug Policy</title><p>Erythroxylum species, especially <italic toggle="yes">Erythroxylum coca</italic>, are globally banned for cultivation and consumption. Current legislation only allows their use for medical and scientific purposes or as an extract in drinks such as Coca-Cola. However, in Bolivia, Colombia, and Peru, cocaine-based products such as medical products and food are available on the market, although coca continues to be sold illegally, against the law [<xref rid="B56-pharmacy-13-00007" ref-type="bibr">56</xref>].</p></sec><sec id="sec3dot2dot3-pharmacy-13-00007"><title>3.2.3. Pharmacological Properties and Health Implications</title><p>Cocaine, the primary alkaloid found in <italic toggle="yes">Erythroxylum coca</italic>, has been the subject of extensive research due to its pharmacological effects and societal implications. The alkaloid is naturally found in the leaves of coca plants. It has been associated with anesthetic properties, with cocaine being a prototype for modern local anesthetics [<xref rid="B116-pharmacy-13-00007" ref-type="bibr">116</xref>]. Studies have shown that cocaine and cinnamoyl-cocaine in <italic toggle="yes">Erythroxylum coca</italic> are stored in the vacuoles of the plants and complexed with hydroxycinnamoyl quinate esters [<xref rid="B57-pharmacy-13-00007" ref-type="bibr">57</xref>]. Additionally, research has indicated that cocaine functions as a plant&#x02019;s natural insecticide, suggesting its role in defense mechanisms against herbivores [<xref rid="B117-pharmacy-13-00007" ref-type="bibr">117</xref>].</p><p>The domestication and cultivation of <italic toggle="yes">Erythroxylum coca</italic> have been of interest to researchers studying the origins and genetic diversity of the plant. Genomic studies have revealed multiple independent domestications of coca from its progenitor, <italic toggle="yes">Erythroxylum gracilipes</italic>, highlighting the evolutionary history of the plant. Phylogenetic analyses have provided insights into the relationships within the Erythroxylum genus, informing taxonomy, biogeography, and the domestication of coca species [<xref rid="B118-pharmacy-13-00007" ref-type="bibr">118</xref>]. Furthermore, the complete genome sequences of <italic toggle="yes">Erythroxylum coca</italic> and <italic toggle="yes">Erythroxylum novogranatense</italic> have been elucidated, shedding light on the genetic makeup of these important cultigens [<xref rid="B119-pharmacy-13-00007" ref-type="bibr">119</xref>].</p><p>Chemical analyses of <italic toggle="yes">Erythroxylum coca</italic> have identified various alkaloids present in the plant, including cocaine, cinnamoyl-cocaine, and tropane alkaloids [<xref rid="B115-pharmacy-13-00007" ref-type="bibr">115</xref>]. The biosynthesis of tropane alkaloids in <italic toggle="yes">Erythroxylum coca</italic> has been investigated, revealing the enzymatic pathways involved in the production of these pharmacologically significant compounds [<xref rid="B119-pharmacy-13-00007" ref-type="bibr">119</xref>]. Studies have also assessed the distribution of cocaine in different wild Erythroxylum species, highlighting variations in alkaloid content among different plant populations [<xref rid="B120-pharmacy-13-00007" ref-type="bibr">120</xref>].</p><p>In contemporary times, the consumption of coca leaves and derived products has evolved, with a shift toward recreational and narcotic purposes. The chemical compounds found in <italic toggle="yes">Erythroxylum coca</italic>, such as tropane alkaloids like cocaine, are responsible for its psychoactive effects [<xref rid="B121-pharmacy-13-00007" ref-type="bibr">121</xref>]. These compounds act on the central nervous system, leading to stimulant effects that induce euphoria and increased energy levels, making them desirable for recreational use. However, the consumption of coca products, especially in the form of cocaine, is associated with various adverse effects on health [<xref rid="B122-pharmacy-13-00007" ref-type="bibr">122</xref>].</p><p>The narcotic and recreational effects of coca products, particularly cocaine, are well documented. Cocaine acts as a potent stimulant, affecting neurotransmitter levels in the brain, particularly dopamine, which leads to its addictive properties and potential for abuse [<xref rid="B123-pharmacy-13-00007" ref-type="bibr">123</xref>]. Chronic use of cocaine can result in a range of adverse health effects, including cardiovascular complications, neurological disorders, psychiatric symptoms, and even overdose-related fatalities. The addictive nature of cocaine further exacerbates its negative impact on individuals, leading to a cycle of dependence and potential long-term health consequences [<xref rid="B121-pharmacy-13-00007" ref-type="bibr">121</xref>].</p></sec><sec id="sec3dot2dot4-pharmacy-13-00007"><title>3.2.4. Mechanism of Action</title><p>The primary anesthetic effect of cocaine is due to the inhibition of voltage-gated sodium channels, blocking the entry of sodium ions into cells and, consequently, preventing the transmission of nerve impulses. Since the transmission of nerve impulses is blocked when sodium ions are inhibited, the use of cocaine as a topical anesthetic is becoming less common. At the dopaminergic level, cocaine inhibits the dopamine transporter (DAT), causing the accumulation of extracellular dopamine, which produces euphoria. At the cardiac level, cocaine exhibits cardiotoxic effects by inhibiting norepinephrine reuptake, leading to vasoconstriction. In the central nervous system, by interacting with sigma and kappa-opioid receptors, cocaine affects the structure and function of dopamine receptors, thus contributing to its psychoactive effects [<xref rid="B35-pharmacy-13-00007" ref-type="bibr">35</xref>].</p><p>From a public health perspective, the widespread use of coca products, especially cocaine, poses significant challenges. The addictive nature of cocaine contributes to substance abuse disorders and societal issues related to drug dependence [<xref rid="B124-pharmacy-13-00007" ref-type="bibr">124</xref>]. Additionally, the illicit production and trafficking of cocaine have fueled organized crime and violence in regions where coca cultivation is prevalent, further complicating efforts to address the public health implications of coca consumption. The adverse health outcomes associated with cocaine use underscore the importance of comprehensive strategies to prevent substance abuse and provide support for individuals struggling with addiction [<xref rid="B125-pharmacy-13-00007" ref-type="bibr">125</xref>].</p></sec><sec id="sec3dot2dot5-pharmacy-13-00007"><title>3.2.5. Future Perspectives on Public Health</title><p>Looking toward the future, addressing the public health implications of coca consumption requires a multifaceted approach. Education and awareness programs are essential to inform the public about the risks associated with coca products, particularly cocaine, and to promote healthy lifestyle choices. Additionally, regulatory measures and law enforcement efforts are crucial to combat illicit drug production and trafficking, reducing the availability of coca products in the black market. Treatment and rehabilitation services play a vital role in supporting individuals affected by substance abuse disorders, offering them the necessary resources to overcome addiction and improve their overall well-being [<xref rid="B126-pharmacy-13-00007" ref-type="bibr">126</xref>].</p></sec><sec id="sec3dot2dot6-pharmacy-13-00007"><title>3.2.6. General Conclusion</title><p>Overall, <italic toggle="yes">Erythroxylum coca</italic>, with its historical significance and psychoactive properties, has been a subject of interest for recreational and narcotic purposes. The chemical compounds present in coca, such as cocaine, have potent effects on the central nervous system, leading to both recreational enjoyment and severe health consequences. Addressing the adverse effects of coca consumption, particularly cocaine abuse, is paramount for public health. By employing multifaceted approaches integrating education, regulation, enforcement, and treatment, societies can effectively address the detrimental effects of coca products on individuals and communities. Extending from historical indigenous practices to modern-day public health challenges, additional research is imperative to elucidate this culturally and scientifically noteworthy botanical specimen&#x02019;s historical, current, and prospective ramifications.</p></sec></sec><sec id="sec3dot3-pharmacy-13-00007"><title>3.3. Papaver somniferum (Opium Poppy)</title><sec id="sec3dot3dot1-pharmacy-13-00007"><title>3.3.1. Historical Background</title><p><italic toggle="yes">Papaver somniferum</italic>, commonly known as opium poppy, is an annual plant belonging to the Papaveraceae family with a rich historical significance as an ancient medicinal plant. It is renowned for being the primary commercial source of various narcotic analgesics such as morphine, codeine, and their semi-synthetic derivatives like oxycodone and hydrocodone. The plant&#x02019;s significance dates back to ancient times when it was utilized for its medicinal properties and continues to be the primary commercial origin of these potent analgesics [<xref rid="B127-pharmacy-13-00007" ref-type="bibr">127</xref>]. Morphine and codeine, the primary alkaloids derived from <italic toggle="yes">Papaver somniferum</italic>, are known for their powerful narcotic effects and are widely used in the pharmaceutical industry [<xref rid="B128-pharmacy-13-00007" ref-type="bibr">128</xref>].</p></sec><sec id="sec3dot3dot2-pharmacy-13-00007"><title>3.3.2. Drug Policy</title><p>The cultivation of opium is only possible in two situations well regulated by law, namely for medicinal purposes and resin. For example, in India, poppy cultivation is legalized under the Narcotic Drugs and Psychotropic Substances (NDPS) Act for medicinal purposes only, under government supervision. Every year, a representative from the government is responsible for verifying the requirements (land area, patience, quality standards), which, if farmers do not fulfill, they do not get approval to cultivate. To ensure control and to reduce the risk of abuse, Indian farmers are obliged to sell their produce to the government at prices set by the authorities [<xref rid="B129-pharmacy-13-00007" ref-type="bibr">129</xref>].</p></sec><sec id="sec3dot3dot3-pharmacy-13-00007"><title>3.3.3. Pharmacological Properties and Health Implications</title><p>Contemporary consumption trends of <italic toggle="yes">Papaver somniferum</italic> highlight its continued relevance in the production of opiates and opioids for medical and recreational purposes [<xref rid="B130-pharmacy-13-00007" ref-type="bibr">130</xref>]. The plant&#x02019;s alkaloids, particularly morphine and codeine, are central to its pharmacological importance and are responsible for its narcotic effects. The biosynthesis of these alkaloids occurs in specialized cells within the plant, known as laticifers, emphasizing the intricate biochemical processes involved in producing these potent [<xref rid="B131-pharmacy-13-00007" ref-type="bibr">131</xref>]. The presence of these alkaloids in <italic toggle="yes">Papaver somniferum</italic> has led to its widespread cultivation and utilization for both medicinal and recreational purposes [<xref rid="B130-pharmacy-13-00007" ref-type="bibr">130</xref>].</p><p>The chemical compounds responsible for the narcotic and recreational effects of <italic toggle="yes">Papaver somniferum</italic> are primarily benzylisoquinoline alkaloids, including morphine, codeine, and noscapine [<xref rid="B130-pharmacy-13-00007" ref-type="bibr">130</xref>]. These alkaloids play a crucial role in the plant&#x02019;s pharmacological properties, with morphine being a key component due to its potent analgesic effects [<xref rid="B131-pharmacy-13-00007" ref-type="bibr">131</xref>]. The biosynthesis of these alkaloids involves complex pathways and enzymatic reactions within the plant, highlighting the sophisticated mechanisms underlying the production of these bioactive compounds [<xref rid="B132-pharmacy-13-00007" ref-type="bibr">132</xref>]. The presence of these alkaloids in opium poppy seeds has raised concerns regarding consumer exposure to these potent substances [<xref rid="B133-pharmacy-13-00007" ref-type="bibr">133</xref>].</p><p>In terms of adverse effects, the consumption of <italic toggle="yes">Papaver somniferum</italic> and its derivatives for narcotic and recreational purposes can lead to various health risks and unfavorable outcomes. Opioids derived from the plant, such as morphine and codeine, are known for their addictive properties and potential for substance abuse. Prolonged use of these substances can result in physical dependence, tolerance, and withdrawal symptoms, contributing to the global opioid crisis. Additionally, the misuse of opium poppy products can lead to overdose, respiratory depression, and even death, underscoring the severe consequences associated with the recreational and non-medical use of these substances [<xref rid="B134-pharmacy-13-00007" ref-type="bibr">134</xref>].</p></sec><sec id="sec3dot3dot4-pharmacy-13-00007"><title>3.3.4. Mechanism of Action</title><p>Papaverine is a potent vasodilator that increases levels of cAMP and cGMP by inhibiting the phosphodiesterases that break them down. These intracellular messengers are responsible for smooth muscle relaxation. Papaverine may also inhibit the release of intracellular calcium ions, thereby reducing muscle contractions and blocking the entry of ions into the cells, decreasing contraction impulses [<xref rid="B135-pharmacy-13-00007" ref-type="bibr">135</xref>].</p></sec><sec id="sec3dot3dot5-pharmacy-13-00007"><title>3.3.5. Future Perspectives on Public Health</title><p>Looking toward future implications for public health, addressing the challenges posed by the widespread availability and misuse of <italic toggle="yes">Papaver somniferum</italic>-derived products is essential. Strategies focusing on harm reduction, addiction treatment, and public awareness campaigns are crucial in mitigating the negative impact of opioid abuse on individuals and communities [<xref rid="B136-pharmacy-13-00007" ref-type="bibr">136</xref>]. Furthermore, research efforts aimed at developing alternative pain management strategies that reduce reliance on opioid medications derived from opium poppy can help alleviate the burden of opioid-related harm [<xref rid="B137-pharmacy-13-00007" ref-type="bibr">137</xref>]. By promoting responsible prescribing practices, enhancing addiction treatment services, and implementing comprehensive public health interventions, the adverse effects of <italic toggle="yes">Papaver somniferum</italic> consumption can be effectively managed to safeguard public health and well-being.</p></sec><sec id="sec3dot3dot6-pharmacy-13-00007"><title>3.3.6. General Conclusion</title><p>Overall, <italic toggle="yes">Papaver somniferum</italic> is a plant of immense significance, with a long history of medicinal use and a complex relationship with human society. Its chemical compounds, particularly the benzylisoquinoline alkaloids, are responsible for its therapeutic and recreational effects, making it a subject of interest for researchers and policymakers alike. While the plant offers valuable compounds for pharmaceutical purposes, the potential adverse impacts of its recreational use necessitate careful regulation and public health interventions. Future research on <italic toggle="yes">Papaver somniferum</italic> holds promise for uncovering new bioactive compounds and understanding its genetic diversity, paving the way for advancements in medicine and plant science.</p></sec></sec><sec id="sec3dot4-pharmacy-13-00007"><title>3.4. Mitragyna speciosa (Kratom)</title><sec id="sec3dot4dot1-pharmacy-13-00007"><title>3.4.1. Historical Background</title><p><italic toggle="yes">Mitragyna speciosa</italic>, commonly known as kratom, is a tropical tree belonging to the Rubiaceae family, historically used in traditional medicine practices in regions of Africa and Southeast Asia [<xref rid="B85-pharmacy-13-00007" ref-type="bibr">85</xref>]. While traditionally used for its analgesic properties mediated by opioid receptors, it has gained popularity as a recreational psychoactive drug in Western countries [<xref rid="B137-pharmacy-13-00007" ref-type="bibr">137</xref>,<xref rid="B138-pharmacy-13-00007" ref-type="bibr">138</xref>]. Additionally, it has been reported to have psychoactive effects and opium-like characteristics. It has been used to manage opioid addiction and withdrawal symptoms [<xref rid="B139-pharmacy-13-00007" ref-type="bibr">139</xref>]. The plant has a long history of use in Southeast Asia for its stimulant effects, as a traditional herbal medicine, and as a substitute for opium and alcohol. [<xref rid="B138-pharmacy-13-00007" ref-type="bibr">138</xref>]. <italic toggle="yes">Mitragyna speciosa</italic> has also been employed to alleviate pain, hypertension, cough, and diarrhea and as a replacement for morphine in treating people with an addiction [<xref rid="B140-pharmacy-13-00007" ref-type="bibr">140</xref>]. Overall, the traditional uses of <italic toggle="yes">Mitragyna speciosa</italic> encompass many medicinal and psychoactive applications that have been recognized for centuries.</p></sec><sec id="sec3dot4dot2-pharmacy-13-00007"><title>3.4.2. Drug Policy</title><p>Until now, the legalization of the use of kratom, classified in 2016 by the Drug Enforcement Administration (DEA) as a Category I substance, has not yet been regulated worldwide due to a total lack of safety. In Australia, kratom is also not used for medical purposes. However, in Thailand and most states in America, because there are no cases of violence or overdose following its consumption, the use of kratom for medical purposes is possible. In America, kratom is on the market only as a dietary supplement and as a food, and until now, there has been no regulation to ensure its safe use in medical treatment [<xref rid="B141-pharmacy-13-00007" ref-type="bibr">141</xref>].</p></sec><sec id="sec3dot4dot3-pharmacy-13-00007"><title>3.4.3. Pharmacological Properties and Health Implications</title><p>The pharmacology of <italic toggle="yes">Mitragyna speciosa</italic> is complex, with alkaloids such as mitragynine binding to opioid receptors and influencing pain perception [<xref rid="B142-pharmacy-13-00007" ref-type="bibr">142</xref>]. Furthermore, the directed biosynthesis of mitragynine stereoisomers demonstrates the potential for manipulating the chemical composition of kratom for specific purposes [<xref rid="B143-pharmacy-13-00007" ref-type="bibr">143</xref>]. In addition, <italic toggle="yes">Mitragyna speciosa</italic> leaves contain other alkaloids, such as 7-hydroxy mitragynine, which are identified as the main psychoactive components responsible for its effects [<xref rid="B93-pharmacy-13-00007" ref-type="bibr">93</xref>].</p></sec><sec id="sec3dot4dot4-pharmacy-13-00007"><title>3.4.4. Mechanism of Action</title><p>Kratom is a plant recognized for its numerous therapeutic effects, such as analgesic, antipyretic, sedative, antimicrobial, anti-inflammatory, and dopaminergic stimulant. Its natural alkaloid, mitragynine, is responsible for these effects, which induce specific narcotic effects through its interaction with numerous receptors in the nervous system. At low doses, mitragynine exhibits stimulant effects, while at high doses, its agonist action on opioid I receptors and antagonist action on d receptors produces effects specific to conventional opioids. Mitragynine inhibits the COX-2 enzyme and prostaglandin E2 to exert its anti-inflammatory effect. For its analgesic effect, it activates a-2 adrenergic receptors and inhibits Ca<sup>2+</sup> channels [<xref rid="B144-pharmacy-13-00007" ref-type="bibr">144</xref>,<xref rid="B145-pharmacy-13-00007" ref-type="bibr">145</xref>].</p><p>In the United States, there has been an increase in the use of <italic toggle="yes">Mitragyna speciosa</italic> for self-treatment of pain and opioid addiction [<xref rid="B146-pharmacy-13-00007" ref-type="bibr">146</xref>]. While the plant shows promise for pain management and opioid withdrawal, chronic use has been associated with punishment resistance in natural reward-seeking behavior and impaired learning in animal studies [<xref rid="B147-pharmacy-13-00007" ref-type="bibr">147</xref>]. Concerns have also been raised regarding the potential adverse effects, such as addiction and psychomotor impairment associated with the consumption of botanical preparations of <italic toggle="yes">Mitragyna speciosa</italic> to alleviate negative emotions [<xref rid="B148-pharmacy-13-00007" ref-type="bibr">148</xref>,<xref rid="B149-pharmacy-13-00007" ref-type="bibr">149</xref>].</p></sec><sec id="sec3dot4dot5-pharmacy-13-00007"><title>3.4.5. Future Perspectives on Public Health</title><p>Looking toward future public health implications, <italic toggle="yes">Mitragyna speciosa</italic> shows promising potential due to its anti-inflammatory effects and therapeutic properties [<xref rid="B150-pharmacy-13-00007" ref-type="bibr">150</xref>]. Moreover, its cellular toxicology and the risks associated with its dominant alkaloid, mitragynine, are being explored [<xref rid="B151-pharmacy-13-00007" ref-type="bibr">151</xref>]. Understanding the effects of <italic toggle="yes">Mitragyna speciosa</italic> on the central nervous system and behavior is crucial as research progresses [<xref rid="B152-pharmacy-13-00007" ref-type="bibr">152</xref>]. Additionally, exploring this plant&#x02019;s genetic diversity and metabolomics can offer valuable insights into its variability and chemical composition [<xref rid="B143-pharmacy-13-00007" ref-type="bibr">143</xref>,<xref rid="B153-pharmacy-13-00007" ref-type="bibr">153</xref>].</p></sec><sec id="sec3dot4dot6-pharmacy-13-00007"><title>3.4.6. General Conclusion</title><p>Overall, <italic toggle="yes">Mitragyna speciosa</italic> presents a nuanced landscape for recreational and narcotic purposes, with the potential for pain management and opioid addiction treatment. However, the negative consequences of its consumption and associated health risks necessitate careful consideration. A balanced approach that explores its therapeutic potential while mitigating adverse effects is essential for shaping future public health policies and interventions as research on <italic toggle="yes">Mitragyna speciosa</italic> advances.</p></sec></sec><sec id="sec3dot5-pharmacy-13-00007"><title>3.5. Catha edulis (Khat)</title><sec id="sec3dot5dot1-pharmacy-13-00007"><title>3.5.1. Historical Background</title><p><italic toggle="yes">Catha edulis</italic>, commonly known as khat, is a plant with historical and cultural significance, particularly in regions like East Africa and the Arabian Peninsula. Belonging to the Celastraceae family, khat has been traditionally chewed for its stimulant effects, akin to amphetamines, due to the presence of cathinone, a beta-ketone amphetamine analog found in the leaves of the plant [<xref rid="B154-pharmacy-13-00007" ref-type="bibr">154</xref>]. The contemporary consumption trends of khat involve its use for recreational purposes, inducing a sense of euphoria and increased energy levels, making it popular in social settings. This plant has psychoactive effects and is widely used globally, with a prevalence of chewing fresh leaves and twigs for its stimulating properties [<xref rid="B155-pharmacy-13-00007" ref-type="bibr">155</xref>].</p></sec><sec id="sec3dot5dot2-pharmacy-13-00007"><title>3.5.2. Drug Policy</title><p>Until the 1970s, khat was not considered a hazardous substance, as the decision of the United Nations Commission on Narcotic Drugs allowed each country to decide how it wished to regulate its use. However, in 1988, following the discovery of cathinone&#x02014;the active substance in khat most likely to cause the most adverse effects in the general population&#x02014;the WHO included it in Category I of psychoactive substances. In recent years, the ECDD has considered that khat does not pose a very high risk of abuse and addiction, so countries such as Kenya and Ethiopia have legalized the use of khat. However, there are also countries where possession and consumption are illegal, such as Italy, Germany, Saudi Arabia, and Sweden [<xref rid="B156-pharmacy-13-00007" ref-type="bibr">156</xref>].</p></sec><sec id="sec3dot5dot3-pharmacy-13-00007"><title>3.5.3. Pharmacological Properties and Health Implications</title><p>The chemical compounds responsible for khat&#x02019;s narcotic and recreational effects include alkaloids, tannins, flavonoids, terpenes, sterols, and essential oils found in its leaves. These compounds contribute to the plant&#x02019;s psychoactive properties, making it sought after for its stimulant effects [<xref rid="B157-pharmacy-13-00007" ref-type="bibr">157</xref>].</p><p>However, alongside its recreational use, khat consumption has been associated with various adverse effects on health. Studies have reported cases of acute liver failure and autoimmune hepatitis among consumers of <italic toggle="yes">Catha edulis</italic>, highlighting potential hepatotoxicity induced by its use [<xref rid="B158-pharmacy-13-00007" ref-type="bibr">158</xref>]. Additionally, research has shown that khat consumption can lead to adverse effects such as cardiovascular issues and other internal medical problems, emphasizing the need for further investigation into its health implications [<xref rid="B159-pharmacy-13-00007" ref-type="bibr">159</xref>]. Furthermore, the long-term toxicological effects of khat leaves have been studied in animals, revealing increased levels of enzymes like alkaline phosphatase and alanine aminotransferase, indicating potential liver damage [<xref rid="B160-pharmacy-13-00007" ref-type="bibr">160</xref>]. These findings underscore the importance of understanding the risks associated with khat consumption and its impact on various physiological systems.</p></sec><sec id="sec3dot5dot4-pharmacy-13-00007"><title>3.5.4. Mechanism of Action</title><p>Cathinone, the main active compound in khat, primarily acts at the nervous system level by inhibiting dopamine-specific transporters (DAT) and serotonin-specific transporters (SERT). At the dopaminergic level, cathinone has a slightly lower capacity than amphetamine to release tritiated dopamine (3H-DA). However, because it inhibits catecholamine transporters, much like methamphetamine, it is considered similar to it [<xref rid="B161-pharmacy-13-00007" ref-type="bibr">161</xref>].</p></sec><sec id="sec3dot5dot5-pharmacy-13-00007"><title>3.5.5. Future Perspectives on Public Health</title><p>Looking toward the future implications for public health, addressing the growing concerns surrounding khat use and its associated health risks is crucial. Studies have highlighted the need for further research into the pharmacological and medical aspects of khat, considering its widespread social use and potential for substance-related disorders [<xref rid="B162-pharmacy-13-00007" ref-type="bibr">162</xref>]. Moreover, investigations into the development of synthetic cathinone, derived from khat, as substances of abuse have raised concerns about the toxicology and classification of these compounds, necessitating regulatory measures to mitigate their harmful effects. The emergence of designer drugs based on cathinone derivatives underscores the importance of monitoring and regulating the use of such substances to safeguard public health [<xref rid="B163-pharmacy-13-00007" ref-type="bibr">163</xref>].</p></sec><sec id="sec3dot5dot6-pharmacy-13-00007"><title>3.5.6. General Conclusion</title><p>Overall, <italic toggle="yes">Catha edulis</italic> holds a complex position in society, being valued by consumers for its stimulant properties while also posing significant health risks. Its historical significance, contemporary consumption trends, chemical compounds responsible for its effects, negative health implications, and future implications for public health all contribute to a nuanced understanding of this plant. As further research sheds light on the pharmacological, toxicological, and societal aspects of khat use, it is essential to balance cultural practices with public health considerations to ensure the well-being of individuals in communities where khat consumption is prevalent.</p></sec></sec><sec id="sec3dot6-pharmacy-13-00007"><title>3.6. Salvia divinorum (Holy Sage)</title><sec id="sec3dot6dot1-pharmacy-13-00007"><title>3.6.1. Historical Background</title><p><italic toggle="yes">Salvia divinorum</italic>, commonly known as holy sage, is a perennial plant from the Lamiaceae family, native to Mexico, particularly Oaxaca. It is distinguished among Salvia species by containing salvinorin A, a potent psychoactive compound responsible for its hallucinogenic properties [<xref rid="B164-pharmacy-13-00007" ref-type="bibr">164</xref>]. Initially used by the Mazatec people for spiritual and medicinal purposes, <italic toggle="yes">Salvia divinorum</italic> has gained popularity globally for recreational use, often as a substitute for marijuana [<xref rid="B165-pharmacy-13-00007" ref-type="bibr">165</xref>].</p></sec><sec id="sec3dot6dot2-pharmacy-13-00007"><title>3.6.2. Drug Policy</title><p>In the United States, to date, according to the Drug Enforcement Administration (DEA), possession and distribution of <italic toggle="yes">Salvia divinorum</italic> is not prohibited. However, a few countries, such as Australia, Italy, Denmark, and South Korea, have in recent years passed laws banning possession of the plant, classifying it as a Class I substance with a high potential for abuse and no accepted medical use [<xref rid="B166-pharmacy-13-00007" ref-type="bibr">166</xref>].</p></sec><sec id="sec3dot6dot3-pharmacy-13-00007"><title>3.6.3. Pharmacological Properties and Health Implications</title><p>Salvinorin A, the primary active ingredient in <italic toggle="yes">Salvia divinorum</italic>, acts as a highly selective kappa-opioid receptor agonist, leading to hallucinogenic effects such as visual distortions and synesthesia [<xref rid="B167-pharmacy-13-00007" ref-type="bibr">167</xref>].</p><p>Studies on the pharmacokinetics and pharmacodynamics of salvinorin A have provided insights into its absorption, distribution, metabolism, and excretion in the human body [<xref rid="B168-pharmacy-13-00007" ref-type="bibr">168</xref>]. Salvinorin A&#x02019;s impact extends beyond the central nervous system, affecting colonic transit and neurogenic ion transport, suggesting a role in gastrointestinal motility regulation [<xref rid="B169-pharmacy-13-00007" ref-type="bibr">169</xref>]. Furthermore, its inhibitory effects on enteric cholinergic transmission point to potential therapeutic applications in gastrointestinal [<xref rid="B165-pharmacy-13-00007" ref-type="bibr">165</xref>]. Despite its intriguing pharmacological profile, the recreational use of <italic toggle="yes">Salvia divinorum</italic> poses risks. Documented effects of salvinorin A in humans include transient but intense alterations in perception and cognition [<xref rid="B170-pharmacy-13-00007" ref-type="bibr">170</xref>]. Concerns about its abuse potential, impact on the central nervous system, and behavioral effects highlight the importance of caution in its consumption [<xref rid="B171-pharmacy-13-00007" ref-type="bibr">171</xref>]. The availability of <italic toggle="yes">Salvia divinorum</italic> through online sources has raised concerns about misuse among adolescents and associated toxicological implications [<xref rid="B172-pharmacy-13-00007" ref-type="bibr">172</xref>].</p></sec><sec id="sec3dot6dot4-pharmacy-13-00007"><title>3.6.4. Mechanism of Action</title><p>Salvinorin A is responsible for the mechanism of action. This compound binds to the amino acids of the kappa-opioid receptor (KOP) through hydrophobic bonds, leading to analgesia. Salvinorin A is a selective agonist of the KOP, and its activation produces sedation and euphoria by increasing norepinephrine levels while inhibiting dopamine and serotonin. Additionally, salvinorin A interacts with the dopamine transporter (DAT) via KOP, forming heterodimers that interact with cannabinoid CB1 receptors [<xref rid="B173-pharmacy-13-00007" ref-type="bibr">173</xref>].</p></sec><sec id="sec3dot6dot5-pharmacy-13-00007"><title>3.6.5. Future Perspectives on Public Health</title><p>Understanding the effects of <italic toggle="yes">Salvia divinorum</italic> is crucial for public health. Research focusing on the molecular mechanisms of salvinorin A, its long-term impact on cognitive function and mental health, and the development of safer alternatives for pain management can inform regulatory measures and harm reduction strategies [<xref rid="B174-pharmacy-13-00007" ref-type="bibr">174</xref>,<xref rid="B175-pharmacy-13-00007" ref-type="bibr">175</xref>].</p></sec><sec id="sec3dot6dot6-pharmacy-13-00007"><title>3.6.6. General Conclusion</title><p>Overall, <italic toggle="yes">Salvia divinorum</italic>, with its hallmark compound salvinorin A, holds a concerning place among recreational substances. Its historical significance, contemporary use patterns, and pharmacological properties require a comprehensive approach to address its consumption, considering its benefits and risks. A balanced perspective can guide further scientific inquiry and societal well-being by exploring its chemical compounds, mechanisms of action, negative consequences, and future public health implications.</p></sec></sec><sec id="sec3dot7-pharmacy-13-00007"><title>3.7. Lophophora williamsii (Peyote)</title><sec id="sec3dot7dot1-pharmacy-13-00007"><title>3.7.1. Historical Background</title><p><italic toggle="yes">Lophophora williamsii</italic>, commonly known as peyote, is a small, spineless cactus belonging to the Cactaceae family [<xref rid="B176-pharmacy-13-00007" ref-type="bibr">176</xref>]. This cactus is primarily found in dry regions from Central Mexico to Texas, particularly along the Rio Grande [<xref rid="B177-pharmacy-13-00007" ref-type="bibr">177</xref>]. It holds significant historical and cultural importance, especially among indigenous peoples of North America. The plant contains various biologically active alkaloids, with mescaline being the most well-known and studied compound [<xref rid="B178-pharmacy-13-00007" ref-type="bibr">178</xref>]. Mescaline, a phenethylamine compound, is the primary psychoactive component responsible for the narcotic and recreational effects associated with peyote consumption [<xref rid="B179-pharmacy-13-00007" ref-type="bibr">179</xref>]. Despite its long history of use in spiritual and healing rituals, the exact mechanisms through which mescaline exerts its psychoactive effects remain incompletely understood [<xref rid="B180-pharmacy-13-00007" ref-type="bibr">180</xref>].</p></sec><sec id="sec3dot7dot2-pharmacy-13-00007"><title>3.7.2. Drug Policy</title><p>Peyote is not fully legalized, with restrictions on its use still in place. Soldiers in Vietnam were using peyote in the war at the same time as the number of drug-related deaths was rising worldwide. Since the 1970s, peyote has been considered a high-risk plant for health, being classified as a category one substance with a high risk of abuse. However, in 1994, following protests by Indigenous Americans, its use was regulated for religious purposes only [<xref rid="B181-pharmacy-13-00007" ref-type="bibr">181</xref>].</p></sec><sec id="sec3dot7dot3-pharmacy-13-00007"><title>3.7.3. Pharmacological Properties and Health Implications</title><p>Peyote has been traditionally used for millennia in spiritual and folk healing rituals, reflecting its deep-rooted historical significance [<xref rid="B182-pharmacy-13-00007" ref-type="bibr">182</xref>]. The plant&#x02019;s psychoactive properties have intrigued researchers, leading to investigations into its chemical composition and structure&#x02013;activity relationships [<xref rid="B183-pharmacy-13-00007" ref-type="bibr">183</xref>]. Studies have highlighted the presence of mescaline in high concentrations in <italic toggle="yes">Lophophora williamsii</italic>, emphasizing its role as a potent hallucinogen [<xref rid="B184-pharmacy-13-00007" ref-type="bibr">184</xref>]. Additionally, the identification of peyote based on morphological differences, mescaline content, and genetic sequences has furthered our understanding of this plant and its distinct species [<xref rid="B185-pharmacy-13-00007" ref-type="bibr">185</xref>].</p><p>The consumption trends surrounding <italic toggle="yes">Lophophora williamsii</italic> have evolved, with the plant being recognized for its psychoactive properties and potential therapeutic benefits. The chemical compounds found in <italic toggle="yes">Lophophora williamsii</italic>, particularly mescaline, play a pivotal role in inducing hallucinogenic effects that alter perception, time sense, and visual phenomena upon consumption [<xref rid="B186-pharmacy-13-00007" ref-type="bibr">186</xref>,<xref rid="B187-pharmacy-13-00007" ref-type="bibr">187</xref>]. While peyote has been historically used in cultural and religious contexts, contemporary interest in its recreational use has raised concerns about its negative effects on health [<xref rid="B152-pharmacy-13-00007" ref-type="bibr">152</xref>]. The consumption of <italic toggle="yes">Lophophora williamsii</italic> provides feelings of euphoria and relaxation, which may appeal to individuals seeking relief from stress and negative emotions. Its reported ability to enhance creativity and introspection has made it popular among artists and spiritual seekers. However, it is important to note that repeated use of peyote can lead to psychological dependence, especially in individuals who use it to escape reality or cope with emotional distress [<xref rid="B180-pharmacy-13-00007" ref-type="bibr">180</xref>,<xref rid="B184-pharmacy-13-00007" ref-type="bibr">184</xref>,<xref rid="B188-pharmacy-13-00007" ref-type="bibr">188</xref>].</p></sec><sec id="sec3dot7dot4-pharmacy-13-00007"><title>3.7.4. Mechanism of Action</title><p>Mescaline, the primary active alkaloid in peyote, acts as an agonist of 5-HT2 receptors in the brain and blood vessels. By activating these receptors, mescaline stimulates phospholipase C via Gq proteins, generating chemical signals and releasing Ca&#x000b2;&#x0207a; ions from the endoplasmic reticulum. In addition, due to its interaction with neuronal serotonergic processes, mescaline may, depending on dose, reduce or increase levels of 5-HIAA, the primary metabolite of serotonin [<xref rid="B179-pharmacy-13-00007" ref-type="bibr">179</xref>].</p></sec><sec id="sec3dot7dot5-pharmacy-13-00007"><title>3.7.5. Future Perspectives on Public Health</title><p>Despite its cultural significance and potential therapeutic properties, the overharvesting and habitat loss of <italic toggle="yes">Lophophora williamsii</italic> pose significant threats to its survival in the wild [<xref rid="B189-pharmacy-13-00007" ref-type="bibr">189</xref>]. As researchers continue to explore the pharmacological and toxicological aspects of peyote, there is a growing need to address the implications of its recreational use on public health. Understanding the mechanisms of action of mescaline and other alkaloids present in <italic toggle="yes">Lophophora williamsii</italic> is crucial for developing harm reduction strategies and promoting safe consumption practices [<xref rid="B190-pharmacy-13-00007" ref-type="bibr">190</xref>].</p></sec><sec id="sec3dot7dot6-pharmacy-13-00007"><title>3.7.6. General Conclusion</title><p>Overall, <italic toggle="yes">Lophophora williamsii</italic>, specifically peyote, stands out as a plant with rich historical significance, complex chemical composition, and diverse consumption trends. While its psychoactive properties have captivated researchers and enthusiasts alike, the need to balance cultural traditions with public health concerns remains paramount. Further research into the pharmacology, chemistry, and conservation of <italic toggle="yes">Lophophora williamsii</italic> is essential to ensure its sustainable use and preservation for future generations.</p></sec></sec><sec id="sec3dot8-pharmacy-13-00007"><title>3.8. Banisteriopsis caapi (Soul Vine)</title><sec id="sec3dot8dot1-pharmacy-13-00007"><title>3.8.1. Historical Background</title><p><italic toggle="yes">Banisteriopsis caapi</italic>, a plant native to the Amazon basin, is historically and currently significant for its use in recreational and narcotic contexts. Belonging to the Malpighiaceae family, this plant is a key ingredient in the preparation of the psychoactive brew known as ayahuasca, which is traditionally used in religious ceremonies and is increasingly popular globally [<xref rid="B191-pharmacy-13-00007" ref-type="bibr">191</xref>]. The psychoactive effects of ayahuasca are attributed to the combination of <italic toggle="yes">Banisteriopsis caapi</italic>, containing &#x003b2;-carboline alkaloids like harmine, harmaline, and tetrahydroharmine, and <italic toggle="yes">Psychotria viridis</italic>, which provides the hallucinogenic compound <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyltryptamine (DMT) [<xref rid="B192-pharmacy-13-00007" ref-type="bibr">192</xref>].</p></sec><sec id="sec3dot8dot2-pharmacy-13-00007"><title>3.8.2. Drug Policy</title><p>The regulations surrounding ayahuasca legislation are highly controversial, requiring close monitoring, although the primary active substance, DMT, was classified in 1971 as a Category I drug. Despite its addictive potential, in 2006, the Religious Freedom Restoration Act (RFRA) was passed, which states that ayahuasca can only be used for religious ceremonial purposes in America and Canada [<xref rid="B193-pharmacy-13-00007" ref-type="bibr">193</xref>].</p></sec><sec id="sec3dot8dot3-pharmacy-13-00007"><title>3.8.3. Pharmacological Properties and Health Implications</title><p>Understanding the chemical composition of <italic toggle="yes">Banisteriopsis caapi</italic> is crucial to understanding its effects. The plant contains &#x003b2;-carbolines, such as harmine and harmaline, which act as potent monoamine oxidase inhibitors (MAOIs) [<xref rid="B194-pharmacy-13-00007" ref-type="bibr">194</xref>]. These compounds are essential in the pharmacological actions of ayahuasca, with harmine specifically inhibiting protein kinase DYRK1A and interfering with neurite formation, indicating its impact on neural processes [<xref rid="B195-pharmacy-13-00007" ref-type="bibr">195</xref>]. Additionally, <italic toggle="yes">Banisteriopsis caapi</italic> has been found to stimulate adult neurogenesis in vitro, suggesting potential neuroprotective and regenerative properties [<xref rid="B196-pharmacy-13-00007" ref-type="bibr">196</xref>].</p><p>The consumption trends of <italic toggle="yes">Banisteriopsis caapi</italic> and ayahuasca have gained popularity in both traditional and contemporary contexts. The plant&#x02019;s alkaloids, particularly the &#x003b2;-carbolines, inhibit monoamine oxidase and activate the 5-HT 2A receptor, leading to hallucinatory experiences in users [<xref rid="B197-pharmacy-13-00007" ref-type="bibr">197</xref>]. Furthermore, <italic toggle="yes">Banisteriopsis caapi</italic> has been researched for potential therapeutic applications in neurodegenerative disorders like Parkinson&#x02019;s disease, with its chemical profile showing promise in treating such conditions [<xref rid="B198-pharmacy-13-00007" ref-type="bibr">198</xref>].</p><p>Despite its potential benefits, the excessive consumption of <italic toggle="yes">Banisteriopsis caapi</italic> and ayahuasca is not without negative effects. Therefore, caution should be exercised regarding the long-term and recreational use of <italic toggle="yes">Banisteriopsis caapi</italic> due to its potential adverse effects on cardiovascular health and cognitive functions [<xref rid="B192-pharmacy-13-00007" ref-type="bibr">192</xref>]. It is essential to note that the plant&#x02019;s alkaloids can have intense cardiovascular effects when used intravenously in large doses [<xref rid="B199-pharmacy-13-00007" ref-type="bibr">199</xref>]. Additionally, the synergistic interaction of &#x003b2;-carbolines and <italic toggle="yes">N</italic>, <italic toggle="yes">N</italic>-dimethyltryptamine in <italic toggle="yes">Banisteriopsis caapi</italic> may impact cognitive thinking styles and affect, potentially leading to ego dissolution [<xref rid="B200-pharmacy-13-00007" ref-type="bibr">200</xref>,<xref rid="B201-pharmacy-13-00007" ref-type="bibr">201</xref>]. Moreover, the &#x003b2;-carboline alkaloids present in <italic toggle="yes">Banisteriopsis caapi</italic> have been associated with mutagenicity, raising concerns about the safety of prolonged or excessive consumption [<xref rid="B202-pharmacy-13-00007" ref-type="bibr">202</xref>].</p></sec><sec id="sec3dot8dot4-pharmacy-13-00007"><title>3.8.4. Future Perspectives on Public Health</title><p>Looking ahead, the future implications for public health regarding the recreational and narcotic use of <italic toggle="yes">Banisteriopsis caapi</italic> are multifaceted. While research indicates the therapeutic potential of this plant in treating neurological disorders, comprehensive studies on its long-term effects and safety profile are needed [<xref rid="B203-pharmacy-13-00007" ref-type="bibr">203</xref>]. Public health initiatives should focus on promoting responsible use, conducting further research on its pharmacological properties, and raising awareness about the potential risks associated with its consumption.</p></sec><sec id="sec3dot8dot5-pharmacy-13-00007"><title>3.8.5. General Conclusion</title><p>Overall, <italic toggle="yes">Banisteriopsis caapi</italic> is a plant of great significance due to its historical use in traditional rituals and its contemporary relevance in recreational and narcotic contexts. The chemical compounds in this plant, particularly the &#x003b2;-carbolines, play a crucial role in its psychoactive effects and potential therapeutic applications. However, the adverse effects and safety concerns associated with its consumption highlight the importance of continued research and public health measures to ensure the safe and informed use of <italic toggle="yes">Banisteriopsis caapi</italic>.</p></sec></sec><sec id="sec3dot9-pharmacy-13-00007"><title>3.9. Datura stramonium (Devil&#x02019;s Trumpet)</title><sec id="sec3dot9dot1-pharmacy-13-00007"><title>3.9.1. Historical Background</title><p><italic toggle="yes">Datura stramonium</italic>, commonly known as Jimson weed or devil&#x02019;s trumpet, belongs to the Solanaceae family and is widely distributed across regions like Asia, the United States, Canada, and the West Indies [<xref rid="B204-pharmacy-13-00007" ref-type="bibr">204</xref>]. This plant has a rich historical significance, with references to its use dating back centuries for various purposes. In contemporary times, <italic toggle="yes">Datura stramonium</italic> has gained popularity for its recreational and narcotic effects, leading to concerning consumption trends. The plant contains various chemical compounds responsible for its effects, including alkaloids, saponins, tannins, flavonoids, and glycosides. These compounds contribute to the plant&#x02019;s pharmacological properties, making it attractive for recreational use [<xref rid="B205-pharmacy-13-00007" ref-type="bibr">205</xref>].</p></sec><sec id="sec3dot9dot2-pharmacy-13-00007"><title>3.9.2. Drug Policy</title><p>Due to limited safety and efficacy data, the Food and Drug Administration (FDA) does not consider the belladonna alkaloids present in <italic toggle="yes">Datura stramonium</italic> safe or effective in over-the-counter cough and cold preparations. In this regard, several states, including Tennessee, Connecticut, and New Jersey, have passed legislation to control the use of jimsonweed. In Tennessee, possessing jimsonweed seeds on school grounds is classified as a Class A misdemeanor. Connecticut includes <italic toggle="yes">Datura stramonium</italic> in the category of &#x0201c;restricted drugs or substances&#x0201d;. In New Jersey, the use or possession of stramonium preparations is illegal unless prescribed by a licensed physician. However, at the federal level, Jimsonweed (<italic toggle="yes">Datura stramonium</italic>) is not regulated as an illegal substance [<xref rid="B206-pharmacy-13-00007" ref-type="bibr">206</xref>].</p></sec><sec id="sec3dot9dot3-pharmacy-13-00007"><title>3.9.3. Pharmacological Properties and Health Implications</title><p>The mechanism behind the narcotic and recreational purposes of <italic toggle="yes">Datura stramonium</italic> lies in its alkaloid content, particularly hyoscyamine, scopolamine, and atropine. These alkaloids have potent psychoactive effects on the central nervous system, leading to visual hallucinations, agitation, lack of coordination, aggressiveness, delirium, drowsiness leading to comatose states, and other altered states of consciousness when consumed in sufficient quantities. The presence of these compounds makes <italic toggle="yes">Datura stramonium</italic> a sought-after plant for individuals seeking intense psychoactive experiences [<xref rid="B207-pharmacy-13-00007" ref-type="bibr">207</xref>,<xref rid="B208-pharmacy-13-00007" ref-type="bibr">208</xref>]. It is sometimes combined with tobacco to create a potent mixture for inhalation or smoking, resulting in psychoactive effects that can last for several days. These effects can pose potential dangers compared to other hallucinogens like LSD or psilocybin [<xref rid="B209-pharmacy-13-00007" ref-type="bibr">209</xref>].</p><p>However, the consumption of <italic toggle="yes">Datura stramonium</italic> for recreational or narcotic purposes is not without its risks. The plant is known to cause a range of adverse effects, including anticholinergic toxicity, which can manifest as dry mouth, blurred vision, tachycardia, urinary retention, and central nervous system disturbances [<xref rid="B210-pharmacy-13-00007" ref-type="bibr">210</xref>]. In severe cases, <italic toggle="yes">Datura stramonium</italic> poisoning can lead to coma, seizures, and even death, highlighting the severe consequences of its misuse [<xref rid="B211-pharmacy-13-00007" ref-type="bibr">211</xref>]. Additionally, <italic toggle="yes">Datura stramonium</italic> has been implicated in cases of acute renal failure, further underscoring the potential dangers associated with its consumption [<xref rid="B212-pharmacy-13-00007" ref-type="bibr">212</xref>].</p><p>Consumption of Datura seeds for their hallucinogenic properties has a long history, with Native Americans using them as a euphoric [<xref rid="B213-pharmacy-13-00007" ref-type="bibr">213</xref>]. Datura plants contain tropane alkaloids, particularly in their seeds, flowers, leaves, and roots, responsible for their hallucinogenic effects [<xref rid="B211-pharmacy-13-00007" ref-type="bibr">211</xref>]. These alkaloids can lead to severe anticholinergic effects, causing toxicity when any part of the plant is consumed [<xref rid="B212-pharmacy-13-00007" ref-type="bibr">212</xref>]. The intentional ingestion of Datura for its psychoactive effects has increased, especially among adolescents and youths [<xref rid="B213-pharmacy-13-00007" ref-type="bibr">213</xref>,<xref rid="B214-pharmacy-13-00007" ref-type="bibr">214</xref>]. The toxicity of Datura largely depends on the solvent used for extraction, with the polarity and non-polarity of the solvent being linked to the plant&#x02019;s toxicity [<xref rid="B215-pharmacy-13-00007" ref-type="bibr">215</xref>]. Furthermore, Datura could be consumed in various ways, including ingesting the seeds, flowers, or roots, which could lead to adverse physiological changes and severe anticholinergic reactions [<xref rid="B205-pharmacy-13-00007" ref-type="bibr">205</xref>,<xref rid="B216-pharmacy-13-00007" ref-type="bibr">216</xref>]. The plant&#x02019;s hallucinogenic properties have led to its use for substance abuse, with ingestion, usually of the seeds, being the most common route of exposure [<xref rid="B217-pharmacy-13-00007" ref-type="bibr">217</xref>]. Additionally, Datura producers have been known to create hallucination-inducing brews by boiling leaves and seeds, sometimes mixing Datura with other substances [<xref rid="B218-pharmacy-13-00007" ref-type="bibr">218</xref>].</p><p>The consumption of <italic toggle="yes">Datura stramonium</italic> seeds for hallucinogenic effects and other mind-altering effects is a practice that poses significant risks and dangers to individuals [<xref rid="B219-pharmacy-13-00007" ref-type="bibr">219</xref>]. Long-term consumption of Datura seeds has been associated with severe consequences, including the onset of paranoid schizophrenia, aggressive behavior, and altered states of consciousness [<xref rid="B93-pharmacy-13-00007" ref-type="bibr">93</xref>]. Additionally, <italic toggle="yes">Datura stramonium</italic> seed extracts have been found to exhibit toxicity affecting various organs such as the liver, kidney, heart, and brain, with mechanisms including lipid peroxidation contributing to oxidative stress in these organs [<xref rid="B215-pharmacy-13-00007" ref-type="bibr">215</xref>]. Furthermore, acute intoxication with <italic toggle="yes">Datura stramonium</italic> seeds can lead to symptoms such as coma, further highlighting the dangerous effects of this plant [<xref rid="B210-pharmacy-13-00007" ref-type="bibr">210</xref>].</p></sec><sec id="sec3dot9dot4-pharmacy-13-00007"><title>3.9.4. Mechanism of Action</title><p>Hyoscyamine, scopolamine, and atropine, the alkaloids found in D. stramonium, act on the nervous system by antagonizing the muscarinic receptors M2, M4, and M5 of acetylcholine. In the context of asthma, blocking these receptors induces bronchodilation. Additionally, these alkaloids can be used in the treatment of gliomas, as they can induce cell apoptosis and neutralize free radicals, thereby preventing oxidative stress [<xref rid="B220-pharmacy-13-00007" ref-type="bibr">220</xref>,<xref rid="B221-pharmacy-13-00007" ref-type="bibr">221</xref>].</p></sec><sec id="sec3dot9dot5-pharmacy-13-00007"><title>3.9.5. Future Perspectives on Public Health</title><p>Looking toward the future, the implications of <italic toggle="yes">Datura stramonium</italic> use for public health are significant. As the plant continues to be consumed for recreational purposes, there is a growing need for public health interventions to raise awareness about its dangers and regulate it [<xref rid="B204-pharmacy-13-00007" ref-type="bibr">204</xref>]. Education campaigns targeting at-risk populations, such as adolescents and young adults, could help prevent instances of <italic toggle="yes">Datura stramonium</italic> poisoning and associated health complications. Furthermore, healthcare providers should be trained to recognize the signs of Datura intoxication and provide appropriate medical care to affected individuals [<xref rid="B222-pharmacy-13-00007" ref-type="bibr">222</xref>].</p></sec><sec id="sec3dot9dot6-pharmacy-13-00007"><title>3.9.6. General Conclusion</title><p>Overall, <italic toggle="yes">Datura stramonium</italic> holds a complex position in society, with its historical significance, contemporary consumption trends, pharmacological mechanisms, chemical compounds, adverse effects, and public health implications all contributing to a nuanced understanding of this plant. While it may offer psychoactive experiences sought by some, the risks associated with its use cannot be overlooked. A balanced approach considering <italic toggle="yes">Datura stramonium</italic>&#x02019;s cultural significance and potential harms is essential for promoting public health and safety.</p></sec></sec><sec id="sec3dot10-pharmacy-13-00007"><title>3.10. Ipomoea violacea, Ipomoea tricolor (Morning Glory)</title><sec id="sec3dot10dot1-pharmacy-13-00007"><title>3.10.1. Historical Background</title><p>Ipomoea, a genus of flowering plants in the family Convolvulaceae, commonly known as morning glories, has a rich historical significance dating back to its traditional uses in various cultures for medicinal, recreational, and narcotic purposes. The genus includes several species like <italic toggle="yes">Ipomoea violacea</italic>, <italic toggle="yes">Ipomoea tricolor</italic>, and <italic toggle="yes">Ipomoea carnea</italic>. In contemporary times, Ipomoea species have gained attention for their psychoactive effects, with some being used as &#x0201c;herbal highs&#x0201d; due to their active principles. These plants are often easily accessible through online platforms, contributing to their widespread consumption [<xref rid="B93-pharmacy-13-00007" ref-type="bibr">93</xref>].</p></sec><sec id="sec3dot10dot2-pharmacy-13-00007"><title>3.10.2. Drug Policy</title><p>Although the authorities have made numerous efforts to stop the cultivation, possession, and use of drugs, the number of people and cases of drug users and deaths associated with them is still on the rise. Nigerian communities are using psychoactive plants such as Morning Glory for non-medical purposes, particularly in religious ceremonies. The state has legalized their use for recreational purposes only based on their low safety [<xref rid="B221-pharmacy-13-00007" ref-type="bibr">221</xref>].</p></sec><sec id="sec3dot10dot3-pharmacy-13-00007"><title>3.10.3. Pharmacological Properties and Health Implications</title><p>One of the key chemical compounds found in Ipomoea species that are responsible for their effects is resin glycosides such as tricolorin A [<xref rid="B223-pharmacy-13-00007" ref-type="bibr">223</xref>]. The plants also contain various chemical compounds that contribute to their biological activities, such as flavonoids and phenols [<xref rid="B224-pharmacy-13-00007" ref-type="bibr">224</xref>,<xref rid="B225-pharmacy-13-00007" ref-type="bibr">225</xref>]. Additionally, various phytochemical constituents present in Ipomoea species have been associated with anti-inflammatory, detoxification, and therapeutic activities, showcasing their potential in treating various diseases such as diabetes, hypertension, and inflammation. These diverse pharmacological activities highlight the versatility of Ipomoea plants in traditional medicine and alternative therapies [<xref rid="B226-pharmacy-13-00007" ref-type="bibr">226</xref>]. The presence of compounds like tetrasaccharides and pentasaccharide glycosides in Ipomoea roots has been linked to antimycobacterial activity, cytotoxicity, and effects on the central nervous system, indicating a complex interplay of bioactive components within these plants [<xref rid="B227-pharmacy-13-00007" ref-type="bibr">227</xref>].</p><p>While Ipomoea species offer a range of potential benefits, there are also adverse effects associated with their consumption. Studies have highlighted potential toxicity risks, especially when wild Ipomoea varieties are ingested, emphasizing the importance of properly identifying and understanding these plants to prevent adverse outcomes [<xref rid="B228-pharmacy-13-00007" ref-type="bibr">228</xref>]. Furthermore, compounds like tyrianthinic acids in certain Ipomoea species raise concerns about cytotoxicity and central nervous system effects, underscoring the need for cautious consumption [<xref rid="B227-pharmacy-13-00007" ref-type="bibr">227</xref>].</p></sec><sec id="sec3dot10dot4-pharmacy-13-00007"><title>3.10.4. Mechanism of Action</title><p>The hallucinogenic effects of Ipomoea are attributed to the presence of the ergine alkaloid d-lysergic acid amide (LSA). LSA is known to produce hallucinogenic and psychedelic effects when ingested [<xref rid="B229-pharmacy-13-00007" ref-type="bibr">229</xref>]. These effects are similar to those induced by other hallucinogens like LSD, psilocybin, and mescaline, which profoundly impact perception, cognition, and mood [<xref rid="B230-pharmacy-13-00007" ref-type="bibr">230</xref>]. The psychoactive properties of LSA are distinct from LSD and more akin to scopolamine [<xref rid="B231-pharmacy-13-00007" ref-type="bibr">231</xref>]. LSD has a complex mechanism of action, which is responsible for a wide range of effects. At the serotonergic level, it acts both on 5-HT1 receptors (5-HT1A, 5-HT1B, 5-HT1D), with an inhibitory effect, and on 5-HT2 receptors as a stimulator, being able to modify its effect. Through its agonist effect on 5-HT2A receptors, LSD is thus considered to be responsible for the hallucinogenic effects following administration of Ipomoea, but also of other substances in the class of phenethylamine and indolamine derivatives. At the dopaminergic level, LSD interacts with D1 and D2 receptors about 90 min after administration, while activation of serotonergic receptors occurs after about 30 min [<xref rid="B232-pharmacy-13-00007" ref-type="bibr">232</xref>].</p><p>Moreover, the alkaloids present in Ipomoea, such as ergine and ergometrine, are known to have psychoactive properties that contribute to the hallucinogenic experiences associated with consuming Ipomoea [<xref rid="B233-pharmacy-13-00007" ref-type="bibr">233</xref>].</p></sec><sec id="sec3dot10dot5-pharmacy-13-00007"><title>3.10.5. Future Perspectives on Public Health</title><p>Looking ahead, the future implications for public health concerning Ipomoea plants are multifaceted. On the one hand, the rich chemical diversity in these species offers opportunities for drug discovery and the development of novel therapeutic agents for various [<xref rid="B234-pharmacy-13-00007" ref-type="bibr">234</xref>]. However, the recreational and narcotic potential of certain Ipomoea species also pose challenges in terms of regulation, safety, and public awareness regarding their effects. As more research delves into Ipomoea plants&#x02019; pharmacological, toxicological, and ecological aspects, a comprehensive understanding of their benefits and risks will be crucial for informed decision-making in healthcare and regulatory frameworks [<xref rid="B233-pharmacy-13-00007" ref-type="bibr">233</xref>].</p></sec><sec id="sec3dot10dot6-pharmacy-13-00007"><title>3.10.6. General Conclusion</title><p>Overall, Ipomoea plants stand at the intersection of traditional medicine, recreational use, and scientific exploration, offering a complex tapestry of bioactive compounds with diverse effects on the human body. From their historical significance to contemporary consumption trends and future implications for public health, Ipomoea species continue to intrigue researchers and health professionals alike. By unraveling the mechanisms behind their narcotic and recreational properties, identifying key chemical compounds responsible for these effects, understanding the negative consequences of consumption, and exploring their potential in therapeutic applications, Ipomoea plants remain a subject of fascination and scrutiny in the realm of phytopharmacology.</p></sec></sec><sec id="sec3dot11-pharmacy-13-00007"><title>3.11. Nicotiana tabacum (Tobacco)</title><sec id="sec3dot11dot1-pharmacy-13-00007"><title>3.11.1. Historical Background</title><p><italic toggle="yes">Nicotiana tabacum</italic>, commonly known as tobacco, is a perennial herbaceous plant belonging to the Solanaceae family. It is an allotetraploid plant that evolved approximately 200,000 years ago through interspecific hybridization between the ancestors of <italic toggle="yes">Nicotiana sylvestris</italic> and <italic toggle="yes">Nicotiana tomentosiformis</italic> [<xref rid="B235-pharmacy-13-00007" ref-type="bibr">235</xref>]. This plant species has been cultivated for centuries for recreational and narcotic purposes. The consumption trends of tobacco have evolved over time, with recreational use primarily through smoking, chewing, vaping, and narcotic use due to the presence of nicotine, which acts as a stimulant affecting the central nervous system [<xref rid="B236-pharmacy-13-00007" ref-type="bibr">236</xref>].</p></sec><sec id="sec3dot11dot2-pharmacy-13-00007"><title>3.11.2. Drug Policy</title><p>The Tobacco Products Directive (TPD) was implemented by the European Union in 2014, and by 2021, all 27 Member States had adopted this law. Some regulations imposed on tobacco-related products include the requirement for e-cigarette leaflets with detailed information on usage, warnings, a maximum nicotine limit of 20 mg/mL, and child-resistant packaging. To date, following the implementation of this law, the number of neonatal and stillbirths caused by tobacco has dropped considerably by about 7%, demonstrating the importance of implementing such regulations worldwide [<xref rid="B237-pharmacy-13-00007" ref-type="bibr">237</xref>].</p></sec><sec id="sec3dot11dot3-pharmacy-13-00007"><title>3.11.3. Mechanism of Action</title><p>The mechanism behind the narcotic and recreational effects of <italic toggle="yes">Nicotiana tabacum</italic> primarily lies in its chemical composition. Nicotine, an alkaloid predominantly found in tobacco leaves, is the primary compound responsible for the addictive properties of [<xref rid="B238-pharmacy-13-00007" ref-type="bibr">238</xref>]. Additionally, other alkaloids present in tobacco, such as piperidine alkaloids, contribute to its physiological effects [<xref rid="B239-pharmacy-13-00007" ref-type="bibr">239</xref>]. The presence of terpenes, heavy metals, and alkaloids in <italic toggle="yes">Nicotiana tabacum</italic> further adds to its chemical complexity and diverse effects on the human body [<xref rid="B240-pharmacy-13-00007" ref-type="bibr">240</xref>].</p><p>Nicotine, the principal phytochemical in <italic toggle="yes">Nicotiana tabacum</italic>, is a well-known stimulant that affects various neurotransmitter systems in the brain, particularly the cholinergic system. It acts as an agonist at nicotinic acetylcholine receptors, leading to the release of neurotransmitters such as dopamine, norepinephrine, and serotonin. These neurotransmitters are associated with feelings of pleasure, alertness, and increased focus, contributing to the psychostimulant effects of nicotine [<xref rid="B241-pharmacy-13-00007" ref-type="bibr">241</xref>]. Moreover, the pyrrolidine ring of nicotine plays a crucial role in its stimulant properties [<xref rid="B242-pharmacy-13-00007" ref-type="bibr">242</xref>]. Nicotine, along with other alkaloids present in tobacco, influences the reward pathways in the brain, reinforcing the addictive nature of nicotine [<xref rid="B243-pharmacy-13-00007" ref-type="bibr">243</xref>]. Additionally, the alkaloids contained in <italic toggle="yes">Nicotiana tabacum</italic> are known to have psychoactive effects that can enhance cognitive function, mood, and arousal, making tobacco a sought-after recreational plant [<xref rid="B244-pharmacy-13-00007" ref-type="bibr">244</xref>].</p></sec><sec id="sec3dot11dot4-pharmacy-13-00007"><title>3.11.4. Pharmacological Properties and Health Implications</title><p>While <italic toggle="yes">Nicotiana tabacum</italic> has been widely consumed for recreational and narcotic purposes, it is crucial to acknowledge the adverse effects associated with its use. Tobacco consumption has been linked to various health issues, including but not limited to respiratory diseases, cardiovascular disorders, and an increased risk of cancer [<xref rid="B245-pharmacy-13-00007" ref-type="bibr">245</xref>]. The addictive nature of nicotine also poses challenges for individuals trying to quit tobacco use, leading to long-term dependency and withdrawal symptoms upon cessation [<xref rid="B244-pharmacy-13-00007" ref-type="bibr">244</xref>].</p></sec><sec id="sec3dot11dot5-pharmacy-13-00007"><title>3.11.5. Future Perspectives on Public Health</title><p>Looking toward the future, the implications of <italic toggle="yes">Nicotiana tabacum</italic> on public health remain a critical concern. With increasing awareness of the health risks associated with tobacco use, there is a growing need for comprehensive tobacco control measures to mitigate the negative impact on individuals and society as a whole. Public health campaigns, regulatory policies, and smoking cessation programs play a vital role in addressing the challenges posed by tobacco consumption [<xref rid="B245-pharmacy-13-00007" ref-type="bibr">245</xref>].</p></sec><sec id="sec3dot11dot6-pharmacy-13-00007"><title>3.11.6. General Conclusion</title><p>Overall, <italic toggle="yes">Nicotiana tabacum</italic>, with its long historical significance and complex chemical composition, continues to be a plant of interest for both recreational and narcotic purposes. Understanding the mechanisms behind its effects, the chemical compounds responsible, the negative consequences of consumption, and the future implications for public health is essential in shaping policies and interventions to address the challenges associated with tobacco use. By synthesizing research findings and staying informed about the latest developments in the field, stakeholders can work toward promoting healthier lifestyles and reducing the burden of tobacco-related diseases on individuals and communities.</p></sec></sec><sec id="sec3dot12-pharmacy-13-00007"><title>3.12. Mandragora officinarum (Mandrake)</title><sec id="sec3dot12dot1-pharmacy-13-00007"><title>3.12.1. Historical Background</title><p><italic toggle="yes">Mandragora officinarum</italic>, commonly known as Mandrake, is a perennial plant belonging to the Solanaceae family and is native to the eastern Mediterranean region. This plant has a rich historical significance, with mentions dating back to ancient times when it was used for various purposes, including medicinal and ritualistic practices. <italic toggle="yes">Mandragora officinarum</italic> contains potent active compounds such as scopolamine and atropine, which contribute to its narcotic and recreational effects [<xref rid="B246-pharmacy-13-00007" ref-type="bibr">246</xref>]. The plant has been traditionally associated with mystical and magical properties, often linked to witchcraft and folklore due to its psychoactive properties [<xref rid="B247-pharmacy-13-00007" ref-type="bibr">247</xref>].</p><p>Historically, the plant was used for its sedative and analgesic properties, often used in surgical procedures to relieve pain [<xref rid="B248-pharmacy-13-00007" ref-type="bibr">248</xref>]. However, due to its potent effects and potential toxicity, the use of <italic toggle="yes">Mandragora officinarum</italic> for sedative and analgesic properties purposes has become less common in modern times. Nevertheless, there is still a niche interest in exploring the psychoactive potential of this plant, especially in alternative medicine practices [<xref rid="B249-pharmacy-13-00007" ref-type="bibr">249</xref>].</p></sec><sec id="sec3dot12dot2-pharmacy-13-00007"><title>3.12.2. Mechanism of Action</title><p>In contemporary times, <italic toggle="yes">Mandragora officinarum</italic> continues to be of interest due to its potential for recreational and narcotic purposes. The plant has been studied for its chemical composition, with compounds like nolides being isolated, contributing to its pharmacological effects [<xref rid="B250-pharmacy-13-00007" ref-type="bibr">250</xref>]. Additionally, alkaloids like atropine, scopolamine, and hyoscyamine have been identified in <italic toggle="yes">Mandragora officinarum</italic>, which are known for their psychoactive properties [<xref rid="B251-pharmacy-13-00007" ref-type="bibr">251</xref>]. Alkaloids like atropine and scopolamine act on the central nervous system, producing sedative and hallucinogenic effects [<xref rid="B251-pharmacy-13-00007" ref-type="bibr">251</xref>], while anolides have been associated with anti-inflammatory and neuroprotective properties, which may contribute to their recreational potential [<xref rid="B250-pharmacy-13-00007" ref-type="bibr">250</xref>]. These compounds interact with various receptors in the body, leading to the psychoactive effects observed upon consumption of <italic toggle="yes">Mandragora officinarum</italic>.</p></sec><sec id="sec3dot12dot3-pharmacy-13-00007"><title>3.12.3. Pharmacological Properties and Health Implications</title><p>Despite its potential benefits, the consumption of <italic toggle="yes">Mandragora officinarum</italic> for recreational and narcotic purposes is not without risks. The plant contains potent compounds that can adversely affect human health, especially when consumed in high quantities or inappropriately. Studies have shown that prolonged use of <italic toggle="yes">Mandragora officinarum</italic> can lead to hepatotoxicity and other serious health complications. Additionally, the plant&#x02019;s psychoactive properties can pose risks of addiction and overdose if not used cautiously [<xref rid="B250-pharmacy-13-00007" ref-type="bibr">250</xref>].</p></sec><sec id="sec3dot12dot4-pharmacy-13-00007"><title>3.12.4. Future Perspectives on Public Health</title><p>Looking toward the future, the implications of <italic toggle="yes">Mandragora officinarum</italic> for public health remain a topic of concern. While the plant has a long history of traditional use, its recreational and narcotic potential raises questions about regulation and safety. Public health authorities need to be aware of the risks associated with the consumption of <italic toggle="yes">Mandragora officinarum</italic> and provide guidance on its responsible use. Further research is needed to understand better the pharmacological effects and toxicological profile of this plant to ensure the safety of individuals who may be inclined to use it for recreational purposes [<xref rid="B251-pharmacy-13-00007" ref-type="bibr">251</xref>].</p></sec><sec id="sec3dot12dot5-pharmacy-13-00007"><title>3.12.5. General Conclusion</title><p>Overall, <italic toggle="yes">Mandragora officinarum</italic>, with its historical significance and potent chemical composition, presents a complex picture when it comes to its recreational and narcotic potential. While the plant has been traditionally revered for its mystical properties, its modern-day consumption trends raise important safety and public health considerations. Understanding the mechanisms through which <italic toggle="yes">Mandragora officinarum</italic> exerts its effects, the chemical compounds responsible for its psychoactive properties, the associated adverse effects of consumption, and the future implications for public health are crucial in navigating the use of this plant in recreational and narcotic contexts. Vigilance, regulation, and further research are essential to ensure that the recreational use of <italic toggle="yes">Mandragora officinarum</italic> is approached with caution and awareness of its potential risks.</p><p><xref rid="pharmacy-13-00007-t001" ref-type="table">Table 1</xref> outlines the most commonly used plants for recreational and narcotic purposes, along with the associated phytocompounds. The table includes the plant&#x02019;s scientific name, common name, plant family, used parts, and the specific phytocompounds responsible for the effects. This information provides a comprehensive overview of the botanical sources and chemical constituents utilized for recreational and narcotic purposes, aiding in understanding the pharmacological basis of these plants&#x02019; effects.</p></sec></sec></sec><sec id="sec4-pharmacy-13-00007"><title>4. Popularity, Availability, Effects, and Risks of Medication and Substance Abuse</title><sec id="sec4dot1-pharmacy-13-00007"><title>4.1. Popularity and Availability of Medication and Substance Abuse</title><p>The analysis of consumption patterns, coupled with the legislative developments surrounding psychoactive substances, provides valuable insights into the global prevalence and dissemination of these substances. The ramifications of the legalization of both medicinal and recreational cannabis remain ambiguous within the current discourse. Nevertheless, legalization has engendered a surge in market activity characterized by a proliferation of retail outlets [<xref rid="B252-pharmacy-13-00007" ref-type="bibr">252</xref>]. Notably, in Canada, the pricing dynamics of recreational cannabis have been scrutinized. Research indicates that the cost of a gram of marijuana ranges from USD 5 to USD 14, with pricing differentials attributed to product quality and geographical location [<xref rid="B253-pharmacy-13-00007" ref-type="bibr">253</xref>]. The affordability of cannabis has facilitated access for individuals from socioeconomically disadvantaged backgrounds. Initially, price hikes were contemplated as a deterrent to consumption; however, this strategy was rescinded to mitigate the incentivization of illicit, lower-priced cannabis products [<xref rid="B254-pharmacy-13-00007" ref-type="bibr">254</xref>]. The proliferation of retail establishments has inadvertently fostered a misconception that cannabis consumption carries minimal risks [<xref rid="B255-pharmacy-13-00007" ref-type="bibr">255</xref>]. Countries such as Spain and the Netherlands have adopted distinctive approaches to accommodate and regulate cannabis consumption. Spain has instituted Cannabis Social Clubs, which are dedicated to the legal cultivation and communal use of marijuana. Similarly, Amsterdam has established coffee shops that serve as venues for the controlled consumption of cannabis [<xref rid="B256-pharmacy-13-00007" ref-type="bibr">256</xref>,<xref rid="B257-pharmacy-13-00007" ref-type="bibr">257</xref>].</p><p>Tobacco, a widely consumed legal substance, is ubiquitously available globally and retailed in local convenience stores, gas stations, and specialized tobacco outlets [<xref rid="B9-pharmacy-13-00007" ref-type="bibr">9</xref>,<xref rid="B258-pharmacy-13-00007" ref-type="bibr">258</xref>]. The accessibility of tobacco products in these retail establishments poses a significant challenge, as their commercial presence exerts a direct influence on the behavior of smokers. The unrestricted availability of tobacco products serves as a potent temptation for individuals who smoke, thereby impeding efforts toward smoking cessation. Moreover, marketing strategies employed by tobacco companies often target vulnerable populations, strategically siting cigarettes in easily accessible locations frequented by the target demographic [<xref rid="B259-pharmacy-13-00007" ref-type="bibr">259</xref>,<xref rid="B260-pharmacy-13-00007" ref-type="bibr">260</xref>]. In addition to physical stores, tobacco products are equally prevalent online, further extending their reach to consumers. The marketing tactics utilized in online retail spaces have also played a pivotal role in shaping consumer preferences by introducing a variety of flavors to attract and retain customers. This diversification of product offerings through flavor enhancement has been instrumental in expanding tobacco companies&#x02019; customer base, thereby perpetuating tobacco product consumption [<xref rid="B261-pharmacy-13-00007" ref-type="bibr">261</xref>].</p><p>When examining the landscape of opioid availability, it becomes apparent that these substances originate from diverse channels. They may be acquired through legitimate means, such as a valid prescription from a healthcare professional or illicit avenues involving unauthorized procurement of pain-relieving medications [<xref rid="B262-pharmacy-13-00007" ref-type="bibr">262</xref>]. The dispensation of opioid prescriptions is typically reserved for cases where deemed essential, with established protocols in place to govern their appropriate administration. Nevertheless, individuals belonging to high-risk cohorts may engage in deceptive practices to manipulate prescribers into authorizing opioid medications, resorting to subterfuge if initial attempts prove unsuccessful, often resorting to illicit means of acquisition [<xref rid="B263-pharmacy-13-00007" ref-type="bibr">263</xref>,<xref rid="B264-pharmacy-13-00007" ref-type="bibr">264</xref>]. The dissemination of opioids in over-the-counter (OTC) formulations is notably observed in instances involving codeine and dextromethorphan [<xref rid="B265-pharmacy-13-00007" ref-type="bibr">265</xref>]. Notably, products containing codeine have garnered significant popularity in various nations, including Italy, Poland, the United Kingdom, Spain, Germany, and the United States [<xref rid="B266-pharmacy-13-00007" ref-type="bibr">266</xref>]. The literature documents instances of substance abuse and addiction stemming from the misuse of OTC medications, underscoring the potential risks associated with their unregulated availability [<xref rid="B267-pharmacy-13-00007" ref-type="bibr">267</xref>]. Despite the widespread accessibility of these substances, certain countries have taken regulatory measures to curtail the sale of OTC products containing codeine, exemplified by Australia and France, in a bid to mitigate associated hazards [<xref rid="B268-pharmacy-13-00007" ref-type="bibr">268</xref>].</p><p>Classified as a controlled substance, cocaine exhibits limited availability within the realm of illicit commerce. Noteworthy source nations implicated in the trade of this substance include Colombia, Mexico, and Afghanistan [<xref rid="B269-pharmacy-13-00007" ref-type="bibr">269</xref>,<xref rid="B270-pharmacy-13-00007" ref-type="bibr">270</xref>]. The production of narcotics transpires within these source countries, subsequently necessitating their transportation to intermediary transit nations. The market value of cocaine is intrinsically linked to its accessibility. Source countries, characterized by extensive manufacturing operations, typically offer this substance at a comparatively lower cost. Conversely, the price per kilogram escalates significantly, potentially up to a hundredfold, upon reaching the importing nations [<xref rid="B270-pharmacy-13-00007" ref-type="bibr">270</xref>].</p><p>Understanding the multifaceted dimensions of substance availability is paramount in formulating effective interventions and policy changes to combat substance abuse. By delving into the various facets of substance availability, policymakers and stakeholders can gain a comprehensive insight into the intricate dynamics that underlie substance abuse trends. This nuanced understanding serves as a foundational basis for the strategic recalibration of existing laws and regulations, with the ultimate goal of curbing the prevalence of substance abuse within society. In the realm of substance abuse prevention and control, a thorough comprehension of the availability of different substances is indispensable. This comprehension extends beyond mere recognition of the physical presence of substances within communities to encompass a holistic grasp of the socioeconomic, cultural, and environmental factors that contribute to their accessibility. By dissecting the intricate web of factors that influence substance availability, policymakers can tailor interventions that address the root causes of substance abuse, thereby fostering more sustainable and impactful outcomes in the realm of public health and safety.</p></sec><sec id="sec4dot2-pharmacy-13-00007"><title>4.2. Effects and Risks of Medication and Substance Abuse</title><p>Substances of abuse can alter the consciousness of individuals who consume them. The psychoactive properties of these substances can elicit a state of euphoria [<xref rid="B271-pharmacy-13-00007" ref-type="bibr">271</xref>]. For instance, cocaine exerts stimulant effects on the central nervous system, leading to heightened energy levels and enhanced cognitive focus [<xref rid="B272-pharmacy-13-00007" ref-type="bibr">272</xref>]. Similarly, tobacco is recognized for its ability to induce a transient surge in energy [<xref rid="B271-pharmacy-13-00007" ref-type="bibr">271</xref>]. In the case of cannabis, its consumption can impact motor coordination and cognitive judgment. Common experiences associated with marijuana use include feelings of anxiety, paranoia, and increased appetite [<xref rid="B272-pharmacy-13-00007" ref-type="bibr">272</xref>,<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>].</p><p>Respiratory depression represents a critical adverse effect associated with opioid misuse, culminating in apnea that may ultimately lead to cardiac arrest. The onset of symptoms varies, typically manifesting within minutes following opioid administration, contingent upon the route of delivery. Concurrent administration of cocaine with opioids has been identified as a factor exacerbating the likelihood of overdose [<xref rid="B274-pharmacy-13-00007" ref-type="bibr">274</xref>]. Hyperalgesia emerges as an unfavorable response to opioid therapy, predisposing individuals to addiction. This phenomenon may be misconstrued by both healthcare providers and patients as disease progression, prompting an escalation in dosage [<xref rid="B68-pharmacy-13-00007" ref-type="bibr">68</xref>].</p><p>The cardiac implications of cocaine use can manifest acutely following ingestion or may become apparent following prolonged exposure. Acute cardiovascular manifestations of cocaine consumption include elevated blood pressure, increased heart rate, and, in severe instances, coronary artery spasms that can precipitate myocardial infarction. Chronic cocaine use is linked to a spectrum of cardiac complications, impacting various aspects of cardiac function, with non-ischemic cardiomyopathy emerging as a notable consequence. Research has established a correlation between cocaine abuse and conditions such as myocarditis, left ventricular hypertrophy, and heart failure [<xref rid="B275-pharmacy-13-00007" ref-type="bibr">275</xref>,<xref rid="B276-pharmacy-13-00007" ref-type="bibr">276</xref>]. The onset of the desired effects sought by users typically occurs within 5 min of administration, with peak effects typically observed around 30 min post-administration [<xref rid="B272-pharmacy-13-00007" ref-type="bibr">272</xref>]. The morbidity and mortality rates among individuals who smoke are primarily attributed to cardiovascular diseases and cancer. Smoking-induced oxidative damage is identified as the primary etiological factor contributing to the development of various types of cancer. While lung cancer stands out as the most prevalent consequence, smoking significantly influences the incidence of cancer affecting the upper and lower gastrointestinal tract as well as the urogenital system [<xref rid="B271-pharmacy-13-00007" ref-type="bibr">271</xref>,<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>].</p><p>The occurrence of sudden death among individuals using cannabis is likely associated with cardiovascular events [<xref rid="B274-pharmacy-13-00007" ref-type="bibr">274</xref>]. Due to the legal restrictions on cannabis in certain regions, the body of research in this area remains somewhat inconclusive, although certain effects of cannabis use have been identified. Reports indicate that cannabis consumption can lead to impaired verbal and working memory, as well as potential alterations in brain function; however, the variability of these findings is influenced by factors such as the frequency of exposure and the concurrent use of substances like tobacco or cannabidiol [<xref rid="B277-pharmacy-13-00007" ref-type="bibr">277</xref>]. Furthermore, the respiratory issues observed in cannabis users are often attributed to the combined use of tobacco and cannabis [<xref rid="B278-pharmacy-13-00007" ref-type="bibr">278</xref>]. The effects of cannabis consumption typically manifest within approximately 10 min. Research has shown that detectable levels of tetrahydrocannabinol (THC) can persist in the bloodstream for up to 1&#x02013;2 days in occasional users and up to 7 days in chronic users [<xref rid="B276-pharmacy-13-00007" ref-type="bibr">276</xref>]. Following the cessation of cannabis use, individuals may experience a complex array of withdrawal symptoms encompassing both psychological and physical manifestations. Psychological symptoms may include insomnia, anxiety, depression, irritability, weight loss, aggression, and anger, while physical symptoms may manifest as fever, tremors, headaches, and sweating. These withdrawal symptoms typically emerge throughout one to two weeks and can onset as early as the first day of abstinence [<xref rid="B277-pharmacy-13-00007" ref-type="bibr">277</xref>].</p><p><xref rid="pharmacy-13-00007-t002" ref-type="table">Table 2</xref> presents the adverse reaction profile of the most frequently used substances of abuse. This table includes data on the various adverse effects associated with commonly abused substances such as opioids, cocaine, tobacco, and cannabis. The information provided in <xref rid="pharmacy-13-00007-t002" ref-type="table">Table 2</xref> points out the potential risks and harms associated with substance abuse. This information is valuable for developing interventions, treatment strategies, and harm reduction approaches to address substance abuse and its consequences.</p></sec></sec><sec id="sec5-pharmacy-13-00007"><title>5. Novel Insights on Substance Abuse Addiction</title><p>Substance abuse addiction is a significant global health issue, with a substantial burden on individuals and societies worldwide. According to the Global Burden of Disease 2010 Project (GBD), mental and substance use disorders contribute significantly to the burden of disease, with substance dependence being a complex disorder influenced by genetic and environmental factors [<xref rid="B278-pharmacy-13-00007" ref-type="bibr">278</xref>,<xref rid="B282-pharmacy-13-00007" ref-type="bibr">282</xref>]. The transition to parenthood has been identified as a novel mechanism of addiction vulnerability, highlighting the importance of understanding the neurobiology of addictive processes from a parenting-specific perspective [<xref rid="B283-pharmacy-13-00007" ref-type="bibr">283</xref>]. Moreover, the modulation of the endocannabinoid system has been recognized as a vulnerability factor and a potential treatment target for stimulant addiction, emphasizing the role of neurobiological substrates in addiction [<xref rid="B284-pharmacy-13-00007" ref-type="bibr">284</xref>].</p><p>Addiction is a multifaceted process characterized by neurobiological deficits that lead to a compulsive search for and use of addictive substances despite adverse consequences [<xref rid="B285-pharmacy-13-00007" ref-type="bibr">285</xref>]. This compulsive behavior is underpinned by the reward-reinforcement circuit, which is implicated not only in addictive disorders but also in other psychiatric syndromes, highlighting the complex interplay of neurobiology in addiction and related behaviors [<xref rid="B286-pharmacy-13-00007" ref-type="bibr">286</xref>]. The component model of addiction treatment targets enduring psychological, cognitive, and neurobiological vulnerabilities common to all addictive disorders, emphasizing the modifiability of these characteristics [<xref rid="B279-pharmacy-13-00007" ref-type="bibr">279</xref>]. Substance abuse, including addiction, is a significant contributor to the global burden of disease, with substantial economic costs that are expected to increase significantly in the coming years [<xref rid="B287-pharmacy-13-00007" ref-type="bibr">287</xref>].</p><p>Behavioral addictions, with their genetic and neurobiological aspects, are also crucial to recognize and understand to develop effective prevention and treatment strategies [<xref rid="B288-pharmacy-13-00007" ref-type="bibr">288</xref>]. Epidemiological studies have shed light on the prevalence and patterns of substance abuse in different populations, such as college students, medical interns, and professional college students, highlighting the widespread nature of substance abuse across various demographics [<xref rid="B280-pharmacy-13-00007" ref-type="bibr">280</xref>,<xref rid="B289-pharmacy-13-00007" ref-type="bibr">289</xref>,<xref rid="B290-pharmacy-13-00007" ref-type="bibr">290</xref>]. Socioeconomic disparities have been identified as influencing the uptake of substances of abuse, emphasizing the role of social factors in substance abuse behaviors [<xref rid="B281-pharmacy-13-00007" ref-type="bibr">281</xref>].</p><p>The challenges faced by parents of youth abusing substances, such as non-adherence to medical instructions and violent behavior, underscore the complex social dynamics that contribute to substance abuse within families and communities [<xref rid="B291-pharmacy-13-00007" ref-type="bibr">291</xref>]. Substance abuse not only affects individuals but also has broader implications for society, including increased levels of crime and misconduct associated with reduced self-control and increased impulsivity [<xref rid="B292-pharmacy-13-00007" ref-type="bibr">292</xref>]. The prevalence of comorbidities associated with substance abuse, particularly opioid abuse, highlights the complex interplay between substance abuse and other health conditions, further emphasizing the multifaceted nature of addiction [<xref rid="B293-pharmacy-13-00007" ref-type="bibr">293</xref>].</p><p>Neurobiological research has shown that substance abuse, particularly methamphetamine dependence, can lead to abnormalities in pituitary hormonal regulation, indicating the profound impact of substance abuse on physiological processes [<xref rid="B294-pharmacy-13-00007" ref-type="bibr">294</xref>]. Additionally, the treatment of methamphetamine withdrawal with medications like methylphenidate and modafinil underscores the challenges associated with managing substance abuse and the need for effective pharmacological interventions to address withdrawal symptoms and cravings [<xref rid="B295-pharmacy-13-00007" ref-type="bibr">295</xref>]. The elevated plasma prolactin levels observed in abstinent methamphetamine-dependent individuals further highlight the physiological changes that occur as a result of substance abuse [<xref rid="B294-pharmacy-13-00007" ref-type="bibr">294</xref>]</p><p>Overall, substance abuse addiction is a complex and multifaceted issue with significant global implications. Understanding the neurobiological mechanisms underlying addiction is crucial for developing effective prevention and treatment strategies. By addressing the genetic, environmental, and social factors that contribute to substance abuse, it is possible to mitigate the burden of addiction on individuals and societies. Further research into the neurobiology of addiction and the development of targeted interventions are essential for combating the pervasive impact of substance abuse on public health.</p><sec id="sec5dot1-pharmacy-13-00007"><title>5.1. Neurobiological Mechanisms of Substance Abuse Addiction</title><p>The brain&#x02019;s reward system is integral to substance abuse addiction, involving a complex interplay of neurobiological processes that drive addictive behaviors. Addiction is characterized by dysregulation in motivational circuits, encompassing heightened incentive salience, habit formation, reward deficits, stress dysregulation, and compromised executive function. This dysregulation leads to significant neurobiological changes, including alterations in the reward system, overactivation of brain stress systems, and impaired prefrontal cortex function [<xref rid="B295-pharmacy-13-00007" ref-type="bibr">295</xref>]. The addictive process disrupts stress and rewards neural circuits, shedding light on how substance use can impact caregiving processes [<xref rid="B296-pharmacy-13-00007" ref-type="bibr">296</xref>].</p><p>The neurobiological foundation of addiction centers around the mesocorticolimbic dopamine system, where addictive substances elevate dopamine neurotransmission, attributing incentive salience to drug-related cues and contexts. Prolonged exposure to these substances induces enduring adaptations in the brain&#x02019;s reward pathways, heightening sensitivity to drugs and associated cues [<xref rid="B297-pharmacy-13-00007" ref-type="bibr">297</xref>]. Moreover, irregularities in dopamine regulation in the prefrontal cortex contribute to addictive behaviors, enhancing motivational value and diminishing control over substance use [<xref rid="B298-pharmacy-13-00007" ref-type="bibr">298</xref>].</p><p>Understanding drug craving is pivotal in comprehending addiction, with clinical neurobiological research elucidating the neurobiological basis of craving and its role in addiction&#x02019;s pathophysiology. Drug craving is linked to alterations in dopamine signaling and compulsive drug-seeking behavior, emphasizing the intricate connection between neurobiology and addictive behaviors [<xref rid="B299-pharmacy-13-00007" ref-type="bibr">299</xref>]. Furthermore, addiction-induced dysregulation of stress and reward neural circuits can impact caregiving processes [<xref rid="B300-pharmacy-13-00007" ref-type="bibr">300</xref>].</p><p>Genetic factors also significantly influence addiction, with specific genes impacting various aspects of addiction neurobiology, such as anxiety, impulsivity, and reward processing [<xref rid="B301-pharmacy-13-00007" ref-type="bibr">301</xref>]. Common neurobiological vulnerabilities between addiction and other psychiatric disorders, like ADHD, highlight the shared neurobiology of these conditions, particularly in terms of impulsivity, reward sensitivity, and control deficits [<xref rid="B300-pharmacy-13-00007" ref-type="bibr">300</xref>]. Pharmacotherapy targeting neurobiological alterations associated with addiction, including withdrawal symptoms, craving, and aberrant reward processing, offers a promising avenue for treating substance use disorders [<xref rid="B302-pharmacy-13-00007" ref-type="bibr">302</xref>].</p><p>Substance dependence also has an underlying genetic influence, demonstrated mainly through twin and adoption studies. For example, suppose one sibling is addicted to alcohol, cannabis, cocaine, or other drugs. In that case, the risk of other siblings developing the same addictions is increased, with a prevalence rate of up to 80% [<xref rid="B303-pharmacy-13-00007" ref-type="bibr">303</xref>].</p><p>The inheritance of addiction is determined by the interaction of several genes, known as polymorphisms, which can influence the organism&#x02019;s normal functioning through changes in the DNA sequence. The most common and well-known polymorphisms are single-nucleotide variations (SNPs), which occur when one base is replaced by another, contributing to an increased risk of developing certain conditions, including addiction [<xref rid="B304-pharmacy-13-00007" ref-type="bibr">304</xref>]. Genome-wide association studies (GWAS) are performed to explore genetic variants (SNPs) and to identify links between these variants and specific traits or diseases [<xref rid="B305-pharmacy-13-00007" ref-type="bibr">305</xref>].</p><p>To explore the connection between nicotine addiction and genetic influence, a genome-wide association study (GWAS) focused on nicotinic acetylcholine receptor genes was conducted. The results indicated that the regions involved were chromosome 15 with the CHRNA5-CHRNA3-CHRNB4 genes and chromosome 8 with the CHRNA6-CHRNB3 genes. These regions were further analyzed by correlating single-nucleotide polymorphisms (SNPs) with the average daily number of cigarettes, thus demonstrating excessive smoking [<xref rid="B303-pharmacy-13-00007" ref-type="bibr">303</xref>].</p><p>For other substances of abuse, such as cocaine, the genes involved in addiction are located on chromosomes 9 and 12. For opioids, dopaminergic genes and chromosome 14q or 17 are associated with excessive use. For cannabis, withdrawal syndrome is associated with chromosomes 1, 3, 6, 7, 9, 16, and 19 in the context of addiction [<xref rid="B303-pharmacy-13-00007" ref-type="bibr">303</xref>,<xref rid="B306-pharmacy-13-00007" ref-type="bibr">306</xref>].</p><p>Another important factor in the development of addiction is heritable changes in genomic phenotypes, which DNA does not directly determine. These changes, such as acetylation, phosphorylation, and methylation at the chromatin level, are known as epigenetics and are triggered by drug use [<xref rid="B307-pharmacy-13-00007" ref-type="bibr">307</xref>,<xref rid="B308-pharmacy-13-00007" ref-type="bibr">308</xref>].</p><p>DNA methylation plays a significant role in genetic imprinting. It involves adding a methyl group on cytosine (5-mC), inhibiting gene transcription. DNA methylation is carried out by DNA methyltransferases (DNMTs), and DNMT3a plays a crucial role in the postnatal brain. In former heroin users, excessive methylation of the OPRM1 promoter varies between ethnic groups, reducing binding to transcription factors such as Sp1. Maternal exposure to opioids may influence offspring behavior and morphine sensitivity, suggesting a possible epigenetic transmission [<xref rid="B308-pharmacy-13-00007" ref-type="bibr">308</xref>].</p><p>Acetylation of histones reduces electrostatic interactions with DNA, allowing chromatin to relax and making DNA more easily accessible. Acetylation of histones H3 and H4, regulated by histone acetyltransferases (HATs) and CREB-binding proteins (CBPs), plays a role in the cocaine response. These histone changes influence the transcriptional activity of genes involved in drug-induced behaviors, including in brain areas such as the nucleus accumbens (NAc) and prefrontal cortex (PFC) [<xref rid="B307-pharmacy-13-00007" ref-type="bibr">307</xref>].</p><p>The brain&#x02019;s reward system intricately links to substance abuse addiction, with dysregulation in motivational circuits, dopamine signaling, and stress pathways contributing to the onset and perpetuation of addictive behaviors. Understanding the neurobiological foundations of addiction, encompassing dopamine, stress systems, and genetic influences, is crucial for developing effective interventions and treatments for individuals grappling with substance abuse disorders [<xref rid="B309-pharmacy-13-00007" ref-type="bibr">309</xref>].</p><p>The neurobiological basis of substance abuse addiction involves intricate mechanisms that encompass sensitization, tolerance, and neuroplasticity. Sensitization and tolerance are adaptive responses of the brain to repeated exposure to drugs of abuse, leading to changes in the brain&#x02019;s reward circuitry. Tolerance often develops to the pleasurable effects of substances like cocaine and heroin, prompting individuals to increase their dosage and exacerbating the molecular changes that underlie addiction [<xref rid="B310-pharmacy-13-00007" ref-type="bibr">310</xref>]. On the other hand, neuroplasticity refers to the brain&#x02019;s ability to reorganize itself by forming new neural connections. It plays a crucial role in addiction by mediating the highly efficient and stable memory abnormalities associated with substance abuse [<xref rid="B311-pharmacy-13-00007" ref-type="bibr">311</xref>].</p><p>The neural rejuvenation hypothesis of cocaine addiction posits that repeated exposure to drugs induces plasticity mechanisms within the brain&#x02019;s reward circuitry, leading to stable memory abnormalities characteristic of addiction [<xref rid="B312-pharmacy-13-00007" ref-type="bibr">312</xref>]. This hypothesis underscores the role of neuroplasticity in shaping the addictive processes. It highlights how drug-induced changes in the brain&#x02019;s structure and function contribute to the persistence of addictive behaviors. Understanding the molecular mechanisms underlying substance abuse is essential for developing effective therapeutic strategies to combat addiction [<xref rid="B313-pharmacy-13-00007" ref-type="bibr">313</xref>].</p><p>Studies have shown that addiction involves a series of neuroplastic changes in the mesolimbic reward pathway, emphasizing the role of neuroplasticity in the development and maintenance of addictive behaviors [<xref rid="B314-pharmacy-13-00007" ref-type="bibr">314</xref>]. Neuroplasticity in cholinergic neurons of the laterodorsal tegmental nucleus has been implicated in the development of cocaine addiction, underscoring the intricate interplay between different brain regions involved in reward processing and reinforcement learning. These findings highlight the complex neural adaptations that occur in response to drug exposure and how they contribute to the addictive process [<xref rid="B315-pharmacy-13-00007" ref-type="bibr">315</xref>].</p><p>Drug-induced neuroplasticity, characterized by changes in neurotransmitter systems such as serotonin, glutamic acid, dopamine, and gamma-aminobutyric acid, plays a pivotal role in the pathophysiology of addiction [<xref rid="B316-pharmacy-13-00007" ref-type="bibr">316</xref>]. The dysregulation of these neurotransmitter systems due to repeated substance abuse leads to maladaptive changes in the brain&#x02019;s reward circuitry, contributing to the compulsive drug-seeking behaviors observed in addiction. Addiction is increasingly recognized as a neurobiological disorder that disrupts normal brain circuitry, leading to drug-induced neuroplastic changes that perpetuate addictive behaviors [<xref rid="B317-pharmacy-13-00007" ref-type="bibr">317</xref>].</p><p>The role of hippocampal neurogenesis in addiction highlights the impact of addictive drugs on the brain&#x02019;s ability to generate new neurons, with addictive substances suppressing neurogenic proliferation in the hippocampus. These neuroadaptive processes within motivation circuits regulated by the hippocampus contribute to the development of addictive behaviors and underscore the importance of understanding the neurobiological basis of addiction [<xref rid="B318-pharmacy-13-00007" ref-type="bibr">318</xref>]. Cell adhesion molecule genes, particularly CDH13, have been implicated in regulating neuroplasticity in addiction, emphasizing the genetic and molecular underpinnings of addictive behaviors [<xref rid="B319-pharmacy-13-00007" ref-type="bibr">319</xref>].</p><p>MeCP2, a protein involved in gene regulation, has been implicated in controlling brain-derived neurotrophic factor expression and cocaine intake, suggesting a role in the neurobiological mechanisms of addiction [<xref rid="B320-pharmacy-13-00007" ref-type="bibr">320</xref>]. Distress tolerance has been identified as a predictor of early treatment dropout in substance abuse facilities, highlighting the psychological factors that influence treatment outcomes in addiction [<xref rid="B321-pharmacy-13-00007" ref-type="bibr">321</xref>]. Furthermore, brain anatomy alterations associated with social networking site addiction underscore the impact of excessive behaviors on brain morphology and neuroplasticity [<xref rid="B322-pharmacy-13-00007" ref-type="bibr">322</xref>].</p><p>Addiction neuroscience aims to uncover the neural basis of addiction by mapping changes in the brains of individuals with substance use disorders, shedding light on the neurobiological underpinnings of addictive behaviors [<xref rid="B323-pharmacy-13-00007" ref-type="bibr">323</xref>]. Psychedelic-induced neuroplasticity has also been studied in the context of addiction, emphasizing the role of neuroplastic changes in dopaminergic neurons in driving addictive phenomena [<xref rid="B324-pharmacy-13-00007" ref-type="bibr">324</xref>]. Neuromodulation therapies targeting specific brain regions have shown promise in reducing relapse in alcohol addiction, highlighting the potential of neuroscientific interventions in addiction treatment [<xref rid="B325-pharmacy-13-00007" ref-type="bibr">325</xref>].</p><p>The dysregulation of prefrontal cortical control over the nucleus accumbens core due to high-fat diets has been implicated in triggering drug-seeking behaviors and relapse, underscoring the role of neuroplastic changes in addiction [<xref rid="B326-pharmacy-13-00007" ref-type="bibr">326</xref>]. GABA receptor modulators have been shown to affect neuroadaptation to alcohol and cocaine, suggesting a link between GABAergic neurotransmission and addictive behaviors [<xref rid="B327-pharmacy-13-00007" ref-type="bibr">327</xref>]. Addiction is increasingly viewed as a disorder of experience-dependent neuroplasticity, emphasizing the role of synaptic remodeling in reward and motivation circuits in driving addictive behaviors [<xref rid="B328-pharmacy-13-00007" ref-type="bibr">328</xref>].</p><p>Overall, the neurobiological basis of substance abuse addiction involves a complex interplay of sensitization, tolerance, and neuroplasticity mechanisms that underlie the development and persistence of addictive behaviors. Understanding how drugs of abuse affect the brain&#x02019;s reward circuitry, neurotransmitter systems, and gene regulation is crucial for developing effective interventions to combat addiction. By unraveling the molecular and neural processes involved in addiction, researchers can pave the way for innovative treatment strategies that target the root causes of substance abuse disorders.</p><p>Substance abuse has a significant impact on brain function and behavior, leading to cognitive impairment, emotional dysregulation, behavioral changes, and the progression from substance use to addiction. Chronic alcoholism, for example, is linked to cognitive deficits affecting memory, attention, and decision-making [<xref rid="B329-pharmacy-13-00007" ref-type="bibr">329</xref>]. Individuals with substance use disorders commonly experience emotional dysregulation, resulting in mood swings, anxiety, and depression [<xref rid="B330-pharmacy-13-00007" ref-type="bibr">330</xref>]. This emotional dysregulation can contribute to risky behaviors such as compulsive drug seeking and relapse [<xref rid="B331-pharmacy-13-00007" ref-type="bibr">331</xref>]. The transition from substance use to addiction involves intricate neurobiological processes, including the development of craving and dependence [<xref rid="B332-pharmacy-13-00007" ref-type="bibr">332</xref>].</p><p>Research has extensively documented the impact of substance abuse on cognitive function, emphasizing the cognitive deficits seen in individuals with alcohol use disorders [<xref rid="B329-pharmacy-13-00007" ref-type="bibr">329</xref>]. These deficits can affect various cognitive domains, including memory, attention, and executive functions, ultimately influencing decision-making abilities. Substance abuse can lead to structural changes in the brain that worsen cognitive impairments, particularly in areas related to impulse control. Chronic substance abuse not only acutely affects cognitive function but also contributes to long-term brain dysfunction, perpetuating impulsive behaviors and cognitive deficits [<xref rid="B333-pharmacy-13-00007" ref-type="bibr">333</xref>].</p><p>Emotional dysregulation is a common consequence of substance abuse, with individuals often experiencing mood swings, anxiety, and depression [<xref rid="B331-pharmacy-13-00007" ref-type="bibr">331</xref>]. This emotional dysregulation can be a maladaptive coping mechanism, leading to impulsive behaviors and risky decision-making. Studies have highlighted the significant role of emotional dysregulation in the development of various psychiatric disorders, including substance use disorders [<xref rid="B331-pharmacy-13-00007" ref-type="bibr">331</xref>]. Additionally, childhood abuse has been associated with emotion dysregulation in adulthood, heightening the risk of substance abuse and related behavioral issues [<xref rid="B330-pharmacy-13-00007" ref-type="bibr">330</xref>].</p><p>Behavioral changes linked to substance abuse encompass compulsive drug seeking and relapse, driven by alterations in brain function and reward pathways. Individuals with substance use disorders frequently display compulsive behaviors aimed at acquiring and using drugs despite negative consequences. These behavioral changes are closely tied to the neurobiological basis of addiction, involving modifications in the brain&#x02019;s reward circuitry and the development of tolerance [<xref rid="B332-pharmacy-13-00007" ref-type="bibr">332</xref>]. Furthermore, substance abuse can lead to changes in brain regions responsible for impulse control, further fueling compulsive drug-seeking behaviors [<xref rid="B333-pharmacy-13-00007" ref-type="bibr">333</xref>].</p><p>The transition from substance use to addiction involves a complex interplay of neurobiological factors, including craving and dependence. Craving, characterized by an intense desire for a substance, is a key feature of addiction and is associated with changes in brain regions involved in reward processing. Dependence reflects the body&#x02019;s adaptation to the substance, resulting in withdrawal symptoms upon cessation of use. The neurobiological underpinnings of craving and dependence underscore the chronic nature of addiction and the difficulties in achieving and maintaining sobriety [<xref rid="B332-pharmacy-13-00007" ref-type="bibr">332</xref>].</p><p>In summary, substance abuse has a multifaceted impact on brain function and behavior, encompassing cognitive impairment, emotional dysregulation, behavioral changes, and the progression from substance use to addiction. Chronic substance use disorders are associated with cognitive deficits, emotional dysregulation, and compulsive behaviors driven by alterations in brain function and reward pathways. Understanding the neurobiological basis of substance abuse is crucial for developing effective interventions targeting cognitive, emotional, and behavioral aspects of addiction.</p></sec><sec id="sec5dot2-pharmacy-13-00007"><title>5.2. Treatment Approaches and Interventions Regarding Substance Abuse Addiction</title><p>Substance abuse addiction is a multifaceted issue that necessitates a comprehensive approach for effective treatment. Various interventions, such as pharmacological, behavioral, psychotherapeutic, and emerging therapies, are crucial in addressing substance abuse addiction. Pharmacological interventions involve the use of medications to manage addiction and withdrawal symptoms [<xref rid="B334-pharmacy-13-00007" ref-type="bibr">334</xref>]. These medications target different aspects of addiction, such as reducing cravings or blocking the effects of drugs, to support individuals in their recovery process. Behavioral therapies, including cognitive-behavioral therapy (CBT) and Motivational Interviewing, are widely recognized as practical approaches to treating substance abuse addiction. CBT helps individuals identify and change negative thought patterns and behaviors associated with substance abuse. At the same time, Motivational Interviewing aims to enhance motivation and commitment to change addictive behaviors [<xref rid="B335-pharmacy-13-00007" ref-type="bibr">335</xref>,<xref rid="B336-pharmacy-13-00007" ref-type="bibr">336</xref>].</p><p>Psychotherapeutic approaches are essential in addressing underlying mental health issues that may contribute to substance abuse addiction [<xref rid="B337-pharmacy-13-00007" ref-type="bibr">337</xref>]. Individuals with co-occurring disorders, such as substance use disorder and posttraumatic stress disorder, benefit from integrated treatment that addresses both conditions simultaneously. Emerging therapies, including neurostimulation and gene therapy, offer innovative ways to target the neurological mechanisms involved in addiction. These therapies hold promise in advancing treatment strategies for addictions and dual-diagnosis disorders by enhancing adaptive regulation of brain functions [<xref rid="B317-pharmacy-13-00007" ref-type="bibr">317</xref>].</p><p>Research has shown that cognitive bias modification and cognitive control training are valuable tools in addressing addiction and related psychopathology [<xref rid="B338-pharmacy-13-00007" ref-type="bibr">338</xref>]. These interventions target cognitive processes contributing to addictive behaviors, helping individuals develop healthier thinking patterns and decision-making skills. Additionally, cognitive-behavioral therapy has been identified as a leading behavioral approach for treating alcohol and other drug use disorders. By addressing maladaptive thoughts and behaviors, CBT equips individuals with coping strategies to manage triggers and prevent relapse [<xref rid="B335-pharmacy-13-00007" ref-type="bibr">335</xref>].</p><p>Furthermore, motivational variables and interventions play a significant role in treatment outcomes for addictive behaviors [<xref rid="B339-pharmacy-13-00007" ref-type="bibr">339</xref>]. Motivation for treatment is a crucial factor in determining engagement, compliance, and success in overcoming addiction. Patient-centered approaches, such as those based on motivational interviewing, emphasize the importance of aligning treatment goals with the individual&#x02019;s preferences and values. By involving patients in decision-making and goal-setting, treatment interventions can be more tailored and effective in supporting long-term recovery [<xref rid="B340-pharmacy-13-00007" ref-type="bibr">340</xref>].</p><p>In the realm of psychotherapy, interventions like cognitive-behavioral therapy have demonstrated efficacy in treating substance use disorders, particularly when combined with motivational strategies [<xref rid="B341-pharmacy-13-00007" ref-type="bibr">341</xref>]. These evidence-based interventions provide individuals with the skills and support needed to address addictive behaviors and maintain sobriety. Additionally, coping strategy training, as part of cognitive-behavioral therapy, helps individuals develop effective ways to manage stressors and cravings that may lead to relapse [<xref rid="B342-pharmacy-13-00007" ref-type="bibr">342</xref>].</p><p>In addition to cognitive-behavioral therapy (CBT), systemic therapy is another effective treatment for substance dependence. The systemic treatments addressed for substance abuse date back as far as the 1986s and are currently making a significant impact in addiction treatment. Systemic addiction treatment is structured in five levels. At level 1, the family is not involved, and therapy is isolated. At level 2, the counselor educates and advises the family, often recommending family therapy. At level 3, the counselor works more directly with the family, helping each member cope. Level 4 involves analyzing and intervening in dysfunctional family patterns. Family therapy for systemic addiction treatment is only implemented at level 5, and from this point on, interventions become more complex. Over the years, the best results in reducing substance use have been achieved in treatment settings in which family and life partners have been actively involved [<xref rid="B343-pharmacy-13-00007" ref-type="bibr">343</xref>].</p><p>The life partners of those who are substance abusers are most strongly affected by addictive behavior. Despite their best efforts to help them overcome this behavior, the people close to them often refuse to offer help because of helplessness and disobedience. In these situations, psychologists recommend that the couple participate in motivational interviewing (MI), helping them analyze their behavior and find and introduce the motivation to change, thus overcoming difficult moments together [<xref rid="B344-pharmacy-13-00007" ref-type="bibr">344</xref>].</p><p>If the addicted person is in a stable relationship in which neither partner has a co-existing psychiatric condition, behavioral couple therapy (BCT) is recommended for about 20 weeks. During this time, the partner supports the partner in trying to help stop substance use and strengthen the relationship. In solution-focused therapy (SFT), patients are encouraged to discuss their problems or concerns openly. With the therapist&#x02019;s help, they identify solutions and set goals to improve their hope for change. Research shows that 36% of patients who attend at least two SFT sessions can improve their behavior [<xref rid="B344-pharmacy-13-00007" ref-type="bibr">344</xref>].</p><p>Another type of systemic therapy is multisystemic family therapy (MFT). Family members play a crucial role in the patient&#x02019;s recovery process, offering help by providing an environment that keeps them away from the negative influences of substances. The family will be assigned specific tasks to address the current problems so they can work together daily and weekly to accomplish them, one step closer to solving the central issue. Galanter and colleagues evaluated the effectiveness of network therapy compared with individual counseling; both included in a buprenorphine maintenance protocol. The results showed a significantly higher rate of opioid abstinence in the group receiving network therapy (about 65%) compared with those receiving individual therapy (about 45%) [<xref rid="B3-pharmacy-13-00007" ref-type="bibr">3</xref>,<xref rid="B4-pharmacy-13-00007" ref-type="bibr">4</xref>]. Because the family has a significant role during this time in treatment, the Center for Substance Abuse Treatment classifies this approach as level 3. Level 2 is the Johnson-style intervention, in which for 4 weeks, family and friends of the addicted person are taught how to encourage him/her in the treatment process. During the meeting, the patient explained in a calm, caring, and supportive tone how his relationships with everyone close to him had changed negatively [<xref rid="B345-pharmacy-13-00007" ref-type="bibr">345</xref>,<xref rid="B346-pharmacy-13-00007" ref-type="bibr">346</xref>].</p><p>Nowadays, the number of teenage substance users is increasing, so addiction treatment is also very vital. One of the approaches is SOFT therapy or strengths-oriented family therapy, in which, for 2 h, adolescents participate in family groups, where each member&#x02019;s strengths are assessed and used to solve problems. In the case of runaway adolescents, Ecological Family Therapy (EBFT), where each family member meets with the adolescent in separate sessions to discuss the factors that led to the runaway, after which the therapist helps the family to keep the adolescent at home [<xref rid="B347-pharmacy-13-00007" ref-type="bibr">347</xref>]. Another treatment approach is multisystemic therapy (MST), which involves the family providing support at school and in circles of friends and community. Initially, with the help of the parents, the therapist will gather information on how the adolescent integrates substances with daily activities, thus determining how to approach the problem. The progress of the therapy will be evaluated over a maximum period of 6 months, with the help of unique forms that mention all the behavioral and communication changes that the parents should gradually introduce in the relationship with the adolescent [<xref rid="B347-pharmacy-13-00007" ref-type="bibr">347</xref>,<xref rid="B348-pharmacy-13-00007" ref-type="bibr">348</xref>].</p><p>Occupational therapy services have also been recommended for individuals with substance abuse disorders, highlighting the importance of a holistic and interdisciplinary approach to treatment [<xref rid="B349-pharmacy-13-00007" ref-type="bibr">349</xref>]. By addressing the functional aspects of daily living and promoting meaningful activities, occupational therapists can support individuals in their recovery journey. Moreover, interventions tailored to specific stages of change and coping skills acquisition are essential for individualized treatment approaches in addiction therapy. Understanding where individuals are in their readiness to change and equipping them with coping mechanisms can enhance treatment outcomes and reduce the risk of relapse [<xref rid="B350-pharmacy-13-00007" ref-type="bibr">350</xref>].</p><p>Substance abuse addiction is a complex issue affecting individuals globally. The misuse of substances like alcohol, opioids, and tobacco poses significant health risks and societal burdens. Addressing substance abuse addiction requires a comprehensive approach that includes pharmacological interventions aimed at mitigating the negative effects of these substances and supporting individuals in their recovery journey [<xref rid="B351-pharmacy-13-00007" ref-type="bibr">351</xref>].</p><p>Alcohol is a commonly abused substance, with medications like acamprosate, naltrexone, and disulfiram used in the treatment of alcohol use disorder. Acamprosate reduces alcohol cravings by acting on glutamate receptors, while naltrexone blocks opioid receptors, diminishing the rewarding effects of alcohol consumption. Disulfiram induces an unpleasant reaction when alcohol is consumed, acting as a deterrent [<xref rid="B352-pharmacy-13-00007" ref-type="bibr">352</xref>].</p><p>Opioids are another class of substances commonly associated with addiction. Medications such as methadone and buprenorphine are utilized in opioid addiction treatment. Methadone reduces withdrawal symptoms and cravings by acting on opioid receptors, while buprenorphine, a partial opioid agonist, helps manage cravings without producing the same high as full opioids [<xref rid="B352-pharmacy-13-00007" ref-type="bibr">352</xref>].</p><p>Tobacco use disorder is prevalent among individuals with substance abuse issues. Smoking cessation interventions, including counseling and pharmacotherapy, are crucial in supporting individuals undergoing substance abuse treatment. Providing quit-smoking medications as part of substance abuse treatment programs can significantly enhance outcomes and reduce the overall burden of tobacco-related health issues [<xref rid="B353-pharmacy-13-00007" ref-type="bibr">353</xref>].</p><p>Integrating primary medical care with addiction treatment has been shown to be beneficial for individuals with substance abuse and medical comorbidities. This integrated approach not only improves health outcomes but also proves to be cost-effective in the long run. By addressing both addiction and underlying medical conditions simultaneously, individuals receive comprehensive care that addresses their holistic needs [<xref rid="B354-pharmacy-13-00007" ref-type="bibr">354</xref>].</p><p>Psychotropic drugs targeting various neurotransmitter systems in the brain, such as GABA, glutamate, dopamine, and opioids, play a crucial role in the pharmacological treatment of substance abuse disorders. These medications act on specific receptors to modulate the effects of addictive substances, helping individuals manage cravings, withdrawal symptoms, and the reinforcing effects of drugs [<xref rid="B355-pharmacy-13-00007" ref-type="bibr">355</xref>].</p><p>Faith-based interventions have also been explored in the treatment of substance addiction, emphasizing a holistic approach that includes biological, psychological, environmental, and spiritual aspects of recovery. Such interventions often incorporate detoxification strategies, counseling, skill training, and social support alongside religious and spiritual growth to aid in the recovery process [<xref rid="B356-pharmacy-13-00007" ref-type="bibr">356</xref>].</p><p>In the realm of addiction treatment, primary care physicians play a pivotal role in recognizing addiction, providing interventions for intoxication and withdrawal, and offering long-term care for individuals with substance use disorders [<xref rid="B357-pharmacy-13-00007" ref-type="bibr">357</xref>]. Brief interventions by primary care providers can have a significant impact on early intervention and treatment initiation for substance abuse, leading to improved outcomes and reduced societal costs associated with addiction [<xref rid="B358-pharmacy-13-00007" ref-type="bibr">358</xref>].</p><p>The pharmacological treatment approaches for substance abuse addiction encompass a diverse range of medications targeting different substances and neurotransmitter systems in the brain. From alcohol and opioids to tobacco and other illicit substances, medications play a crucial role in managing cravings, withdrawal symptoms, and the reinforcing effects of drugs. Integrating primary medical care and the expertise of primary care physicians further enhances the effectiveness of addiction treatment programs, offering individuals comprehensive support on their path to recovery [<xref rid="B352-pharmacy-13-00007" ref-type="bibr">352</xref>,<xref rid="B354-pharmacy-13-00007" ref-type="bibr">354</xref>].</p><p>Overall, the treatment of substance abuse addiction requires a comprehensive and integrated approach that combines pharmacological, behavioral, psychotherapeutic, and emerging therapies. By addressing the biological, psychological, and social aspects of addiction, individuals can receive tailored interventions that support their recovery and long-term well-being. Through evidence-based practices, patient-centered care, and interdisciplinary collaboration, the field of addiction treatment continues to evolve to meet the diverse needs of individuals struggling with substance abuse.</p></sec></sec><sec id="sec6-pharmacy-13-00007"><title>6. Advancements in Technology for Detection of Substance Abuse</title><p>Substance abuse detection is a crucial aspect of addressing the challenges posed by drug misuse and addiction. Various methodologies and devices have been developed to identify the presence of substances in individuals. One common approach involves using immunologic techniques in analyzing bodily fluids like sweat and saliva. These techniques have been instrumental in detecting a wide range of substances, including illicit drugs, providing a non-invasive and efficient means of screening individuals for substance abuse. Additionally, advanced analytical methods such as thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and capillary electrophoresis (CE) have been employed for substance abuse detection, offering high sensitivity and specificity in identifying different substances [<xref rid="B359-pharmacy-13-00007" ref-type="bibr">359</xref>].</p><p>Substance abuse encompasses the misuse of various drugs, including marijuana, alcohol, cocaine, heroin, and cigarettes [<xref rid="B360-pharmacy-13-00007" ref-type="bibr">360</xref>]. Detection methods tailored to these specific substances are crucial in effectively identifying and addressing substance abuse issues. For instance, in the context of sports, detecting the abuse of growth hormones presents unique challenges, but utilizing discriminant functions based on multiple markers has shown promise in enhancing sensitivity and specificity in detecting growth hormone abuse. This highlights the importance of employing specialized detection methodologies for different substances to ensure accurate and reliable results [<xref rid="B361-pharmacy-13-00007" ref-type="bibr">361</xref>].</p><p>Moreover, the prevalence of substance abuse extends to different populations, including older adults, where brief interventions by primary care providers have been shown to significantly impact preventing medical morbidity and improving quality of life [<xref rid="B362-pharmacy-13-00007" ref-type="bibr">362</xref>]. Tailoring detection methods to suit the needs of specific demographics, such as older individuals, is essential in addressing substance abuse effectively. Additionally, the use of biochip array technology has emerged as a highly sensitive and specific technique for detecting substances of abuse in hair samples, offering a valuable tool in substance abuse detection [<xref rid="B363-pharmacy-13-00007" ref-type="bibr">363</xref>].</p><p>The incidence of substance abuse has exhibited a notable escalation in recent years, prompting a corresponding surge in efforts to detect these substances. Detection methodologies predominantly rely on metabolite analysis, a delicate process owing to the higher concentration of these metabolites in urine compared to blood. Conventional blood and urine screening methods have proven inadequate for precise determinations. They are susceptible to cross-reactivities [<xref rid="B359-pharmacy-13-00007" ref-type="bibr">359</xref>,<xref rid="B364-pharmacy-13-00007" ref-type="bibr">364</xref>].</p><p>One of the most effective methodologies for detecting substances such as nicotine and opioids is rooted in immunological principles, involving the development of antibodies and vaccines tailored to target these specific compounds [<xref rid="B359-pharmacy-13-00007" ref-type="bibr">359</xref>]. These vaccines stimulate the production of high-quality antibodies that work to counteract the presence of the substances in the bloodstream. By utilizing this vaccine, the ability of the drug to traverse the blood&#x02013;brain barrier is impeded, consequently mitigating the majority of the pharmacodynamic responses associated with these substances. While initial iterations of these vaccines, particularly those designed against nicotine, yielded unremarkable outcomes in clinical trials, subsequent generations have demonstrated significantly improved efficacy in preclinical models [<xref rid="B359-pharmacy-13-00007" ref-type="bibr">359</xref>,<xref rid="B365-pharmacy-13-00007" ref-type="bibr">365</xref>]. Furthermore, biochemical analysis can provide insights into nicotine usage. Carbon monoxide (CO) levels can serve as an indicator of recent tobacco smoke exposure from various sources such as pipes, cigarettes, hookahs, and cigars. The assessment of CO concentrations takes into account the typical environmental exposure of patients, with any elevation exceeding 1&#x02013;2 parts per million (ppm) surpassing the endogenous production of CO within the human body [<xref rid="B366-pharmacy-13-00007" ref-type="bibr">366</xref>].</p><p>Detection methods that exhibit high sensitivity toward minute sample volumes have gained significant attention, particularly within the realm of opioid detection. Among these methods, biosensors utilizing nanomaterials have emerged as a prominent approach. Nanobiosensors feature a nanostructure serving as a signal transducer, with a biological recognition molecule being incorporated onto the surface of this nanostructure. Notably, optical sensor systems utilizing nanomaterials, such as colorimetry and fluorescence-based methods, have been extensively explored for detection purposes. Gold and silver nanoparticles are commonly employed in these systems due to their capacity to induce Surface Plasmon Resonance [<xref rid="B365-pharmacy-13-00007" ref-type="bibr">365</xref>,<xref rid="B367-pharmacy-13-00007" ref-type="bibr">367</xref>].</p><p>The identification of illegal substances poses a significant challenge in various settings, including schools and institutions. One potential method for detection involves the analysis of sewage water to assess the prevalence of illicit drugs. A recent study conducted in Slovakia aimed to investigate the occurrence of drugs within school environments. The researchers employed solid-phase extraction combined with direct injection combined ultra-performance liquid chromatography-tandem mass spectrometry to analyze the samples. The findings from this study revealed the presence of several biomarkers, with notable detections, including those specific to nicotine, cannabis, morphine, and codeine [<xref rid="B368-pharmacy-13-00007" ref-type="bibr">368</xref>].</p><p>In the context of cannabis detection, tetrahydrocannabinol (THC) serves as the primary psychoactive component of interest. Various biological samples such as urine, blood, and saliva are commonly utilized for THC analysis in laboratory settings. Noteworthy advancements in THC detection methods include the utilization of colorimetric electrochemical affinity biosensors, giant magnetoresistive biosensors, competitive volumetric bar-chart chip assays, dye-displacement assays employing aptamers, as well as colorimetric and fluorescence-based lateral flow assays [<xref rid="B369-pharmacy-13-00007" ref-type="bibr">369</xref>,<xref rid="B370-pharmacy-13-00007" ref-type="bibr">370</xref>].</p><p>In the context of roadside testing conducted on drivers for the identification of cannabis use, superior levels of specificity, sensitivity, and accuracy were observed in devices capable of detecting lower concentrations of THC, as opposed to those designed to identify higher levels of this compound [<xref rid="B371-pharmacy-13-00007" ref-type="bibr">371</xref>].</p><p>The field of substance abuse detection continues to evolve with advancements in technology and methodologies. Various detection tools are available for identifying abused substances, from immunologic techniques and chromatography methods to biochip array technology. Tailoring detection methods to specific substances and populations, such as athletes, teenagers, older adults, and individuals with co-occurring disorders, is crucial in effectively addressing substance abuse. By integrating substance abuse detection into healthcare practices, counseling programs, and educational curricula, professionals can play a vital role in combating substance abuse and promoting overall well-being in individuals affected by drug misuse.</p></sec><sec sec-type="conclusions" id="sec7-pharmacy-13-00007"><title>7. Conclusions</title><p>In the present article, a thorough investigation into the historical, societal, and scientific aspects of medication, substance abuse, and plant use for recreational and narcotic purposes was conducted. The review delved into the early utilization of plants for such purposes, the evolution of laws and regulations surrounding these substances, and the profound impact that medication and substance abuse have had on society. Furthermore, the article explored the most commonly used plants for recreational and narcotic purposes in contemporary times. The popularity, availability, effects, and risks associated with these substances were meticulously examined, shedding light on the complex interplay between human behavior, societal norms, and pharmacological effects.</p><p>The review article also delved into novel insights on substance abuse addiction, elucidating the neurobiological mechanisms that underlie addiction to substances. By exploring the intricate pathways in the brain that are involved in addiction, the article provided a deeper understanding of why individuals may become dependent on substances and the challenges they face in overcoming addiction. Additionally, the review discussed various treatment approaches and interventions for substance abuse addiction, highlighting the importance of a multidisciplinary approach that integrates pharmacological, psychological, and social interventions to address the complex nature of addiction. Moreover, advancements in technology for the detection of substance abuse were explored, showcasing how innovative tools and techniques are being developed to identify and monitor substance abuse more effectively.</p><p>Further research in this field is essential to deepen our understanding of the complexities of medications, substance abuse, and plant use for recreational and narcotic purposes. Studies should focus on elucidating the mechanisms underlying addiction, exploring novel treatment modalities, and developing targeted interventions to address substance abuse effectively. Additionally, education plays a crucial role in raising awareness about the risks associated with substance abuse and promoting responsible use of medications and plants for recreational purposes. By disseminating accurate information and fostering a culture of informed decision-making, education can empower individuals to make healthier choices and reduce the prevalence of substance abuse in society.</p><p>The implications of the findings presented in the current paper are far-reaching, with implications for public health, policy-making, and clinical practice. By recognizing the complex interplay between biological, psychological, and social factors in substance abuse, policymakers can develop more effective strategies to prevent and treat addiction. Healthcare providers can also benefit from a deeper understanding of the neurobiological mechanisms of addiction, enabling them to tailor treatment approaches to individual patients&#x02019; needs. Furthermore, the insights gleaned from advancements in technology for detecting substance abuse can inform the development of more sensitive and specific screening tools, enhancing early intervention and support for individuals struggling with addiction.</p><p>In light of the complexities surrounding medications, substance abuse, and plant use for recreational and narcotic purposes, several recommendations can be made to improve substance abuse management. Firstly, there is a need for enhanced collaboration between researchers, healthcare providers, policymakers, and community stakeholders to address substance abuse comprehensively. By fostering interdisciplinary partnerships, a more holistic approach to substance abuse prevention and treatment can be developed, integrating insights from various fields to create tailored solutions for individuals at risk of addiction.</p><p>Secondly, efforts should be made to destigmatize addiction and promote a compassionate and non-judgmental approach to individuals struggling with substance abuse. By reducing the stigma associated with addiction, individuals may be more inclined to seek help and engage in treatment, ultimately improving outcomes and reducing the burden of substance abuse on society. Education campaigns that raise awareness about the complexities of addiction and challenge misconceptions about substance abuse can play a pivotal role in shifting societal attitudes toward a more empathetic and supportive stance.</p><p>Thirdly, the development of evidence-based interventions that target the underlying mechanisms of addiction is crucial for improving substance abuse management. By investing in research that elucidates the neurobiological pathways involved in addiction, novel treatment modalities can be developed that address the root causes of substance abuse and promote long-term recovery. Additionally, the integration of technology-driven approaches for detecting substance abuse can enhance early intervention and monitoring, enabling healthcare providers to intervene proactively and support individuals in their recovery journey.</p><p>Overall, the article provides a comprehensive overview of the historical, societal, and scientific dimensions of substance use and abuse. By synthesizing a wealth of information on medications, substance abuse, and plant use for recreational and narcotic purposes, the article sheds light on the multifaceted nature of addiction and the challenges it poses to individuals and society at large. The key points highlighted in the article underscored the historical roots of substance use, the evolving legal landscape surrounding these substances, the societal implications of substance abuse, and the pharmacological effects of various plants used for recreational purposes. By examining the most commonly used plants for recreational and narcotic purposes, the review sheds light on the diverse array of substances that individuals may encounter in today&#x02019;s society, each with its unique effects and risks. Further research, education, and collaboration are essential to address the complexities of substance abuse effectively and promote healthier outcomes for individuals struggling with addiction.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge &#x0201c;Victor Babes&#x0201d; University of Medicine and Pharmacy Timisoara for their support in covering the publication costs for this paper.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, I.-A.P., A.-R.J. and D.P.; methodology, I.-A.P., A.-R.J., A.-L.-V.P. and E.-A.M.; software, A.-R.J., D.P., E.-L.P. and C.T.; validation, C.T., C.O. and C.A.D.; formal analysis, I.-A.P., A.-R.J., A.-L.-V.P., E.-L.P. and E.-A.M.; investigation, A.-R.J. and D.P.; resources, C.O. and C.A.D.; data curation, I.-A.P., A.-R.J., D.P. and E.-L.P.; writing&#x02014;original draft preparation, I.-A.P., A.-R.J., A.-L.-V.P., D.P. and E.-A.M.; writing&#x02014;review and editing, C.T., C.O. and C.A.D.; visualization, E.-A.M., C.O. and C.A.D.; supervision, C.T., C.O., C.A.D. and E.-A.M.; project administration, I.-A.P., D.P. and E.-A.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmacy-13-00007"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jonas</surname><given-names>S.</given-names></name>
</person-group><article-title>Is substance abuse a medical problem?</article-title><source>Addict. Disord. Their Treat.</source><year>2003</year><volume>2</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1097/00132576-200302040-00003</pub-id></element-citation></ref><ref id="B2-pharmacy-13-00007"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>N.D.</given-names></name>
<name><surname>Blanco</surname><given-names>C.</given-names></name>
</person-group><article-title>Substance use disorders: A comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention</article-title><source>World Psychiatry Off. J. World Psychiatr. Assoc. (WPA)</source><year>2023</year><volume>22</volume><fpage>203</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1002/wps.21073</pub-id><pub-id pub-id-type="pmid">37159360</pub-id>
</element-citation></ref><ref id="B3-pharmacy-13-00007"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinha</surname><given-names>R.</given-names></name>
</person-group><article-title>Chronic stress, drug use, and vulnerability to addiction</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2008</year><volume>1141</volume><fpage>105</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1196/annals.1441.030</pub-id><pub-id pub-id-type="pmid">18991954</pub-id>
</element-citation></ref><ref id="B4-pharmacy-13-00007"><label>4.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>National Cancer Institute at the National Institutes of Health</collab>
</person-group><article-title>Dictionary of Cancer Terms</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/substance-abuse" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/substance-abuse</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B5-pharmacy-13-00007"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uhl</surname><given-names>G.R.</given-names></name>
<name><surname>Koob</surname><given-names>G.F.</given-names></name>
<name><surname>Cable</surname><given-names>J.</given-names></name>
</person-group><article-title>The neurobiology of addiction</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2019</year><volume>1451</volume><fpage>5</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/nyas.13989</pub-id><pub-id pub-id-type="pmid">30644552</pub-id>
</element-citation></ref><ref id="B6-pharmacy-13-00007"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olsen</surname><given-names>Y.</given-names></name>
</person-group><article-title>What Is Addiction? History, Terminology, and Core Concepts</article-title><source>Med. Clin. N. Am.</source><year>2022</year><volume>106</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.mcna.2021.08.001</pub-id><pub-id pub-id-type="pmid">34823724</pub-id>
</element-citation></ref><ref id="B7-pharmacy-13-00007"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>d&#x02019;Oleire Uquillas</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
</person-group><article-title>Definition of Substance and Non-substance Addiction</article-title><source>Substance and Non-Substance Addiction</source><publisher-name>Springer Nature</publisher-name><publisher-loc>Singapore</publisher-loc><year>2017</year><fpage>21</fpage><lpage>41</lpage></element-citation></ref><ref id="B8-pharmacy-13-00007"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bowser</surname><given-names>B.P.</given-names></name>
<name><surname>Word</surname><given-names>C.O.</given-names></name>
<name><surname>Seddon</surname><given-names>T.</given-names></name>
</person-group><source>Understanding Drug Use and Abuse: A Global Perspective</source><publisher-name>Palgrave Macmillan</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B9-pharmacy-13-00007"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lo</surname><given-names>T.W.</given-names></name>
<name><surname>Yeung</surname><given-names>J.W.K.</given-names></name>
<name><surname>Tam</surname><given-names>C.H.L.</given-names></name>
</person-group><article-title>Substance Abuse and Public Health: A Multilevel Perspective and Multiple Responses</article-title><source>Int. J. Environ. Res. Public Health</source><year>2020</year><volume>17</volume><elocation-id>2610</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17072610</pub-id><pub-id pub-id-type="pmid">32290248</pub-id>
</element-citation></ref><ref id="B10-pharmacy-13-00007"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corder</surname><given-names>G.</given-names></name>
<name><surname>Castro</surname><given-names>D.C.</given-names></name>
<name><surname>Bruchas</surname><given-names>M.R.</given-names></name>
<name><surname>Scherrer</surname><given-names>G.</given-names></name>
</person-group><article-title>Endogenous and Exogenous Opioids in Pain</article-title><source>Annu. Rev. Neurosci.</source><year>2018</year><volume>41</volume><fpage>453</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-080317-061522</pub-id><pub-id pub-id-type="pmid">29852083</pub-id>
</element-citation></ref><ref id="B11-pharmacy-13-00007"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawler</surname><given-names>J.</given-names></name>
<name><surname>Stout</surname><given-names>J.</given-names></name>
<name><surname>Gardner</surname><given-names>K.</given-names></name>
<name><surname>Hudson</surname><given-names>D.</given-names></name>
<name><surname>Vidmar</surname><given-names>J.</given-names></name>
<name><surname>Butler</surname><given-names>L.</given-names></name>
<name><surname>Page</surname><given-names>J.E.</given-names></name>
<name><surname>Myles</surname><given-names>S.</given-names></name>
</person-group><article-title>The genetic structure of marijuana and hemp</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0133292</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0133292</pub-id><pub-id pub-id-type="pmid">26308334</pub-id>
</element-citation></ref><ref id="B12-pharmacy-13-00007"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurgobin</surname><given-names>B.</given-names></name>
<name><surname>Tamiru-Oli</surname><given-names>M.</given-names></name>
<name><surname>Welling</surname><given-names>M.</given-names></name>
<name><surname>Doblin</surname><given-names>M.</given-names></name>
<name><surname>Bacic</surname><given-names>A.</given-names></name>
<name><surname>Whelan</surname><given-names>J.</given-names></name>
<name><surname>Lewsey</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Recent advances in <italic toggle="yes">Cannabis sativa</italic> genomics research</article-title><source>New Phytol.</source><year>2021</year><volume>230</volume><fpage>73</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1111/nph.17140</pub-id><pub-id pub-id-type="pmid">33283274</pub-id>
</element-citation></ref><ref id="B13-pharmacy-13-00007"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kollar</surname><given-names>A.</given-names></name>
<name><surname>Hausman</surname><given-names>J.</given-names></name>
<name><surname>Guerriero</surname><given-names>G.G.</given-names></name>
</person-group><article-title><italic toggle="yes">Cannabis sativa</italic>: The plant of the thousand and one molecules</article-title><source>Front. Plant Sci.</source><year>2016</year><volume>7</volume><elocation-id>19</elocation-id><pub-id pub-id-type="pmid">26870049</pub-id>
</element-citation></ref><ref id="B14-pharmacy-13-00007"><label>14.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>National Institute on Drug Abuse</collab>
</person-group><article-title>Drug Overdose Death Rates</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates" ext-link-type="uri">https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B15-pharmacy-13-00007"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhugaonkar</surname><given-names>M.</given-names></name>
<name><surname>Jha</surname><given-names>R.</given-names></name>
<name><surname>Zilate</surname><given-names>S.</given-names></name>
</person-group><article-title>Review on overview of substance abuse among medical practitioners</article-title><source>J. Pharm. Res. Int.</source><year>2021</year><volume>33</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.9734/jpri/2021/v33i38B32097</pub-id></element-citation></ref><ref id="B16-pharmacy-13-00007"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roy</surname><given-names>R.</given-names></name>
<name><surname>Roy</surname><given-names>D.</given-names></name>
<name><surname>Goit</surname><given-names>R.</given-names></name>
</person-group><article-title>Substance abuse among medical students&#x02014;A survey in a medical college in Nepal</article-title><source>J. Nepalgunj Med. Coll.</source><year>2018</year><volume>16</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3126/jngmc.v16i1.24236</pub-id></element-citation></ref><ref id="B17-pharmacy-13-00007"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lojszczyk</surname><given-names>A.</given-names></name>
</person-group><article-title>Motivational characteristics of recreational drug use among emerging adults in social settings: An integrative literature review</article-title><source>Front. Public Health</source><year>2023</year><volume>11</volume><elocation-id>1235387</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2023.1235387</pub-id><pub-id pub-id-type="pmid">38026351</pub-id>
</element-citation></ref><ref id="B18-pharmacy-13-00007"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCabe</surname><given-names>S.</given-names></name>
<name><surname>West</surname><given-names>B.</given-names></name>
<name><surname>Boyd</surname><given-names>C.</given-names></name>
</person-group><article-title>Motives for medical misuse of prescription opioids among adolescents</article-title><source>J. Pain</source><year>2013</year><volume>14</volume><fpage>1208</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2013.05.004</pub-id><pub-id pub-id-type="pmid">23954519</pub-id>
</element-citation></ref><ref id="B19-pharmacy-13-00007"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitz</surname><given-names>A.</given-names></name>
</person-group><article-title>Benzodiazepine use, misuse, and abuse: A review</article-title><source>Ment. Health Clin.</source><year>2016</year><volume>6</volume><fpage>120</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.9740/mhc.2016.05.120</pub-id><pub-id pub-id-type="pmid">29955458</pub-id>
</element-citation></ref><ref id="B20-pharmacy-13-00007"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tveito</surname><given-names>K.</given-names></name>
</person-group><article-title>Opioids, power and abuse</article-title><source>Tidsskr. Den Nor. Laegeforening</source><year>2019</year><volume>139</volume><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="B21-pharmacy-13-00007"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gangu</surname><given-names>K.</given-names></name>
<name><surname>Bobba</surname><given-names>A.</given-names></name>
<name><surname>Basida</surname><given-names>S.D.</given-names></name>
<name><surname>Avula</surname><given-names>S.</given-names></name>
<name><surname>Chela</surname><given-names>H.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
</person-group><article-title>Trends of cocaine use and manifestations in hospitalized patients: A cross-sectional study</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e22090</fpage><pub-id pub-id-type="doi">10.7759/cureus.22090</pub-id><pub-id pub-id-type="pmid">35165645</pub-id>
</element-citation></ref><ref id="B22-pharmacy-13-00007"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Connor</surname><given-names>J.P.</given-names></name>
<name><surname>Stjepanovi&#x00107;</surname><given-names>D.</given-names></name>
<name><surname>Le Foll</surname><given-names>B.</given-names></name>
<name><surname>Hoch</surname><given-names>E.</given-names></name>
<name><surname>Budney</surname><given-names>A.J.</given-names></name>
<name><surname>Hall</surname><given-names>W.D.</given-names></name>
</person-group><article-title>Cannabis use and cannabis use disorder</article-title><source>Nat. Rev. Dis. Primers</source><year>2021</year><volume>7</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00247-4</pub-id><pub-id pub-id-type="pmid">33627670</pub-id>
</element-citation></ref><ref id="B23-pharmacy-13-00007"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dewey</surname><given-names>R.E.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular genetics of alkaloid biosynthesis in Nicotiana tabacum</article-title><source>Phytochemistry</source><year>2013</year><volume>94</volume><fpage>10</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2013.06.002</pub-id><pub-id pub-id-type="pmid">23953973</pub-id>
</element-citation></ref><ref id="B24-pharmacy-13-00007"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leas</surname><given-names>E.C.</given-names></name>
<name><surname>Trinidad</surname><given-names>D.R.</given-names></name>
<name><surname>Pierce</surname><given-names>J.P.</given-names></name>
<name><surname>McMenamin</surname><given-names>S.B.</given-names></name>
<name><surname>Messer</surname><given-names>K.</given-names></name>
</person-group><article-title>Trends in cigarette consumption across the United States, with projections to 2035</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0282893</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0282893</pub-id><pub-id pub-id-type="pmid">36913367</pub-id>
</element-citation></ref><ref id="B25-pharmacy-13-00007"><label>25.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Youth and Tobacco Use</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm" ext-link-type="uri">https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B26-pharmacy-13-00007"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallol</surname><given-names>J.</given-names></name>
<name><surname>Urrutia-Pereira</surname><given-names>M.</given-names></name>
<name><surname>Mallol-Simmonds</surname><given-names>M.J.</given-names></name>
<name><surname>Calder&#x000f3;n-Rodr&#x000ed;guez</surname><given-names>L.</given-names></name>
<name><surname>Osses-Vergara</surname><given-names>F.</given-names></name>
<name><surname>Matamala-Bezmalinovic</surname><given-names>A.</given-names></name>
</person-group><article-title>Prevalence and determinants of tobacco smoking among low-income urban adolescents</article-title><source>Pediatr. Allergy Immunol. Pulmonol.</source><year>2021</year><volume>34</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1089/ped.2021.0018</pub-id><pub-id pub-id-type="pmid">34107753</pub-id>
</element-citation></ref><ref id="B27-pharmacy-13-00007"><label>27.</label><element-citation publication-type="other"><person-group person-group-type="author">
<name><surname>Rajabalipour</surname><given-names>M.</given-names></name>
<name><surname>Shafian</surname><given-names>H.</given-names></name>
<name><surname>Iranpour</surname><given-names>A.</given-names></name>
</person-group><article-title>A study of courses related to drug abuse prevention in medical sciences curriculum in Iran</article-title><source>Strides Dev. Med. Educ.</source><year>2019</year><comment>
<italic toggle="yes">in press</italic>
</comment><pub-id pub-id-type="doi">10.5812/sdme.86701</pub-id></element-citation></ref><ref id="B28-pharmacy-13-00007"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cornett</surname><given-names>E.M.</given-names></name>
<name><surname>Budish</surname><given-names>R.</given-names></name>
<name><surname>Latimer</surname><given-names>D.</given-names></name>
<name><surname>Hart</surname><given-names>B.</given-names></name>
<name><surname>Urman</surname><given-names>R.D.</given-names></name>
<name><surname>Kaye</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Management of challenging pharmacologic issues in chronic pain and substance abuse disorders</article-title><source>Anesthesiol. Clin.</source><year>2018</year><volume>36</volume><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.anclin.2018.07.009</pub-id><pub-id pub-id-type="pmid">30390782</pub-id>
</element-citation></ref><ref id="B29-pharmacy-13-00007"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatsukami</surname><given-names>D.K.</given-names></name>
<name><surname>Carroll</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Tobacco harm reduction: History, current controversies and a proposed approach for the future</article-title><source>Prev. Med.</source><year>2020</year><volume>140</volume><fpage>106099</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2020.106099</pub-id><pub-id pub-id-type="pmid">32335031</pub-id>
</element-citation></ref><ref id="B30-pharmacy-13-00007"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fallin</surname><given-names>A.</given-names></name>
<name><surname>Glantz</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Tobacco-control policies in tobacco-growing states: Where tobacco was king</article-title><source>Milbank Q.</source><year>2015</year><volume>93</volume><fpage>319</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1111/1468-0009.12124</pub-id><pub-id pub-id-type="pmid">26044632</pub-id>
</element-citation></ref><ref id="B31-pharmacy-13-00007"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stockings</surname><given-names>E.</given-names></name>
<name><surname>Hall</surname><given-names>W.D.</given-names></name>
<name><surname>Lynskey</surname><given-names>M.</given-names></name>
<name><surname>Morley</surname><given-names>K.I.</given-names></name>
<name><surname>Reavley</surname><given-names>N.</given-names></name>
<name><surname>Strang</surname><given-names>J.</given-names></name>
<name><surname>Patton</surname><given-names>G.</given-names></name>
<name><surname>Degenhardt</surname><given-names>L.</given-names></name>
</person-group><article-title>Prevention, early intervention, harm reduction, and treatment of substance use in young people</article-title><source>Lancet Psychiatry</source><year>2016</year><volume>3</volume><fpage>280</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(16)00002-X</pub-id><pub-id pub-id-type="pmid">26905481</pub-id>
</element-citation></ref><ref id="B32-pharmacy-13-00007"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kampman</surname><given-names>K.M.</given-names></name>
</person-group><article-title>The treatment of cocaine use disorder</article-title><source>Sci. Adv.</source><year>2019</year><volume>5</volume><fpage>eaax1532</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aax1532</pub-id><pub-id pub-id-type="pmid">31663022</pub-id>
</element-citation></ref><ref id="B33-pharmacy-13-00007"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollastro</surname><given-names>F.</given-names></name>
<name><surname>Petrocellis</surname><given-names>L.</given-names></name>
<name><surname>Schiano-Moriello</surname><given-names>A.</given-names></name>
<name><surname>Chianese</surname><given-names>G.</given-names></name>
<name><surname>Heyman</surname><given-names>H.</given-names></name>
<name><surname>Appendino</surname><given-names>G.</given-names></name>
<name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name>
</person-group><article-title>Amorfrutin-type phytocannabinoids from Helichrysum umbraculigerum</article-title><source>Fitoterapia</source><year>2017</year><volume>123</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2017.09.010</pub-id><pub-id pub-id-type="pmid">28941742</pub-id>
</element-citation></ref><ref id="B34-pharmacy-13-00007"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dafni</surname><given-names>A.</given-names></name>
<name><surname>Blanch&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Khatib</surname><given-names>S.</given-names></name>
<name><surname>Petanidou</surname><given-names>T.</given-names></name>
<name><surname>Ayta&#x000e7;</surname><given-names>B.</given-names></name>
<name><surname>Pacini</surname><given-names>E.</given-names></name>
<name><surname>Kozuharova</surname><given-names>E.</given-names></name>
<name><surname>Geva-Kleinberger</surname><given-names>A.</given-names></name>
<name><surname>Shahvar</surname><given-names>S.</given-names></name>
<name><surname>Dajic</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Search of traces of the mandrake myth&#x02014;The etymological, historical, and ethnobotanical roots of its vernacular names</article-title><source>J. Ethnobiol. Ethnomed.</source><year>2021</year><volume>17</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/s13002-021-00494-5</pub-id><pub-id pub-id-type="pmid">34863248</pub-id>
</element-citation></ref><ref id="B35-pharmacy-13-00007"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalise</surname><given-names>U.</given-names></name>
</person-group><article-title>The poppy plant: Phytochemistry and pharmacology</article-title><source>Indo Glob. J. Pharm. Sci.</source><year>2015</year><volume>5</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.35652/IGJPS.2015.24</pub-id></element-citation></ref><ref id="B36-pharmacy-13-00007"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roque Bravo</surname><given-names>R.</given-names></name>
<name><surname>Faria</surname><given-names>A.C.</given-names></name>
<name><surname>Brito-da-Costa</surname><given-names>A.M.</given-names></name>
<name><surname>Carmo</surname><given-names>H.</given-names></name>
<name><surname>Mlad&#x0011b;nka</surname><given-names>P.</given-names></name>
<name><surname>Dias da Silva</surname><given-names>D.</given-names></name>
<name><surname>Remi&#x000e3;o</surname><given-names>F.</given-names></name>
</person-group><article-title>Cocaine: An updated overview on chemistry, detection, biokinetics, and pharmacotoxicological aspects including abuse pattern</article-title><source>Toxins</source><year>2022</year><volume>14</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.3390/toxins14040278</pub-id><pub-id pub-id-type="pmid">35448887</pub-id>
</element-citation></ref><ref id="B37-pharmacy-13-00007"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buchanan</surname><given-names>W.W.</given-names></name>
<name><surname>Rainsford</surname><given-names>K.D.</given-names></name>
<name><surname>Kean</surname><given-names>C.A.</given-names></name>
<name><surname>Kean</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Narcotic analgesics</article-title><source>Inflammopharmacology</source><year>2024</year><volume>32</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s10787-023-01304-y</pub-id><pub-id pub-id-type="pmid">37515654</pub-id>
</element-citation></ref><ref id="B38-pharmacy-13-00007"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wicks</surname><given-names>C.</given-names></name>
<name><surname>Hudlicky</surname><given-names>T.</given-names></name>
<name><surname>Rinner</surname><given-names>U.</given-names></name>
</person-group><article-title>Morphine alkaloids: History, biology, and synthesis</article-title><source>Alkaloids Chem. Biol.</source><year>2021</year><volume>86</volume><fpage>145</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">34565506</pub-id>
</element-citation></ref><ref id="B39-pharmacy-13-00007"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosztafi</surname><given-names>S.</given-names></name>
</person-group><article-title>A heroin t&#x000f6;rt&#x000e9;nete [The history of heroin]</article-title><source>Acta Pharm. Hung.</source><year>2001</year><volume>71</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">11862675</pub-id>
</element-citation></ref><ref id="B40-pharmacy-13-00007"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crocq</surname><given-names>M.A.</given-names></name>
</person-group><article-title>History of cannabis and the endocannabinoid system</article-title><source>Dialogues Clin. Neurosci.</source><year>2020</year><volume>22</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2020.22.3/mcrocq</pub-id><pub-id pub-id-type="pmid">33162765</pub-id>
</element-citation></ref><ref id="B41-pharmacy-13-00007"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Svrakic</surname><given-names>D.M.</given-names></name>
<name><surname>Lustman</surname><given-names>P.J.</given-names></name>
<name><surname>Mallya</surname><given-names>A.</given-names></name>
<name><surname>Lynn</surname><given-names>T.A.</given-names></name>
<name><surname>Finney</surname><given-names>R.</given-names></name>
<name><surname>Svrakic</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Legalization, decriminalization and medicinal use of cannabis: A scientific and public health perspective</article-title><source>Mo. Med.</source><year>2012</year><volume>109</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">22675784</pub-id>
</element-citation></ref><ref id="B42-pharmacy-13-00007"><label>42.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>NIDA</collab>
</person-group><article-title>Cannabis (Marijuana) DrugFacts. Retrieved on 26 March 2024</article-title><comment>Available online: <ext-link xlink:href="https://nida.nih.gov/publications/drugfacts/cannabis-marijuana" ext-link-type="uri">https://nida.nih.gov/publications/drugfacts/cannabis-marijuana</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-02">(accessed on 2 October 2024)</date-in-citation></element-citation></ref><ref id="B43-pharmacy-13-00007"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Godlaski</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Holy smoke: Tobacco use among Native American tribes in North America</article-title><source>Subst. Use Misuse</source><year>2013</year><volume>48</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3109/10826084.2012.739490</pub-id><pub-id pub-id-type="pmid">23153043</pub-id>
</element-citation></ref><ref id="B44-pharmacy-13-00007"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rawat</surname><given-names>A.</given-names></name>
<name><surname>Mal</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Phytochemical properties and pharmacological activities of Nicotiana tabacum: A review</article-title><source>Indian J. Pharm. Biol. Res.</source><year>2013</year><volume>1</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.30750/ijpbr.1.2.9</pub-id></element-citation></ref><ref id="B45-pharmacy-13-00007"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Mahato</surname><given-names>D.</given-names></name>
<name><surname>Kamle</surname><given-names>M.</given-names></name>
<name><surname>Borah</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>B.</given-names></name>
<name><surname>Pandhi</surname><given-names>S.</given-names></name>
<name><surname>Tripathi</surname><given-names>V.</given-names></name>
<name><surname>Yadav</surname><given-names>H.S.</given-names></name>
<name><surname>Devi</surname><given-names>S.</given-names></name>
<name><surname>Patil</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Pharmacological properties, therapeutic potential, and legal status of <italic toggle="yes">Cannabis sativa</italic> L.: An overview</article-title><source>Phytother. Res.</source><year>2021</year><volume>35</volume><fpage>6010</fpage><lpage>6029</lpage><pub-id pub-id-type="doi">10.1002/ptr.7213</pub-id><pub-id pub-id-type="pmid">34237796</pub-id>
</element-citation></ref><ref id="B46-pharmacy-13-00007"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melchior</surname><given-names>M.</given-names></name>
<name><surname>Nakamura</surname><given-names>A.</given-names></name>
<name><surname>Bolze</surname><given-names>C.</given-names></name>
<name><surname>Hausfater</surname><given-names>F.</given-names></name>
<name><surname>El-Khoury</surname><given-names>F.</given-names></name>
<name><surname>Mary-Krause</surname><given-names>M.</given-names></name>
<name><surname>Azevedo Da Silva</surname><given-names>M.</given-names></name>
</person-group><article-title>Does liberalization of cannabis policy influence levels of use in adolescents and young adults? A systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><fpage>e025880</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-025880</pub-id></element-citation></ref><ref id="B47-pharmacy-13-00007"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hourfane</surname><given-names>S.</given-names></name>
<name><surname>Mechqoq</surname><given-names>H.</given-names></name>
<name><surname>Bekkali</surname><given-names>A.</given-names></name>
<name><surname>Rocha</surname><given-names>J.</given-names></name>
<name><surname>Aouad</surname><given-names>N.</given-names></name>
</person-group><article-title>A comprehensive review of <italic toggle="yes">Cannabis sativa</italic> ethnobotany, phytochemistry, molecular docking, and biological activities</article-title><source>Plants</source><year>2023</year><volume>12</volume><elocation-id>1245</elocation-id><pub-id pub-id-type="doi">10.3390/plants12061245</pub-id><pub-id pub-id-type="pmid">36986932</pub-id>
</element-citation></ref><ref id="B48-pharmacy-13-00007"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salehi</surname><given-names>A.</given-names></name>
<name><surname>Puchalski</surname><given-names>K.</given-names></name>
<name><surname>Shokoohinia</surname><given-names>Y.</given-names></name>
<name><surname>Zolfaghari</surname><given-names>B.</given-names></name>
<name><surname>Asgary</surname><given-names>S.</given-names></name>
</person-group><article-title>Differentiating cannabis products: Drugs, food, and supplements</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>906038</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.906038</pub-id><pub-id pub-id-type="pmid">35833025</pub-id>
</element-citation></ref><ref id="B49-pharmacy-13-00007"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farrelly</surname><given-names>K.N.</given-names></name>
<name><surname>Wardell</surname><given-names>J.D.</given-names></name>
<name><surname>Marsden</surname><given-names>E.</given-names></name>
<name><surname>Scarfe</surname><given-names>M.L.</given-names></name>
<name><surname>Najdzionek</surname><given-names>P.</given-names></name>
<name><surname>Turna</surname><given-names>J.</given-names></name>
<name><surname>MacKillop</surname><given-names>J.</given-names></name>
</person-group><article-title>The impact of recreational cannabis legalization on cannabis use and associated outcomes: A systematic review</article-title><source>Subst. Abus. Res. Treat.</source><year>2023</year><volume>17</volume><fpage>11782218231172054</fpage><pub-id pub-id-type="doi">10.1177/11782218231172054</pub-id><pub-id pub-id-type="pmid">37187466</pub-id>
</element-citation></ref><ref id="B50-pharmacy-13-00007"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manthey</surname><given-names>J.</given-names></name>
<name><surname>Klinger</surname><given-names>S.</given-names></name>
<name><surname>Rosenkranz</surname><given-names>M.</given-names></name>
<name><surname>Schwarzkopf</surname><given-names>L.</given-names></name>
</person-group><article-title>Cannabis use, health problems, and criminal offenses in Germany: National and state-level trends between 2009 and 2021</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2024</year><volume>274</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="B51-pharmacy-13-00007"><label>51.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>U.S. Department of Health and Human Services</collab>
</person-group><source>The Health Consequences of Smoking: 50 Years of Progress</source><publisher-name>Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B52-pharmacy-13-00007"><label>52.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Federal Trade Commission</collab>
</person-group><article-title>Federal Cigarette Labeling and Advertising Act</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.ftc.gov/legal-library/browse/statutes/federal-cigarette-labeling-advertising-act" ext-link-type="uri">https://www.ftc.gov/legal-library/browse/statutes/federal-cigarette-labeling-advertising-act</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-20">(accessed on 20 October 2024)</date-in-citation></element-citation></ref><ref id="B53-pharmacy-13-00007"><label>53.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Preuss</surname><given-names>C.V.</given-names></name>
<name><surname>Kalava</surname><given-names>A.</given-names></name>
<name><surname>King</surname><given-names>K.C.</given-names></name>
</person-group><article-title>Prescription of controlled substances: Benefits and risks</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B54-pharmacy-13-00007"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>C.S.</given-names></name>
<name><surname>Lieberman</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Laws limiting prescribing and dispensing of opioids in the United States, 1989&#x02013;2019</article-title><source>Addiction</source><year>2021</year><volume>116</volume><fpage>1817</fpage><lpage>1827</lpage><pub-id pub-id-type="doi">10.1111/add.15359</pub-id><pub-id pub-id-type="pmid">33245795</pub-id>
</element-citation></ref><ref id="B55-pharmacy-13-00007"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Redman</surname><given-names>M.</given-names></name>
</person-group><article-title>Cocaine: What is the crack? A brief history of the use of cocaine as an anesthetic</article-title><source>Anesth. Pain Med.</source><year>2011</year><volume>1</volume><fpage>95</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.5812/aapm.1890</pub-id><pub-id pub-id-type="pmid">25729664</pub-id>
</element-citation></ref><ref id="B56-pharmacy-13-00007"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>J.K.</given-names></name>
<name><surname>Callaghan</surname><given-names>R.C.</given-names></name>
<name><surname>Liu</surname><given-names>L.M.</given-names></name>
</person-group><article-title>U.S. federal cocaine essential (&#x02018;precursor&#x02019;) chemical regulation impacts on U.S. cocaine availability: An intervention time-series analysis with temporal replication</article-title><source>Addiction</source><year>2015</year><volume>110</volume><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1111/add.12839</pub-id><pub-id pub-id-type="pmid">25559418</pub-id>
</element-citation></ref><ref id="B57-pharmacy-13-00007"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Restrepo</surname><given-names>D.</given-names></name>
<name><surname>Saenz</surname><given-names>E.</given-names></name>
<name><surname>Jara-Mu&#x000f1;oz</surname><given-names>O.</given-names></name>
<name><surname>Calixto-Bot&#x000ed;a</surname><given-names>I.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Su&#x000e1;rez</surname><given-names>S.</given-names></name>
<name><surname>Zuleta</surname><given-names>P.</given-names></name>
<name><surname>Chavez</surname><given-names>B.G.</given-names></name>
<name><surname>Sanchez</surname><given-names>J.A.</given-names></name>
<name><surname>D&#x02019;Auria</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Erythroxylum in focus: An interdisciplinary review of an overlooked genus</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>3788</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24203788</pub-id><pub-id pub-id-type="pmid">31640255</pub-id>
</element-citation></ref><ref id="B58-pharmacy-13-00007"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cunningham</surname><given-names>N.</given-names></name>
</person-group><article-title>Hallucinogenic plants of abuse</article-title><source>Emerg. Med. Australas.</source><year>2008</year><volume>20</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/j.1742-6723.2008.01070.x</pub-id><pub-id pub-id-type="pmid">18377406</pub-id>
</element-citation></ref><ref id="B59-pharmacy-13-00007"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Redonnet</surname><given-names>B.</given-names></name>
<name><surname>Chollet</surname><given-names>A.</given-names></name>
<name><surname>Fombonne</surname><given-names>&#x000c9;.</given-names></name>
<name><surname>Bowes</surname><given-names>L.</given-names></name>
<name><surname>Melchior</surname><given-names>M.</given-names></name>
</person-group><article-title>Tobacco, alcohol, cannabis, and other illegal drug use among young adults: The socioeconomic context</article-title><source>Drug Alcohol Depend.</source><year>2012</year><volume>121</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.09.002</pub-id><pub-id pub-id-type="pmid">21955362</pub-id>
</element-citation></ref><ref id="B60-pharmacy-13-00007"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavalloro</surname><given-names>V.</given-names></name>
</person-group><article-title>Teodorico Borgognoni&#x02019;s formulary for thirteenth-century anesthetic preparations</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>1913</elocation-id><pub-id pub-id-type="doi">10.3390/life13091913</pub-id><pub-id pub-id-type="pmid">37763316</pub-id>
</element-citation></ref><ref id="B61-pharmacy-13-00007"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dirgantara</surname><given-names>M.</given-names></name>
<name><surname>Maksum</surname><given-names>A.</given-names></name>
</person-group><article-title>The dilemma of national security threats in efforts to realize the banning of kratom plants by the National Anti-Narcotics Agency in Kapuas Hulu Regency</article-title><source>Int. J. Multicult. Multireligious Underst.</source><year>2022</year><volume>9</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.18415/ijmmu.v9i12.4181</pub-id></element-citation></ref><ref id="B62-pharmacy-13-00007"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>R.S.</given-names></name>
<name><surname>Goldfrank</surname><given-names>L.R.</given-names></name>
</person-group><article-title>The impact of drug abuse and addiction on society</article-title><source>Emerg. Med. Clin. N. Am.</source><year>1990</year><volume>8</volume><fpage>467</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/S0733-8627(20)30253-4</pub-id></element-citation></ref><ref id="B63-pharmacy-13-00007"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin</surname><given-names>U.</given-names></name>
<name><surname>Malla</surname><given-names>A.M.</given-names></name>
<name><surname>Amin</surname><given-names>I.</given-names></name>
<name><surname>Jan</surname><given-names>R.</given-names></name>
</person-group><article-title>Substance abuse: A public health concern</article-title><source>Indian J. Psychiatr. Nurs.</source><year>2023</year><volume>20</volume><fpage>168</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.4103/iopn.iopn_25_23</pub-id></element-citation></ref><ref id="B64-pharmacy-13-00007"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manthey</surname><given-names>J.</given-names></name>
<name><surname>Armstrong</surname><given-names>M.J.</given-names></name>
<name><surname>Hayer</surname><given-names>T.</given-names></name>
<name><surname>Myran</surname><given-names>D.T.</given-names></name>
<name><surname>Pacula</surname><given-names>R.L.</given-names></name>
<name><surname>Queirolo</surname><given-names>R.</given-names></name>
<name><surname>Rehm</surname><given-names>J.</given-names></name>
<name><surname>Wirth</surname><given-names>M.</given-names></name>
<name><surname>Zobel</surname><given-names>F.</given-names></name>
</person-group><article-title>How to interpret studies on the impact of legalizing cannabis</article-title><source>Addiction</source><year>2023</year><volume>118</volume><fpage>2242</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.1111/add.16314</pub-id><pub-id pub-id-type="pmid">37544768</pub-id>
</element-citation></ref><ref id="B65-pharmacy-13-00007"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeiger</surname><given-names>J.S.</given-names></name>
<name><surname>Silvers</surname><given-names>W.S.</given-names></name>
<name><surname>Naimi</surname><given-names>D.R.</given-names></name>
<name><surname>Skypala</surname><given-names>I.J.</given-names></name>
<name><surname>Ellis</surname><given-names>A.K.</given-names></name>
<name><surname>Connors</surname><given-names>L.</given-names></name>
<name><surname>Jeimy</surname><given-names>S.</given-names></name>
<name><surname>Nayak</surname><given-names>A.P.</given-names></name>
<name><surname>Bernstein</surname><given-names>J.A.</given-names></name>
<name><surname>Zeiger</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Impact of cannabis knowledge and attitudes on real-world practice</article-title><source>Ann. Allergy Asthma Immunol.</source><year>2022</year><volume>129</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2022.04.021</pub-id><pub-id pub-id-type="pmid">35472594</pub-id>
</element-citation></ref><ref id="B66-pharmacy-13-00007"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiolero</surname><given-names>A.</given-names></name>
<name><surname>Wietlisbach</surname><given-names>V.</given-names></name>
<name><surname>Ruffieux</surname><given-names>C.</given-names></name>
<name><surname>Paccaud</surname><given-names>F.</given-names></name>
<name><surname>Cornuz</surname><given-names>J.</given-names></name>
</person-group><article-title>Clustering of risk behaviors with cigarette consumption: A population-based survey</article-title><source>Prev. Med.</source><year>2006</year><volume>42</volume><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2006.01.011</pub-id><pub-id pub-id-type="pmid">16504277</pub-id>
</element-citation></ref><ref id="B67-pharmacy-13-00007"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayo-Yusuf</surname><given-names>O.A.</given-names></name>
<name><surname>Agaku</surname><given-names>I.T.</given-names></name>
</person-group><article-title>The association between smokers&#x02019; perceived importance of the appearance of cigarettes/cigarette packs and smoking sensory experience: A structural equation model</article-title><source>Nicotine Tob. Res.</source><year>2014</year><volume>17</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntu135</pub-id><pub-id pub-id-type="pmid">25200812</pub-id>
</element-citation></ref><ref id="B68-pharmacy-13-00007"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mercadante</surname><given-names>S.</given-names></name>
<name><surname>Arcuri</surname><given-names>E.</given-names></name>
<name><surname>Santoni</surname><given-names>A.</given-names></name>
</person-group><article-title>Opioid-induced tolerance and hyperalgesia</article-title><source>CNS Drugs</source><year>2019</year><volume>33</volume><fpage>943</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1007/s40263-019-00660-0</pub-id><pub-id pub-id-type="pmid">31578704</pub-id>
</element-citation></ref><ref id="B69-pharmacy-13-00007"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruera</surname><given-names>E.</given-names></name>
<name><surname>Paice</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Cancer pain management: Safe and effective use of opioids</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2015</year><volume>35</volume><fpage>e593</fpage><lpage>e599</lpage><pub-id pub-id-type="doi">10.14694/EdBook_AM.2015.35.e593</pub-id></element-citation></ref><ref id="B70-pharmacy-13-00007"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hagemeier</surname><given-names>N.E.</given-names></name>
</person-group><article-title>Introduction to the opioid epidemic: The economic burden on the healthcare system and impact on quality of life</article-title><source>Am. J. Manag. Care</source><year>2018</year><volume>24</volume><issue>(Suppl. S10)</issue><fpage>S200</fpage><lpage>S206</lpage><pub-id pub-id-type="pmid">29851449</pub-id>
</element-citation></ref><ref id="B71-pharmacy-13-00007"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>E.K.C.</given-names></name>
<name><surname>Wolkowicz</surname><given-names>N.R.</given-names></name>
<name><surname>De Aquino</surname><given-names>J.P.</given-names></name>
<name><surname>MacLean</surname><given-names>R.R.</given-names></name>
<name><surname>Sofuoglu</surname><given-names>M.</given-names></name>
</person-group><article-title>Cocaine use disorder (CUD): Current clinical perspectives</article-title><source>Subst. Abus. Rehabil.</source><year>2022</year><volume>13</volume><fpage>25</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.2147/SAR.S337338</pub-id><pub-id pub-id-type="pmid">36093428</pub-id>
</element-citation></ref><ref id="B72-pharmacy-13-00007"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>A.</given-names></name>
<name><surname>Hayhurst</surname><given-names>K.P.</given-names></name>
<name><surname>Jahr</surname><given-names>S.</given-names></name>
<name><surname>White</surname><given-names>M.</given-names></name>
<name><surname>Millar</surname><given-names>T.</given-names></name>
</person-group><article-title>Estimates of the incidence of crack cocaine use in those likely to attend treatment in the English population, 2005&#x02013;2018</article-title><source>Eur. Addict. Res.</source><year>2021</year><volume>27</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1159/000507287</pub-id><pub-id pub-id-type="pmid">32375146</pub-id>
</element-citation></ref><ref id="B73-pharmacy-13-00007"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Hagan</surname><given-names>A.</given-names></name>
<name><surname>Poxon</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Cocaine trafficking and the social impact of cocaine on UK society</article-title><source>Forensic Res. Criminol. Int. J.</source><year>2016</year><volume>2</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.15406/frcij.2016.02.00048</pub-id></element-citation></ref><ref id="B74-pharmacy-13-00007"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hall</surname><given-names>W.</given-names></name>
<name><surname>Lynskey</surname><given-names>M.</given-names></name>
</person-group><article-title>Assessing the public health impacts of legalizing recreational cannabis use: The US experience</article-title><source>World Psychiatry</source><year>2020</year><volume>19</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1002/wps.20735</pub-id><pub-id pub-id-type="pmid">32394566</pub-id>
</element-citation></ref><ref id="B75-pharmacy-13-00007"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burillo-Putze</surname><given-names>G.</given-names></name>
<name><surname>Briz</surname><given-names>E.</given-names></name>
<name><surname>D&#x000ed;az</surname><given-names>B.</given-names></name>
<name><surname>Mas</surname><given-names>P.</given-names></name>
<name><surname>Xarau</surname><given-names>S.</given-names></name>
<name><surname>Pinillos</surname><given-names>M.</given-names></name>
<name><surname>Hoffman</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Drogas emergentes (III): Plantas y hongos alucin&#x000f3;genos</article-title><source>An. Del Sist. Sanit. De Navar.</source><year>2013</year><volume>36</volume><fpage>505</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.4321/S1137-66272013000300015</pub-id><pub-id pub-id-type="pmid">24406363</pub-id>
</element-citation></ref><ref id="B76-pharmacy-13-00007"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
</person-group><article-title>Opportunities in novel psychotropic drug design from natural compounds</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2019</year><volume>22</volume><fpage>601</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyz042</pub-id><pub-id pub-id-type="pmid">31353393</pub-id>
</element-citation></ref><ref id="B77-pharmacy-13-00007"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kovalchuk</surname><given-names>I.</given-names></name>
<name><surname>Pellino</surname><given-names>M.</given-names></name>
<name><surname>Rigault</surname><given-names>P.</given-names></name>
<name><surname>Velzen</surname><given-names>R.</given-names></name>
<name><surname>Ebersbach</surname><given-names>J.</given-names></name>
<name><surname>Ashnest</surname><given-names>J.</given-names></name>
<name><surname>Mau</surname><given-names>M.</given-names></name>
<name><surname>Schranz</surname><given-names>M.E.</given-names></name>
<name><surname>Alcorn</surname><given-names>J.</given-names></name>
<name><surname>Laprairie</surname><given-names>R.B.</given-names></name>
<etal/>
</person-group><article-title>The genomics of cannabis and its close relatives</article-title><source>Annu. Rev. Plant Biol.</source><year>2020</year><volume>71</volume><fpage>713</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1146/annurev-arplant-081519-040203</pub-id><pub-id pub-id-type="pmid">32155342</pub-id>
</element-citation></ref><ref id="B78-pharmacy-13-00007"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarris</surname><given-names>J.</given-names></name>
</person-group><article-title>Herbal medicines in the treatment of psychiatric disorders: 10-year updated review</article-title><source>Phytother. Res.</source><year>2018</year><volume>32</volume><fpage>1147</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1002/ptr.6055</pub-id><pub-id pub-id-type="pmid">29575228</pub-id>
</element-citation></ref><ref id="B79-pharmacy-13-00007"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dorsen</surname><given-names>C.</given-names></name>
<name><surname>Palamar</surname><given-names>J.</given-names></name>
<name><surname>Shedlin</surname><given-names>M.</given-names></name>
</person-group><article-title>Ceremonial &#x02018;plant medicine&#x02019; use and its relationship to recreational drug use: An exploratory study</article-title><source>Addict. Res. Theory</source><year>2018</year><volume>27</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1080/16066359.2018.1455187</pub-id><pub-id pub-id-type="pmid">31534445</pub-id>
</element-citation></ref><ref id="B80-pharmacy-13-00007"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wadley</surname><given-names>G.</given-names></name>
</person-group><article-title>How psychoactive drugs shape human culture: A multidisciplinary perspective</article-title><source>Brain Res. Bull.</source><year>2016</year><volume>126</volume><fpage>138</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.04.008</pub-id><pub-id pub-id-type="pmid">27083300</pub-id>
</element-citation></ref><ref id="B81-pharmacy-13-00007"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fearby</surname><given-names>N.</given-names></name>
<name><surname>Penman</surname><given-names>S.</given-names></name>
<name><surname>Thanos</surname><given-names>P.</given-names></name>
</person-group><article-title>Effects of &#x003b4;9-tetrahydrocannabinol (THC) on obesity at different stages of life: A literature review</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>3174</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19063174</pub-id><pub-id pub-id-type="pmid">35328862</pub-id>
</element-citation></ref><ref id="B82-pharmacy-13-00007"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000f5;ukand</surname><given-names>R.</given-names></name>
<name><surname>Quave</surname><given-names>C.</given-names></name>
<name><surname>Pieroni</surname><given-names>A.</given-names></name>
<name><surname>Pardo-de-Santayana</surname><given-names>M.</given-names></name>
<name><surname>Tard&#x000ed;o</surname><given-names>J.</given-names></name>
<name><surname>Kalle</surname><given-names>R.</given-names></name>
<name><surname>&#x00141;uczaj</surname><given-names>&#x00141;.</given-names></name>
<name><surname>Svanberg</surname><given-names>I.</given-names></name>
<name><surname>Kolosova</surname><given-names>V.</given-names></name>
<name><surname>Aceituno-Mata</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Plants used for making recreational tea in Europe: A review based on specific research sites</article-title><source>J. Ethnobiol. Ethnomedicine</source><year>2013</year><volume>9</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.1186/1746-4269-9-58</pub-id><pub-id pub-id-type="pmid">23941692</pub-id>
</element-citation></ref><ref id="B83-pharmacy-13-00007"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmid</surname><given-names>Y.</given-names></name>
<name><surname>Liechti</surname><given-names>M.</given-names></name>
</person-group><article-title>Long-lasting subjective effects of LSD in normal subjects</article-title><source>Psychopharmacology</source><year>2017</year><volume>235</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1007/s00213-017-4733-3</pub-id><pub-id pub-id-type="pmid">28918441</pub-id>
</element-citation></ref><ref id="B84-pharmacy-13-00007"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brito-da-Costa</surname><given-names>A.</given-names></name>
<name><surname>Silva</surname><given-names>D.</given-names></name>
<name><surname>Gomes</surname><given-names>N.</given-names></name>
<name><surname>Dinis-Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Madureira-Carvalho</surname><given-names>&#x000c1;.</given-names></name>
</person-group><article-title>Toxicokinetics and toxicodynamics of ayahuasca alkaloids N, N-dimethyltryptamine (DMT), harmine, harmaline, and tetrahydroharmine: Clinical and forensic impact</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>334</elocation-id><pub-id pub-id-type="doi">10.3390/ph13110334</pub-id><pub-id pub-id-type="pmid">33114119</pub-id>
</element-citation></ref><ref id="B85-pharmacy-13-00007"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warner</surname><given-names>M.</given-names></name>
<name><surname>Kaufman</surname><given-names>N.</given-names></name>
<name><surname>Grundmann</surname><given-names>O.</given-names></name>
</person-group><article-title>The pharmacology and toxicology of kratom: From traditional herb to drug of abuse</article-title><source>Int. J. Leg. Med.</source><year>2015</year><volume>130</volume><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s00414-015-1279-y</pub-id><pub-id pub-id-type="pmid">26511390</pub-id>
</element-citation></ref><ref id="B86-pharmacy-13-00007"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamill</surname><given-names>J.</given-names></name>
<name><surname>Hallak</surname><given-names>J.</given-names></name>
<name><surname>Dursun</surname><given-names>S.</given-names></name>
<name><surname>Baker</surname><given-names>G.</given-names></name>
</person-group><article-title>Ayahuasca: Psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness</article-title><source>Curr. Neuropharmacol.</source><year>2019</year><volume>17</volume><fpage>108</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.2174/1570159X16666180125095902</pub-id><pub-id pub-id-type="pmid">29366418</pub-id>
</element-citation></ref><ref id="B87-pharmacy-13-00007"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>K.</given-names></name>
<name><surname>Rogers</surname><given-names>J.</given-names></name>
<name><surname>Feldman</surname><given-names>J.</given-names></name>
</person-group><article-title>Kratom&#x02019;s emergence and persistence within the US polydrug epidemic</article-title><source>Curr. Addict. Rep.</source><year>2023</year><volume>10</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s40429-023-00476-5</pub-id><pub-id pub-id-type="pmid">37266191</pub-id>
</element-citation></ref><ref id="B88-pharmacy-13-00007"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbosa</surname><given-names>P.</given-names></name>
<name><surname>Mizumoto</surname><given-names>S.</given-names></name>
<name><surname>Bogenschutz</surname><given-names>M.</given-names></name>
<name><surname>Strassman</surname><given-names>R.</given-names></name>
</person-group><article-title>Health status of ayahuasca users</article-title><source>Drug Test. Anal.</source><year>2012</year><volume>4</volume><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1002/dta.1383</pub-id><pub-id pub-id-type="pmid">22761152</pub-id>
</element-citation></ref><ref id="B89-pharmacy-13-00007"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>K.</given-names></name>
<name><surname>Dunn</surname><given-names>K.</given-names></name>
<name><surname>Rogers</surname><given-names>J.</given-names></name>
<name><surname>Garcia-Romeu</surname><given-names>A.</given-names></name>
<name><surname>Strickland</surname><given-names>J.</given-names></name>
<name><surname>Epstein</surname><given-names>D.</given-names></name>
</person-group><article-title>Assessment of kratom use disorder and withdrawal among an online convenience sample of US adults</article-title><source>J. Addict. Med.</source><year>2022</year><volume>16</volume><fpage>666</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000986</pub-id><pub-id pub-id-type="pmid">35220331</pub-id>
</element-citation></ref><ref id="B90-pharmacy-13-00007"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lanaro</surname><given-names>R.</given-names></name>
<name><surname>Mello</surname><given-names>S.</given-names></name>
<name><surname>Cunha</surname><given-names>K.</given-names></name>
<name><surname>Silveira</surname><given-names>G.</given-names></name>
<name><surname>Corr&#x000ea;a-Neto</surname><given-names>N.</given-names></name>
<name><surname>Hyslop</surname><given-names>S.</given-names></name>
<name><surname>Cabrices</surname><given-names>O.G.</given-names></name>
<name><surname>Costa</surname><given-names>J.L.</given-names></name>
<name><surname>Linardi</surname><given-names>A.</given-names></name>
</person-group><article-title>Kinetic profile of N,N-dimethyltryptamine and &#x003b2;-carbolines in saliva and serum after oral administration of ayahuasca in a religious context</article-title><source>Drug Test. Anal.</source><year>2020</year><volume>13</volume><fpage>664</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/dta.2955</pub-id><pub-id pub-id-type="pmid">33119972</pub-id>
</element-citation></ref><ref id="B91-pharmacy-13-00007"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chambers</surname><given-names>M.</given-names></name>
<name><surname>Osborne</surname><given-names>A.</given-names></name>
<name><surname>Musah</surname><given-names>R.</given-names></name>
</person-group><article-title>Rapid detection and validated quantification of psychoactive compounds in complex plant matrices by direct analysis in accurate time&#x02013;high resolution mass spectrometry: Application to &#x0201c;kava&#x0201d; psychoactive pepper products</article-title><source>Rapid Commun. Mass Spectrom.</source><year>2019</year><volume>33</volume><fpage>1915</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1002/rcm.8532</pub-id><pub-id pub-id-type="pmid">31323704</pub-id>
</element-citation></ref><ref id="B92-pharmacy-13-00007"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kerrigan</surname><given-names>S.</given-names></name>
<name><surname>Basiliere</surname><given-names>S.</given-names></name>
</person-group><article-title>Kratom: A systematic review of toxicological issues</article-title><source>Wiley Interdiscip. Rev. Forensic Sci.</source><year>2021</year><volume>4</volume><fpage>e1420</fpage><pub-id pub-id-type="doi">10.1002/wfs2.1420</pub-id></element-citation></ref><ref id="B93-pharmacy-13-00007"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graziano</surname><given-names>S.</given-names></name>
<name><surname>Orsolini</surname><given-names>L.</given-names></name>
<name><surname>Rotolo</surname><given-names>M.</given-names></name>
<name><surname>Tittarelli</surname><given-names>R.</given-names></name>
<name><surname>Schifano</surname><given-names>F.</given-names></name>
<name><surname>Pichini</surname><given-names>S.</given-names></name>
</person-group><article-title>Herbal highs: Review on psychoactive effects and neuropharmacology</article-title><source>Curr. Neuropharmacol.</source><year>2017</year><volume>15</volume><fpage>750</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.2174/1570159X14666161031144427</pub-id><pub-id pub-id-type="pmid">27799032</pub-id>
</element-citation></ref><ref id="B94-pharmacy-13-00007"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malavika</surname><given-names>J.</given-names></name>
<name><surname>Thenmozhi</surname><given-names>K.</given-names></name>
</person-group><article-title>A comprehensive review of the ethnopharmacological and therapeutic perspectives of psychoactive plants</article-title><source>Kongunadu Res. J.</source><year>2023</year><volume>10</volume><fpage>48</fpage><lpage>52</lpage></element-citation></ref><ref id="B95-pharmacy-13-00007"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orsolini</surname><given-names>L.</given-names></name>
<name><surname>John-Smith</surname><given-names>P.</given-names></name>
<name><surname>McQueen</surname><given-names>D.</given-names></name>
<name><surname>Papanti</surname><given-names>D.</given-names></name>
<name><surname>Corkery</surname><given-names>J.</given-names></name>
<name><surname>Schifano</surname><given-names>F.</given-names></name>
</person-group><article-title>Evolutionary considerations on the emerging subculture of the e-psychonauts and the novel psychoactive substances: A comeback to the shamanism?</article-title><source>Curr. Neuropharmacol.</source><year>2017</year><volume>15</volume><fpage>731</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.2174/1570159X15666161111114838</pub-id><pub-id pub-id-type="pmid">27834144</pub-id>
</element-citation></ref><ref id="B96-pharmacy-13-00007"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pisanti</surname><given-names>S.</given-names></name>
<name><surname>Bifulco</surname><given-names>M.</given-names></name>
</person-group><article-title>Medical cannabis: A premillennial history of an evergreen</article-title><source>J. Cell Physiol.</source><year>2018</year><volume>234</volume><fpage>8342</fpage><lpage>8351</lpage><pub-id pub-id-type="doi">10.1002/jcp.27725</pub-id><pub-id pub-id-type="pmid">30417354</pub-id>
</element-citation></ref><ref id="B97-pharmacy-13-00007"><label>97.</label><element-citation publication-type="journal"><article-title>Cannabis: From cultivar to chemovar II&#x02014;A metabolomics approach to cannabis classification</article-title><source>Cannabis Cannabinoid Res.</source><year>2016</year><volume>1</volume><fpage>202</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1089/can.2016.0017</pub-id></element-citation></ref><ref id="B98-pharmacy-13-00007"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clarke</surname><given-names>K.</given-names></name>
<name><surname>Porter</surname><given-names>R.</given-names></name>
<name><surname>Facey</surname><given-names>P.</given-names></name>
<name><surname>Thoms-Rodriguez</surname><given-names>C.</given-names></name>
</person-group><article-title>Chemical composition and biological activities of Jamaican <italic toggle="yes">Cannabis sativa</italic> essential oils as the plant matures</article-title><source>Flavor Fragr. J.</source><year>2023</year><volume>38</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1002/ffj.3732</pub-id></element-citation></ref><ref id="B99-pharmacy-13-00007"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mano-Sousa</surname><given-names>B.</given-names></name>
<name><surname>Maia</surname><given-names>G.</given-names></name>
<name><surname>Lima</surname><given-names>P.</given-names></name>
<name><surname>Campos</surname><given-names>V.</given-names></name>
<name><surname>Negri</surname><given-names>G.</given-names></name>
<name><surname>Chequer</surname><given-names>F.</given-names></name>
<name><surname>Duarte-Almeida</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Color determination method and evaluation of methods for detecting cannabinoids by thin-layer chromatography (TLC)</article-title><source>J. Forensic Sci.</source><year>2020</year><volume>66</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1111/1556-4029.14659</pub-id><pub-id pub-id-type="pmid">33369752</pub-id>
</element-citation></ref><ref id="B100-pharmacy-13-00007"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malabadi</surname><given-names>R.</given-names></name>
</person-group><article-title>Quantification of THC levels in different varieties of <italic toggle="yes">Cannabis sativa</italic></article-title><source>Int. J. Sci. Res. Arch.</source><year>2023</year><volume>10</volume><fpage>860</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.30574/ijsra.2023.10.2.1029</pub-id></element-citation></ref><ref id="B101-pharmacy-13-00007"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hazekamp</surname><given-names>A.</given-names></name>
<name><surname>Fischedick</surname><given-names>J.</given-names></name>
</person-group><article-title>Cannabis&#x02014;From cultivar to chemovar</article-title><source>Drug Test. Anal.</source><year>2012</year><volume>4</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/dta.407</pub-id><pub-id pub-id-type="pmid">22362625</pub-id>
</element-citation></ref><ref id="B102-pharmacy-13-00007"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arsenault</surname><given-names>T.</given-names></name>
</person-group><article-title>Compliance testing of hemp (<italic toggle="yes">Cannabis sativa</italic> L.) cultivars for total delta-9 THC and total CBD using gas chromatography with flame ionization detection</article-title><source>Plants</source><year>2024</year><volume>13</volume><elocation-id>519</elocation-id><pub-id pub-id-type="doi">10.3390/plants13040519</pub-id><pub-id pub-id-type="pmid">38498421</pub-id>
</element-citation></ref><ref id="B103-pharmacy-13-00007"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Durydivka</surname><given-names>O.</given-names></name>
</person-group><article-title>Hexahydrocannabinol (HHC) and &#x00394;9-tetrahydrocannabinol (&#x00394;9-THC) driven activation of cannabinoid receptor one results in biased intracellular signaling</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>9181</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-58845-7</pub-id><pub-id pub-id-type="pmid">38649680</pub-id>
</element-citation></ref><ref id="B104-pharmacy-13-00007"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>C.</given-names></name>
<name><surname>Fong</surname><given-names>Y.</given-names></name>
</person-group><article-title>Perioperative cannabis as a potential solution for reducing opioid and benzodiazepine dependence</article-title><source>JAMA Surg.</source><year>2021</year><volume>156</volume><fpage>181</fpage><pub-id pub-id-type="doi">10.1001/jamasurg.2020.5545</pub-id><pub-id pub-id-type="pmid">33263719</pub-id>
</element-citation></ref><ref id="B105-pharmacy-13-00007"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Vergara</surname><given-names>D.</given-names></name>
<name><surname>Keegan</surname><given-names>B.</given-names></name>
<name><surname>Jikomes</surname><given-names>N.</given-names></name>
</person-group><article-title>The phytochemical diversity of commercial cannabis in the United States</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0267498</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0267498</pub-id><pub-id pub-id-type="pmid">35588111</pub-id>
</element-citation></ref><ref id="B106-pharmacy-13-00007"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johns</surname><given-names>A.</given-names></name>
</person-group><article-title>Psychiatric effects of cannabis</article-title><source>Br. J. Psychiatry</source><year>2001</year><volume>178</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1192/bjp.178.2.116</pub-id><pub-id pub-id-type="pmid">11157424</pub-id>
</element-citation></ref><ref id="B107-pharmacy-13-00007"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinberger</surname><given-names>A.</given-names></name>
<name><surname>Dierker</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Levin</surname><given-names>J.</given-names></name>
<name><surname>Goodwin</surname><given-names>R.</given-names></name>
</person-group><article-title>Cigarette dependence is more prevalent and increasing among US adolescents and adults who use cannabis, 2002&#x02013;2019</article-title><source>Tob. Control</source><year>2021</year><volume>32</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1136/tobaccocontrol-2021-056723</pub-id><pub-id pub-id-type="pmid">34815363</pub-id>
</element-citation></ref><ref id="B108-pharmacy-13-00007"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gennaro</surname><given-names>G.</given-names></name>
<name><surname>Colizzi</surname><given-names>M.</given-names></name>
</person-group><article-title>Can we interrogate public databases to fill critical gaps in mental health epidemiology? Testing the association between cannabis and psychosis in the UK as an example</article-title><source>Epidemiol. Psychiatr. Sci.</source><year>2023</year><volume>32</volume><fpage>e40</fpage><pub-id pub-id-type="doi">10.1017/S2045796023000537</pub-id><pub-id pub-id-type="pmid">37317558</pub-id>
</element-citation></ref><ref id="B109-pharmacy-13-00007"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciuc&#x00103; Anghel</surname><given-names>D.M.</given-names></name>
<name><surname>Ni&#x0021b;escu</surname><given-names>G.V.</given-names></name>
<name><surname>Tiron</surname><given-names>A.T.</given-names></name>
<name><surname>Gu&#x0021b;u</surname><given-names>C.M.</given-names></name>
<name><surname>Baconi</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Understanding the Mechanisms of Action and Effects of Drugs of Abuse</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>4969</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28134969</pub-id><pub-id pub-id-type="pmid">37446631</pub-id>
</element-citation></ref><ref id="B110-pharmacy-13-00007"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acquavia</surname><given-names>M.</given-names></name>
<name><surname>Tesoro</surname><given-names>C.</given-names></name>
<name><surname>Pascale</surname><given-names>R.</given-names></name>
<name><surname>Ostuni</surname><given-names>A.</given-names></name>
<name><surname>Matera</surname><given-names>I.</given-names></name>
<name><surname>Bianco</surname><given-names>G.</given-names></name>
<name><surname>Scrano</surname><given-names>L.</given-names></name>
<name><surname>Bufo</surname><given-names>S.A.</given-names></name>
<name><surname>Ciriello</surname><given-names>R.</given-names></name>
<name><surname>Di Capua</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Legal <italic toggle="yes">Cannabis sativa</italic> L. dried inflorescences: Cannabinoid content and cytotoxic activity against human HepG2 cell line</article-title><source>Appl. Sci.</source><year>2023</year><volume>13</volume><elocation-id>4960</elocation-id><pub-id pub-id-type="doi">10.3390/app13084960</pub-id></element-citation></ref><ref id="B111-pharmacy-13-00007"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>B.</given-names></name>
<name><surname>Berrada</surname><given-names>A.</given-names></name>
<name><surname>Hudalla</surname><given-names>C.</given-names></name>
<name><surname>Amaducci</surname><given-names>S.</given-names></name>
<name><surname>McKay</surname><given-names>J.</given-names></name>
</person-group><article-title>Genotype &#x000d7; environment interactions of industrial hemp cultivars highlight diverse responses to environmental factors</article-title><source>Agrosystems Geosci. Environ.</source><year>2019</year><volume>2</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.2134/age2018.11.0057</pub-id></element-citation></ref><ref id="B112-pharmacy-13-00007"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>C.</given-names></name>
<name><surname>Grace</surname><given-names>M.</given-names></name>
<name><surname>Smith</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>Medical cannabis and automobile accidents: Evidence from auto insurance</article-title><source>Health Econ.</source><year>2022</year><volume>31</volume><fpage>1878</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1002/hec.4553</pub-id><pub-id pub-id-type="pmid">35691014</pub-id>
</element-citation></ref><ref id="B113-pharmacy-13-00007"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolova</surname><given-names>M.</given-names></name>
<name><surname>Milenova</surname><given-names>V.</given-names></name>
<name><surname>Yosifov</surname><given-names>D.</given-names></name>
<name><surname>Vlahov</surname><given-names>Y.</given-names></name>
<name><surname>Tenev</surname><given-names>V.</given-names></name>
</person-group><article-title>Renal changes in cocaine abuse and addiction</article-title><source>Acta Medica Bulg.</source><year>2019</year><volume>46</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.2478/amb-2019-0020</pub-id></element-citation></ref><ref id="B114-pharmacy-13-00007"><label>114.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Chavez</surname><given-names>B.</given-names></name>
<name><surname>Stewart</surname><given-names>C.</given-names><suffix>Jr.</suffix></name>
<name><surname>D&#x02019;Auria</surname><given-names>J.</given-names></name>
</person-group><article-title>Structure and function of enzymes involved in the biosynthesis of tropane alkaloids</article-title><source>Tropane Alkaloids</source><person-group person-group-type="editor">
<name><surname>Srivastava</surname><given-names>V.</given-names></name>
<name><surname>Mehrotra</surname><given-names>S.</given-names></name>
<name><surname>Mishra</surname><given-names>S.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2021</year><fpage>21</fpage><lpage>50</lpage></element-citation></ref><ref id="B115-pharmacy-13-00007"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenkins</surname><given-names>A.</given-names></name>
<name><surname>Llosa</surname><given-names>T.</given-names></name>
<name><surname>Montoya</surname><given-names>I.</given-names></name>
<name><surname>Cone</surname><given-names>E.</given-names></name>
</person-group><article-title>Identification and quantitation of alkaloids in coca tea</article-title><source>Forensic Sci. Int.</source><year>1996</year><volume>77</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/0379-0738(95)01860-3</pub-id><pub-id pub-id-type="pmid">8819993</pub-id>
</element-citation></ref><ref id="B116-pharmacy-13-00007"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Estrada</surname><given-names>O.</given-names></name>
<name><surname>Chavez</surname><given-names>B.</given-names></name>
<name><surname>Stewart</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;Auria</surname><given-names>J.</given-names></name>
</person-group><article-title>Tropane and granatane alkaloid biosynthesis: A systematic analysis</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>1510</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21111510</pub-id><pub-id pub-id-type="pmid">27845728</pub-id>
</element-citation></ref><ref id="B117-pharmacy-13-00007"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biondich</surname><given-names>A.</given-names></name>
<name><surname>Joslin</surname><given-names>J.</given-names></name>
</person-group><article-title>Coca: High altitude remedy of the ancient Incas</article-title><source>Wilderness Environ. Med.</source><year>2015</year><volume>26</volume><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.wem.2015.07.006</pub-id><pub-id pub-id-type="pmid">26507611</pub-id>
</element-citation></ref><ref id="B118-pharmacy-13-00007"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuchiya</surname><given-names>H.</given-names></name>
</person-group><article-title>Anesthetic agents of plant origin: A review of phytochemicals with anesthetic activity</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1369</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22081369</pub-id><pub-id pub-id-type="pmid">28820497</pub-id>
</element-citation></ref><ref id="B119-pharmacy-13-00007"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nathanson</surname><given-names>J.</given-names></name>
<name><surname>Hunnicutt</surname><given-names>E.</given-names></name>
<name><surname>Kantham</surname><given-names>L.</given-names></name>
<name><surname>Scavone</surname><given-names>C.</given-names></name>
</person-group><article-title>Cocaine as a naturally occurring insecticide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1993</year><volume>90</volume><fpage>9645</fpage><lpage>9648</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.20.9645</pub-id><pub-id pub-id-type="pmid">8415755</pub-id>
</element-citation></ref><ref id="B120-pharmacy-13-00007"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>D.</given-names></name>
<name><surname>Islam</surname><given-names>M.</given-names></name>
<name><surname>Mason-Gamer</surname><given-names>R.</given-names></name>
</person-group><article-title>Phylogenetic inference in section Archerythroxylum informs taxonomy, biogeography, and the domestication of coca (<italic toggle="yes">Erythroxylum</italic> species)</article-title><source>Am. J. Bot.</source><year>2019</year><volume>106</volume><fpage>154</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/ajb2.1224</pub-id><pub-id pub-id-type="pmid">30629286</pub-id>
</element-citation></ref><ref id="B121-pharmacy-13-00007"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>D.</given-names></name>
<name><surname>Meinhardt</surname><given-names>L.</given-names></name>
<name><surname>Bailey</surname><given-names>B.</given-names></name>
<name><surname>Pirro</surname><given-names>S.</given-names></name>
</person-group><article-title>The complete genome sequences of Erythroxylum coca and <italic toggle="yes">Erythroxylum novogranatense</italic></article-title><source>Biodivers Genomes</source><year>2022</year><pub-id pub-id-type="doi">10.56179/001c.39776</pub-id></element-citation></ref><ref id="B122-pharmacy-13-00007"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chavez</surname><given-names>B.</given-names></name>
<name><surname>Srinivasan</surname><given-names>P.</given-names></name>
<name><surname>Glockzin</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>N.</given-names></name>
<name><surname>Estrada</surname><given-names>O.</given-names></name>
<name><surname>Jirschitzka</surname><given-names>J.</given-names></name>
<name><surname>Rowden</surname><given-names>G.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Meinhardt</surname><given-names>L.</given-names></name>
<name><surname>Smolke</surname><given-names>C.D.</given-names></name>
<etal/>
</person-group><article-title>Elucidation of tropane alkaloid biosynthesis in Erythroxylum causing a microbial pathway discovery platform</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2215372119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2215372119</pub-id><pub-id pub-id-type="pmid">36442128</pub-id>
</element-citation></ref><ref id="B123-pharmacy-13-00007"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bieri</surname><given-names>S.</given-names></name>
<name><surname>Brachet</surname><given-names>A.</given-names></name>
<name><surname>Veuthey</surname><given-names>J.</given-names></name>
<name><surname>Christen</surname><given-names>P.</given-names></name>
</person-group><article-title>Cocaine distribution in wild Erythroxylum species</article-title><source>J. Ethnopharmacol.</source><year>2006</year><volume>103</volume><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2005.08.021</pub-id><pub-id pub-id-type="pmid">16199132</pub-id>
</element-citation></ref><ref id="B124-pharmacy-13-00007"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jirschitzka</surname><given-names>J.</given-names></name>
<name><surname>Schmidt</surname><given-names>G.</given-names></name>
<name><surname>Reichelt</surname><given-names>M.</given-names></name>
<name><surname>Schneider</surname><given-names>B.</given-names></name>
<name><surname>Gershenzon</surname><given-names>J.</given-names></name>
<name><surname>D&#x02019;Auria</surname><given-names>J.</given-names></name>
</person-group><article-title>Plant tropane alkaloid biosynthesis evolved independently in the Solanaceae and Erythroxylaceae</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>10304</fpage><lpage>10309</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200473109</pub-id><pub-id pub-id-type="pmid">22665766</pub-id>
</element-citation></ref><ref id="B125-pharmacy-13-00007"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>C.</given-names></name>
<name><surname>Almeida</surname><given-names>C.</given-names></name>
<name><surname>Tenreiro</surname><given-names>S.</given-names></name>
<name><surname>Quintas</surname><given-names>A.</given-names></name>
</person-group><article-title>Neuroprotection or neurotoxicity of illicit drugs on Parkinson&#x02019;s disease</article-title><source>Life</source><year>2020</year><volume>10</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.3390/life10060086</pub-id><pub-id pub-id-type="pmid">32545328</pub-id>
</element-citation></ref><ref id="B126-pharmacy-13-00007"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almeida</surname><given-names>R.</given-names></name>
<name><surname>Zanetti</surname><given-names>G.</given-names></name>
<name><surname>Souza</surname><given-names>A.</given-names></name>
<name><surname>Souza</surname><given-names>L.</given-names></name>
<name><surname>Silva</surname><given-names>J.</given-names></name>
<name><surname>Escuissato</surname><given-names>D.</given-names></name>
<name><surname>Irion</surname><given-names>K.L.</given-names></name>
<name><surname>Man&#x000e7;ano</surname><given-names>A.D.</given-names></name>
<name><surname>Nobre</surname><given-names>L.F.</given-names></name>
<name><surname>Hochhegger</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Cocaine-induced pulmonary changes: HRCT findings</article-title><source>J. Bras. Pneumol.</source><year>2015</year><volume>41</volume><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1590/S1806-37132015000000025</pub-id><pub-id pub-id-type="pmid">26398752</pub-id>
</element-citation></ref><ref id="B127-pharmacy-13-00007"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biondich</surname><given-names>A.</given-names></name>
<name><surname>Joslin</surname><given-names>J.</given-names></name>
</person-group><article-title>Coca: The history and medical significance of an ancient Indian tradition</article-title><source>Emerg. Med. Int.</source><year>2016</year><volume>2016</volume><fpage>4048764</fpage><pub-id pub-id-type="doi">10.1155/2016/4048764</pub-id><pub-id pub-id-type="pmid">27144028</pub-id>
</element-citation></ref><ref id="B128-pharmacy-13-00007"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barlow</surname><given-names>P.</given-names></name>
<name><surname>Serodio</surname><given-names>P.</given-names></name>
<name><surname>Ruskin</surname><given-names>G.</given-names></name>
<name><surname>McKee</surname><given-names>M.</given-names></name>
<name><surname>Stuckler</surname><given-names>D.</given-names></name>
</person-group><article-title>Science organizations and Coca-Cola&#x02019;s &#x02018;war&#x02019; with the public health community: Insights from an internal industry document</article-title><source>J. Epidemiol. Community Health</source><year>2018</year><volume>72</volume><fpage>761</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1136/jech-2017-210375</pub-id><pub-id pub-id-type="pmid">29540465</pub-id>
</element-citation></ref><ref id="B129-pharmacy-13-00007"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaudoin</surname><given-names>G.</given-names></name>
<name><surname>Facchini</surname><given-names>P.</given-names></name>
</person-group><article-title>Benzylisoquinoline alkaloid biosynthesis in opium poppy</article-title><source>Planta</source><year>2014</year><volume>240</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s00425-014-2056-8</pub-id><pub-id pub-id-type="pmid">24671624</pub-id>
</element-citation></ref><ref id="B130-pharmacy-13-00007"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Hamiksha</collab>
</person-group><article-title>The mind-based and most controversial plant: Papaver somniferum&#x02014;The opium poppy: A plant with many faces and roles in human history and culture</article-title><source>Neuropsychiatry</source><year>2024</year><volume>14</volume><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="B131-pharmacy-13-00007"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weid</surname><given-names>M.</given-names></name>
<name><surname>Ziegler</surname><given-names>J.</given-names></name>
<name><surname>Kutchan</surname><given-names>T.</given-names></name>
</person-group><article-title>The roles of latex and the vascular bundle in morphine biosynthesis in the opium poppy, Papaver somniferum</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>13957</fpage><lpage>13962</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405704101</pub-id><pub-id pub-id-type="pmid">15353584</pub-id>
</element-citation></ref><ref id="B132-pharmacy-13-00007"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Facchini</surname><given-names>P.</given-names></name>
</person-group><article-title>Alkaloid biosynthesis in plants: Biochemistry, cell biology, molecular regulation, and metabolic engineering applications</article-title><source>Annu. Rev. Plant Physiol. Plant Mol. Biol.</source><year>2001</year><volume>52</volume><fpage>29</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1146/annurev.arplant.52.1.29</pub-id><pub-id pub-id-type="pmid">11337391</pub-id>
</element-citation></ref><ref id="B133-pharmacy-13-00007"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casado-Hidalgo</surname><given-names>G.</given-names></name>
<name><surname>P&#x000e9;rez-Quintanilla</surname><given-names>D.</given-names></name>
<name><surname>Morante-Zarcero</surname><given-names>S.</given-names></name>
<name><surname>Sierra</surname><given-names>I.</given-names></name>
</person-group><article-title>Mesostructured silica-coated magnetic nanoparticles to extract six opium alkaloids in poppy seeds before ultra-high-performance liquid chromatography-tandem mass spectrometry analysis</article-title><source>Foods</source><year>2021</year><volume>10</volume><elocation-id>1587</elocation-id><pub-id pub-id-type="doi">10.3390/foods10071587</pub-id><pub-id pub-id-type="pmid">34359458</pub-id>
</element-citation></ref><ref id="B134-pharmacy-13-00007"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shafi</surname><given-names>A.</given-names></name>
<name><surname>Berry</surname><given-names>A.</given-names></name>
<name><surname>Sumnall</surname><given-names>H.</given-names></name>
<name><surname>Wood</surname><given-names>D.</given-names></name>
<name><surname>Tracy</surname><given-names>D.</given-names></name>
</person-group><article-title>Synthetic opioids: A review and clinical update</article-title><source>Ther. Adv. Psychopharmacol.</source><year>2022</year><volume>12</volume><fpage>204512532211396</fpage><pub-id pub-id-type="doi">10.1177/20451253221139616</pub-id><pub-id pub-id-type="pmid">36532866</pub-id>
</element-citation></ref><ref id="B135-pharmacy-13-00007"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeBono</surname><given-names>A.</given-names></name>
<name><surname>Capuano</surname><given-names>B.</given-names></name>
<name><surname>Scammells</surname><given-names>P.</given-names></name>
</person-group><article-title>Progress toward the development of noscapine and derivatives as anticancer agents</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>5699</fpage><lpage>5727</lpage><pub-id pub-id-type="doi">10.1021/jm501180v</pub-id><pub-id pub-id-type="pmid">25811651</pub-id>
</element-citation></ref><ref id="B136-pharmacy-13-00007"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashrafi</surname><given-names>S.</given-names></name>
<name><surname>Alam</surname><given-names>S.</given-names></name>
<name><surname>Sultana</surname><given-names>A.</given-names></name>
<name><surname>Raj</surname><given-names>A.</given-names></name>
<name><surname>Emon</surname><given-names>N.U.</given-names></name>
<name><surname>Richi</surname><given-names>F.T.</given-names></name>
<name><surname>Sharmin</surname><given-names>T.</given-names></name>
<name><surname>Moon</surname><given-names>M.</given-names></name>
<name><surname>Park</surname><given-names>M.N.</given-names></name>
<name><surname>Kim</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>3149</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28073149</pub-id><pub-id pub-id-type="pmid">37049912</pub-id>
</element-citation></ref><ref id="B137-pharmacy-13-00007"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takayama</surname><given-names>H.</given-names></name>
<name><surname>Ishikawa</surname><given-names>H.</given-names></name>
<name><surname>Kurihara</surname><given-names>M.</given-names></name>
<name><surname>Kitajima</surname><given-names>M.</given-names></name>
<name><surname>Aimi</surname><given-names>N.</given-names></name>
<name><surname>Ponglux</surname><given-names>D.</given-names></name>
<name><surname>Koyama</surname><given-names>F.</given-names></name>
<name><surname>Matsumoto</surname><given-names>K.</given-names></name>
<name><surname>Moriyama</surname><given-names>T.</given-names></name>
<name><surname>Yamamoto</surname><given-names>L.T.</given-names></name>
<etal/>
</person-group><article-title>Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: Discovery of opioid agonists structurally different from other opioid ligands</article-title><source>J. Med. Chem.</source><year>2002</year><volume>45</volume><fpage>1949</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1021/jm010576e</pub-id><pub-id pub-id-type="pmid">11960505</pub-id>
</element-citation></ref><ref id="B138-pharmacy-13-00007"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cinosi</surname><given-names>E.</given-names></name>
<name><surname>Martinotti</surname><given-names>G.</given-names></name>
<name><surname>Simonato</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>D.</given-names></name>
<name><surname>Demetrovics</surname><given-names>Z.</given-names></name>
<name><surname>Rom&#x000e1;n-Urrestarazu</surname><given-names>A.</given-names></name>
<name><surname>Bersani</surname><given-names>F.S.</given-names></name>
<name><surname>Vicknasingam</surname><given-names>B.</given-names></name>
<name><surname>Piazzon</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>J.-H.</given-names></name>
<etal/>
</person-group><article-title>Following &#x0201c;the roots&#x0201d; of kratom (<italic toggle="yes">Mitragyna speciosa</italic>): The evolution of an enhancer from traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><elocation-id>968786</elocation-id><pub-id pub-id-type="doi">10.1155/2015/968786</pub-id><pub-id pub-id-type="pmid">26640804</pub-id>
</element-citation></ref><ref id="B139-pharmacy-13-00007"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meireles</surname><given-names>V.</given-names></name>
<name><surname>Rosado</surname><given-names>T.</given-names></name>
<name><surname>Barroso</surname><given-names>M.</given-names></name>
<name><surname>Soares</surname><given-names>S.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>J.</given-names></name>
<name><surname>Lu&#x000ed;s</surname><given-names>&#x000c2;.</given-names></name>
<name><surname>Caramelo</surname><given-names>D.</given-names></name>
<name><surname>Sim&#x000e3;o</surname><given-names>A.Y.</given-names></name>
<name><surname>Fern&#x000e1;ndez</surname><given-names>N.</given-names></name>
<name><surname>Duarte</surname><given-names>A.P.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Mitragyna speciosa</italic>: Clinical, toxicological aspects and analysis in biological and non-biological samples</article-title><source>Medicines</source><year>2019</year><volume>6</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.3390/medicines6010035</pub-id><pub-id pub-id-type="pmid">30836609</pub-id>
</element-citation></ref><ref id="B140-pharmacy-13-00007"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apryani</surname><given-names>E.</given-names></name>
<name><surname>Hidayat</surname><given-names>M.</given-names></name>
<name><surname>Moklas</surname><given-names>M.</given-names></name>
<name><surname>Fakurazi</surname><given-names>S.</given-names></name>
<name><surname>Idayu</surname><given-names>N.</given-names></name>
</person-group><article-title>Effects of mitragynine from <italic toggle="yes">Mitragyna speciosa</italic> Korth leaves on working memory</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>129</volume><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.03.036</pub-id><pub-id pub-id-type="pmid">20371280</pub-id>
</element-citation></ref><ref id="B141-pharmacy-13-00007"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adkins</surname><given-names>J.</given-names></name>
<name><surname>Boyer</surname><given-names>E.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.</given-names></name>
</person-group><article-title><italic toggle="yes">Mitragyna speciosa</italic>, a psychoactive tree from Southeast Asia with opioid activity</article-title><source>Current Top. Med. Chem.</source><year>2011</year><volume>11</volume><fpage>1165</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.2174/156802611795371305</pub-id><pub-id pub-id-type="pmid">21050173</pub-id>
</element-citation></ref><ref id="B142-pharmacy-13-00007"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prozialeck</surname><given-names>W.C.</given-names></name>
<name><surname>Avery</surname><given-names>B.A.</given-names></name>
<name><surname>Boyer</surname><given-names>E.W.</given-names></name>
<name><surname>Grundmann</surname><given-names>O.</given-names></name>
<name><surname>Henningfield</surname><given-names>J.E.</given-names></name>
<name><surname>Kruegel</surname><given-names>A.C.</given-names></name>
<name><surname>McMahon</surname><given-names>L.R.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.R.</given-names></name>
<name><surname>Swogger</surname><given-names>M.T.</given-names></name>
<name><surname>Veltri</surname><given-names>C.A.</given-names></name>
<etal/>
</person-group><article-title>Kratom policy: The challenge of balancing therapeutic potential with public safety</article-title><source>Int. J. Drug Policy</source><year>2019</year><volume>70</volume><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2019.05.003</pub-id><pub-id pub-id-type="pmid">31103778</pub-id>
</element-citation></ref><ref id="B143-pharmacy-13-00007"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Kamble</surname><given-names>S.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>F.</given-names></name>
<name><surname>Chear</surname><given-names>N.</given-names></name>
<name><surname>King</surname><given-names>T.</given-names></name>
<name><surname>Berthold</surname><given-names>E.</given-names></name>
<name><surname>Ramanathan</surname><given-names>S.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.R.</given-names></name>
<name><surname>Avery</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Simultaneous quantification of ten key kratom alkaloids in <italic toggle="yes">Mitragyna speciosa</italic> leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry</article-title><source>Drug Test. Anal.</source><year>2019</year><volume>11</volume><fpage>1162</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1002/dta.2604</pub-id><pub-id pub-id-type="pmid">30997725</pub-id>
</element-citation></ref><ref id="B144-pharmacy-13-00007"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prosser</surname><given-names>J.</given-names></name>
<name><surname>Nelson</surname><given-names>L.S.</given-names></name>
</person-group><article-title>The toxicology of bath salts: A review of synthetic cathinones</article-title><source>J. Med. Toxicol.</source><year>2011</year><volume>8</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s13181-011-0193-z</pub-id><pub-id pub-id-type="pmid">22108839</pub-id>
</element-citation></ref><ref id="B145-pharmacy-13-00007"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eastlack</surname><given-names>S.C.</given-names></name>
<name><surname>Cornett</surname><given-names>E.M.</given-names></name>
<name><surname>Kaye</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review</article-title><source>Pain Ther.</source><year>2020</year><volume>9</volume><fpage>55</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s40122-020-00151-x</pub-id><pub-id pub-id-type="pmid">31994019</pub-id>
</element-citation></ref><ref id="B146-pharmacy-13-00007"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Annuar</surname><given-names>N.A.K.</given-names></name>
<name><surname>Azlan</surname><given-names>U.K.</given-names></name>
<name><surname>Mediani</surname><given-names>A.</given-names></name>
<name><surname>Tong</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>R.</given-names></name>
<name><surname>Al-Olayan</surname><given-names>E.</given-names></name>
<name><surname>Baharum</surname><given-names>S.N.</given-names></name>
<name><surname>Bunawan</surname><given-names>H.</given-names></name>
<name><surname>Sarian</surname><given-names>M.N.</given-names></name>
<name><surname>Hamezah</surname><given-names>H.S.</given-names></name>
<etal/>
</person-group><article-title>An insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>171</volume><elocation-id>116134</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116134</pub-id><pub-id pub-id-type="pmid">38219389</pub-id>
</element-citation></ref><ref id="B147-pharmacy-13-00007"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>N.</given-names></name>
<name><surname>Jayabalan</surname><given-names>N.</given-names></name>
<name><surname>Mansor</surname><given-names>S.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>C.</given-names></name>
<name><surname>Mustapha</surname><given-names>M.</given-names></name>
</person-group><article-title>Chronic mitragynine (kratom) enhances punishment resistance in natural reward-seeking and impairs place learning in mice</article-title><source>Addict. Biol.</source><year>2016</year><volume>22</volume><fpage>967</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1111/adb.12385</pub-id><pub-id pub-id-type="pmid">26990882</pub-id>
</element-citation></ref><ref id="B148-pharmacy-13-00007"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papadi</surname><given-names>G.</given-names></name>
<name><surname>Bakhiya</surname><given-names>N.</given-names></name>
<name><surname>Hirsch-Ernst</surname><given-names>K.</given-names></name>
</person-group><article-title>Assessment of the possible health risks associated with the consumption of botanical preparations of <italic toggle="yes">Mitragyna speciosa</italic> (kratom)</article-title><source>EFSA J.</source><year>2022</year><volume>20</volume><fpage>e200415</fpage><pub-id pub-id-type="doi">10.2903/j.efsa.2022.e200415</pub-id><pub-id pub-id-type="pmid">35634550</pub-id>
</element-citation></ref><ref id="B149-pharmacy-13-00007"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>K.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Grundmann</surname><given-names>O.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.</given-names></name>
</person-group><article-title>Kratom alkaloids: A blueprint?</article-title><source>ACS Chem. Neurosci.</source><year>2023</year><volume>14</volume><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.2c00704</pub-id><pub-id pub-id-type="pmid">36594896</pub-id>
</element-citation></ref><ref id="B150-pharmacy-13-00007"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salim</surname><given-names>H.</given-names></name>
<name><surname>Awwalia</surname><given-names>E.</given-names></name>
<name><surname>Alam</surname><given-names>I.</given-names></name>
</person-group><article-title>Anti-inflammatory effects and potential mechanisms of <italic toggle="yes">Mitragyna speciosa</italic> methanol extract on &#x003bb;-carrageenan-induced inflammation model</article-title><source>Bali Med. J.</source><year>2022</year><volume>11</volume><fpage>1172</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.15562/bmj.v11i3.3535</pub-id></element-citation></ref><ref id="B151-pharmacy-13-00007"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saidin</surname><given-names>N.</given-names></name>
<name><surname>Holmes</surname><given-names>E.</given-names></name>
<name><surname>Takayama</surname><given-names>H.</given-names></name>
<name><surname>Gooderham</surname><given-names>N.</given-names></name>
</person-group><article-title>The cellular toxicology of mitragynine, the dominant alkaloid of the narcotic-like herb, <italic toggle="yes">Mitragyna speciosa</italic> Korth</article-title><source>Toxicol. Res.</source><year>2015</year><volume>4</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1039/C5TX00113G</pub-id></element-citation></ref><ref id="B152-pharmacy-13-00007"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gon&#x000e7;alves</surname><given-names>J.</given-names></name>
<name><surname>Lu&#x000ed;s</surname><given-names>&#x000c2;.</given-names></name>
<name><surname>Gallardo</surname><given-names>E.</given-names></name>
<name><surname>Duarte</surname><given-names>A.</given-names></name>
</person-group><article-title>Psychoactive substances of natural origin: Toxicological aspects, therapeutic properties and analysis in biological samples</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>1397</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26051397</pub-id><pub-id pub-id-type="pmid">33807728</pub-id>
</element-citation></ref><ref id="B153-pharmacy-13-00007"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pootakham</surname><given-names>W.</given-names></name>
<name><surname>Yoocha</surname><given-names>T.</given-names></name>
<name><surname>Jomchai</surname><given-names>N.</given-names></name>
<name><surname>Kongkachana</surname><given-names>W.</given-names></name>
<name><surname>Naktang</surname><given-names>C.</given-names></name>
<name><surname>Sonthirod</surname><given-names>C.</given-names></name>
<name><surname>Chowpongpang</surname><given-names>S.</given-names></name>
<name><surname>Aumpuchin</surname><given-names>P.</given-names></name>
<name><surname>Tangphatsornruang</surname><given-names>S.</given-names></name>
</person-group><article-title>A chromosome-scale genome assembly of <italic toggle="yes">Mitragyna speciosa</italic> (kratom) and the assessment of its genetic diversity in Thailand</article-title><source>Biology</source><year>2022</year><volume>11</volume><elocation-id>1492</elocation-id><pub-id pub-id-type="doi">10.3390/biology11101492</pub-id><pub-id pub-id-type="pmid">36290398</pub-id>
</element-citation></ref><ref id="B154-pharmacy-13-00007"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schotte</surname><given-names>C.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Grzech</surname><given-names>D.</given-names></name>
<name><surname>Dang</surname><given-names>T.</given-names></name>
<name><surname>Laforest</surname><given-names>L.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>F.</given-names></name>
<name><surname>Mottinelli</surname><given-names>M.</given-names></name>
<name><surname>Nadakuduti</surname><given-names>S.S.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.R.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>Directed biosynthesis of mitragynine stereoisomers</article-title><source>J. Am. Chem. Soc.</source><year>2023</year><volume>145</volume><fpage>4957</fpage><lpage>4963</lpage><pub-id pub-id-type="doi">10.1021/jacs.2c13644</pub-id><pub-id pub-id-type="pmid">36883326</pub-id>
</element-citation></ref><ref id="B155-pharmacy-13-00007"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Hebshi</surname><given-names>N.</given-names></name>
<name><surname>Skaug</surname><given-names>N.</given-names></name>
</person-group><article-title>Khat (Catha edulis)&#x02014;An updated review</article-title><source>Addict. Biol.</source><year>2005</year><volume>10</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1080/13556210500353020</pub-id><pub-id pub-id-type="pmid">16318950</pub-id>
</element-citation></ref><ref id="B156-pharmacy-13-00007"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chhetri</surname><given-names>B.</given-names></name>
<name><surname>Ali</surname><given-names>N.</given-names></name>
<name><surname>Setzer</surname><given-names>W.</given-names></name>
</person-group><article-title>A survey of chemical compositions and biological activities of Yemeni aromatic medicinal plants</article-title><source>Medicines</source><year>2015</year><volume>2</volume><fpage>67</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.3390/medicines2020067</pub-id><pub-id pub-id-type="pmid">28930202</pub-id>
</element-citation></ref><ref id="B157-pharmacy-13-00007"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>D.M.</given-names></name>
<name><surname>Carrie</surname><given-names>N.C.</given-names></name>
</person-group><article-title>Khat: Social harms and legislation&#x02014;A literature review</article-title><source>Addict Behav.</source><year>2011</year><fpage>1</fpage><lpage>50</lpage></element-citation></ref><ref id="B158-pharmacy-13-00007"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pantano</surname><given-names>F.</given-names></name>
<name><surname>Tittarelli</surname><given-names>R.</given-names></name>
<name><surname>Mannocchi</surname><given-names>G.</given-names></name>
<name><surname>Zaami</surname><given-names>S.</given-names></name>
<name><surname>Ricci</surname><given-names>S.</given-names></name>
<name><surname>Giorgetti</surname><given-names>R.</given-names></name>
<name><surname>Terranova</surname><given-names>D.</given-names></name>
<name><surname>Busard&#x000f2;</surname><given-names>F.P.</given-names></name>
<name><surname>Marinelli</surname><given-names>E.</given-names></name>
</person-group><article-title>Hepatotoxicity induced by &#x0201c;the 3ks&#x0201d;: Kava, kratom, and khat</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>580</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17040580</pub-id><pub-id pub-id-type="pmid">27092496</pub-id>
</element-citation></ref><ref id="B159-pharmacy-13-00007"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Motarreb</surname><given-names>A.</given-names></name>
<name><surname>Al-Habori</surname><given-names>M.</given-names></name>
<name><surname>Broadley</surname><given-names>K.</given-names></name>
</person-group><article-title>Khat chewing, cardiovascular diseases, and other internal medical problems: The current situation and directions for future research</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>132</volume><fpage>540</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.07.001</pub-id><pub-id pub-id-type="pmid">20621179</pub-id>
</element-citation></ref><ref id="B160-pharmacy-13-00007"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Mamary</surname><given-names>M.</given-names></name>
<name><surname>Al-Habori</surname><given-names>M.</given-names></name>
<name><surname>Al-Aghbari</surname><given-names>A.</given-names></name>
<name><surname>Baker</surname><given-names>M.</given-names></name>
</person-group><article-title>Investigation into the toxicological effects of Catha edulis leaves: A short-term study in animals</article-title><source>Phytother. Res.</source><year>2002</year><volume>16</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/ptr.835</pub-id><pub-id pub-id-type="pmid">11933113</pub-id>
</element-citation></ref><ref id="B161-pharmacy-13-00007"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Motarreb</surname><given-names>A.</given-names></name>
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Broadley</surname><given-names>K.</given-names></name>
</person-group><article-title>Khat: Pharmacological and medical aspects and its social use in Yemen</article-title><source>Phytother. Res.</source><year>2002</year><volume>16</volume><fpage>403</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1002/ptr.1106</pub-id><pub-id pub-id-type="pmid">12203257</pub-id>
</element-citation></ref><ref id="B162-pharmacy-13-00007"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.B.</given-names></name>
</person-group><article-title>Khat (Catha edulis Forsk)&#x02014;And now there are three</article-title><source>Brain Res. Bull.</source><year>2019</year><volume>145</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.07.014</pub-id><pub-id pub-id-type="pmid">30059706</pub-id>
</element-citation></ref><ref id="B163-pharmacy-13-00007"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>German</surname><given-names>C.</given-names></name>
<name><surname>Fleckenstein</surname><given-names>A.</given-names></name>
<name><surname>Hanson</surname><given-names>G.</given-names></name>
</person-group><article-title>Bath salts and synthetic cathinones: An emerging designer drug phenomenon</article-title><source>Life Sci.</source><year>2014</year><volume>97</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2013.07.023</pub-id><pub-id pub-id-type="pmid">23911668</pub-id>
</element-citation></ref><ref id="B164-pharmacy-13-00007"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>C.</given-names></name>
<name><surname>Carreiro</surname><given-names>S.</given-names></name>
<name><surname>Babu</surname><given-names>K.</given-names></name>
</person-group><article-title>Here today, gone tomorrow&#x02026;and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinone (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines</article-title><source>J. Med. Toxicol.</source><year>2012</year><volume>8</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s13181-011-0202-2</pub-id><pub-id pub-id-type="pmid">22271566</pub-id>
</element-citation></ref><ref id="B165-pharmacy-13-00007"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capasso</surname><given-names>R.</given-names></name>
<name><surname>Borrelli</surname><given-names>F.</given-names></name>
<name><surname>Zjawiony</surname><given-names>J.</given-names></name>
<name><surname>Kutrzeba</surname><given-names>L.</given-names></name>
<name><surname>Aviello</surname><given-names>G.</given-names></name>
<name><surname>Sarnelli</surname><given-names>G.</given-names></name>
<name><surname>Capasso</surname><given-names>F.</given-names></name>
<name><surname>Izzo</surname><given-names>A.A.</given-names></name>
</person-group><article-title>The hallucinogenic herb Salvia divinorum and its active ingredient, salvinorin A, reduce inflammation-induced hypermotility in mice</article-title><source>Neurogastroenterol. Motil.</source><year>2007</year><volume>20</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2007.00994.x</pub-id><pub-id pub-id-type="pmid">17931335</pub-id>
</element-citation></ref><ref id="B166-pharmacy-13-00007"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babu</surname><given-names>K.</given-names></name>
<name><surname>McCurdy</surname><given-names>C.</given-names></name>
<name><surname>Boyer</surname><given-names>E.</given-names></name>
</person-group><article-title>Opioid receptors and legal highs: Salvia divinorum and kratom</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>46</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1080/15563650701241795</pub-id><pub-id pub-id-type="pmid">18259963</pub-id>
</element-citation></ref><ref id="B167-pharmacy-13-00007"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoover</surname><given-names>V.</given-names></name>
<name><surname>Marlowe</surname><given-names>D.B.</given-names></name>
<name><surname>Patapis</surname><given-names>N.S.</given-names></name>
<name><surname>Festinger</surname><given-names>D.S.</given-names></name>
<name><surname>Forman</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Internet access to Salvia divinorum: Implications for policy, prevention, and treatment</article-title><source>J Subst Abuse Treat.</source><year>2008</year><volume>35</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2007.07.011</pub-id><pub-id pub-id-type="pmid">17931827</pub-id>
</element-citation></ref><ref id="B168-pharmacy-13-00007"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munro</surname><given-names>T.</given-names></name>
<name><surname>Rizzacasa</surname><given-names>M.</given-names></name>
<name><surname>Roth</surname><given-names>B.</given-names></name>
<name><surname>Toth</surname><given-names>B.</given-names></name>
<name><surname>Yan</surname><given-names>F.</given-names></name>
</person-group><article-title>Studies toward the pharmacophore of salvinorin A, a potent &#x003ba;-opioid receptor agonist</article-title><source>J. Med. Chem.</source><year>2004</year><volume>48</volume><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1021/jm049438q</pub-id><pub-id pub-id-type="pmid">15658846</pub-id>
</element-citation></ref><ref id="B169-pharmacy-13-00007"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fichna</surname><given-names>J.</given-names></name>
<name><surname>Schicho</surname><given-names>R.</given-names></name>
<name><surname>Andrews</surname><given-names>C.</given-names></name>
<name><surname>Bashashati</surname><given-names>M.</given-names></name>
<name><surname>Klompus</surname><given-names>M.</given-names></name>
<name><surname>McKay</surname><given-names>D.</given-names></name>
<name><surname>Sharkey</surname><given-names>K.A.</given-names></name>
<name><surname>Zjawiony</surname><given-names>J.K.</given-names></name>
<name><surname>Janecka</surname><given-names>A.</given-names></name>
<name><surname>Storr</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Salvinorin inhibits mice&#x02019;s colonic transit and neurogenic ion transport by activating &#x003ba;-opioid and cannabinoid receptors</article-title><source>Neurogastroenterol. Motil.</source><year>2009</year><volume>21</volume><fpage>1326</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2009.01369.x</pub-id><pub-id pub-id-type="pmid">19650775</pub-id>
</element-citation></ref><ref id="B170-pharmacy-13-00007"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Addy</surname><given-names>P.</given-names></name>
</person-group><article-title>Acute and post-acute behavioral and psychological impact of salvinorin A in humans</article-title><source>Psychopharmacology</source><year>2011</year><volume>220</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2470-6</pub-id><pub-id pub-id-type="pmid">21901316</pub-id>
</element-citation></ref><ref id="B171-pharmacy-13-00007"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butelman</surname><given-names>E.</given-names></name>
<name><surname>Caspers</surname><given-names>M.</given-names></name>
<name><surname>Lovell</surname><given-names>K.</given-names></name>
<name><surname>Kreek</surname><given-names>M.</given-names></name>
<name><surname>Prisinzano</surname><given-names>T.</given-names></name>
</person-group><article-title>Behavioral effects and central nervous system levels of the broadly available &#x003ba;-agonist hallucinogen salvinorin A are affected by p-glycoprotein modulation in vivo</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2012</year><volume>341</volume><fpage>802</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1124/jpet.112.193227</pub-id><pub-id pub-id-type="pmid">22434677</pub-id>
</element-citation></ref><ref id="B172-pharmacy-13-00007"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biggs</surname><given-names>J.</given-names></name>
<name><surname>Morgan</surname><given-names>J.</given-names></name>
<name><surname>Lardieri</surname><given-names>A.</given-names></name>
<name><surname>Kishk</surname><given-names>O.</given-names></name>
</person-group><article-title>Abuse and misuse of selected dietary supplements among adolescents: A look at poison center data</article-title><source>J. Pediatr. Pharmacol. Ther.</source><year>2017</year><volume>22</volume><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.5863/1551-6776-22.6.385</pub-id><pub-id pub-id-type="pmid">29290737</pub-id>
</element-citation></ref><ref id="B173-pharmacy-13-00007"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waters</surname><given-names>K.</given-names></name>
</person-group><article-title>Pharmacologic similarities and differences among hallucinogens</article-title><source>J. Clin. Pharmacol.</source><year>2021</year><volume>61</volume><fpage>S100</fpage><lpage>S113</lpage><pub-id pub-id-type="doi">10.1002/jcph.1917</pub-id><pub-id pub-id-type="pmid">34396556</pub-id>
</element-citation></ref><ref id="B174-pharmacy-13-00007"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brito-da-Costa</surname><given-names>A.</given-names></name>
<name><surname>Silva</surname><given-names>D.</given-names></name>
<name><surname>Gomes</surname><given-names>N.</given-names></name>
<name><surname>Dinis-Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Madureira-Carvalho</surname><given-names>&#x000c1;.</given-names></name>
</person-group><article-title>Clinical and forensic aspects include pharmacokinetics and pharmacodynamics of salvinorin A and Salvia divinorum</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>116</elocation-id><pub-id pub-id-type="doi">10.3390/ph14020116</pub-id><pub-id pub-id-type="pmid">33546518</pub-id>
</element-citation></ref><ref id="B175-pharmacy-13-00007"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maqueda</surname><given-names>A.</given-names></name>
<name><surname>Valle</surname><given-names>M.</given-names></name>
<name><surname>Addy</surname><given-names>P.</given-names></name>
<name><surname>Antonijoan</surname><given-names>R.</given-names></name>
<name><surname>Puntes</surname><given-names>M.</given-names></name>
<name><surname>Coimbra</surname><given-names>J.</given-names></name>
<name><surname>Ballester</surname><given-names>M.R.</given-names></name>
<name><surname>Garrido</surname><given-names>M.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.</given-names></name>
<name><surname>Claramunt</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Salvinorin A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2015</year><volume>18</volume><fpage>pyv065</fpage><pub-id pub-id-type="doi">10.1093/ijnp/pyv065</pub-id><pub-id pub-id-type="pmid">26047623</pub-id>
</element-citation></ref><ref id="B176-pharmacy-13-00007"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braida</surname><given-names>D.</given-names></name>
<name><surname>Capurro</surname><given-names>V.</given-names></name>
<name><surname>Zani</surname><given-names>A.</given-names></name>
<name><surname>Rubino</surname><given-names>T.</given-names></name>
<name><surname>Vigan&#x000f2;</surname><given-names>D.</given-names></name>
<name><surname>Parolaro</surname><given-names>D.</given-names></name>
<name><surname>Sala</surname><given-names>M.</given-names></name>
</person-group><article-title>In rodents, potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum</article-title><source>Br. J. Pharmacol.</source><year>2009</year><volume>157</volume><fpage>844</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00230.x</pub-id><pub-id pub-id-type="pmid">19422370</pub-id>
</element-citation></ref><ref id="B177-pharmacy-13-00007"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco-Molina</surname><given-names>M.</given-names></name>
<name><surname>G&#x000f3;mez-Flores</surname><given-names>R.</given-names></name>
<name><surname>Tamez-Guerra</surname><given-names>P.</given-names></name>
<name><surname>Tam&#x000e9;z-Guerra</surname><given-names>R.</given-names></name>
<name><surname>Castillo-Le&#x000f3;n</surname><given-names>L.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Padilla</surname><given-names>C.</given-names></name>
</person-group><article-title>In vitro immunopotentiating properties and tumor cell toxicity induced by <italic toggle="yes">Lophophora williamsii</italic> (peyote) cactus methanolic extract</article-title><source>Phytother. Res.</source><year>2003</year><volume>17</volume><fpage>1076</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1002/ptr.1313</pub-id><pub-id pub-id-type="pmid">14595591</pub-id>
</element-citation></ref><ref id="B178-pharmacy-13-00007"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleffens</surname><given-names>M.</given-names></name>
</person-group><article-title>An overview of the hallucinogenic peyote and its alkaloid mescaline: The importance of context, ceremony, and culture</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>7942</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28247942</pub-id><pub-id pub-id-type="pmid">38138432</pub-id>
</element-citation></ref><ref id="B179-pharmacy-13-00007"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duan</surname><given-names>W.</given-names></name>
</person-group><article-title>Serotonin 2A receptor (5-HT2AR) agonists: Psychedelics and non-hallucinogenic analogs as emerging antidepressants</article-title><source>Chem. Rev.</source><year>2023</year><volume>124</volume><fpage>124</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.3c00375</pub-id><pub-id pub-id-type="pmid">38033123</pub-id>
</element-citation></ref><ref id="B180-pharmacy-13-00007"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinis-Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Pereira</surname><given-names>C.</given-names></name>
<name><surname>Silva</surname><given-names>D.</given-names></name>
</person-group><article-title>Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions</article-title><source>Curr. Mol. Pharmacol.</source><year>2019</year><volume>12</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.2174/1874467211666181010154139</pub-id><pub-id pub-id-type="pmid">30318013</pub-id>
</element-citation></ref><ref id="B181-pharmacy-13-00007"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tupper</surname><given-names>K.</given-names></name>
<name><surname>Wood</surname><given-names>E.</given-names></name>
<name><surname>Yensen</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>M.</given-names></name>
</person-group><article-title>Psychedelic medicine: A re-emerging therapeutic paradigm</article-title><source>Can. Med. Assoc. J.</source><year>2015</year><volume>187</volume><fpage>1054</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1503/cmaj.141124</pub-id><pub-id pub-id-type="pmid">26350908</pub-id>
</element-citation></ref><ref id="B182-pharmacy-13-00007"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terry</surname><given-names>M.</given-names></name>
<name><surname>Trout</surname><given-names>K.</given-names></name>
</person-group><article-title>Regulation of peyote (<italic toggle="yes">Lophophora williamsii</italic>: Cactaceae) in the U.S.A: A historical victory of religion and politics over science and medicine</article-title><source>J. Bot. Res. Inst. Tex.</source><year>2017</year><volume>11</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.17348/jbrit.v11.i1.1146</pub-id></element-citation></ref><ref id="B183-pharmacy-13-00007"><label>183.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Nichols</surname><given-names>D.</given-names></name>
</person-group><article-title>Chemistry and structure-activity relationships of psychedelics</article-title><source>Behavioral Neurobiology of Psychedelic Drugs</source><person-group person-group-type="editor">
<name><surname>Halberstadt</surname><given-names>A.L.</given-names></name>
<name><surname>Vollenweider</surname><given-names>F.X.</given-names></name>
<name><surname>Nichols</surname><given-names>D.E.</given-names></name>
</person-group><comment>Current Topics in Behavioral Neurosciences</comment><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2017</year><volume>Volume 36</volume><fpage>1</fpage><lpage>43</lpage></element-citation></ref><ref id="B184-pharmacy-13-00007"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassels</surname><given-names>B.</given-names></name>
<name><surname>S&#x000e1;ez-Briones</surname><given-names>P.</given-names></name>
</person-group><article-title>Dark classics in chemical neuroscience: Mescaline</article-title><source>ACS Chem. Neurosci.</source><year>2018</year><volume>9</volume><fpage>2448</fpage><lpage>2458</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.8b00215</pub-id><pub-id pub-id-type="pmid">29847089</pub-id>
</element-citation></ref><ref id="B185-pharmacy-13-00007"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aragane</surname><given-names>M.</given-names></name>
<name><surname>Sasaki</surname><given-names>Y.</given-names></name>
<name><surname>Nakajima</surname><given-names>J.</given-names></name>
<name><surname>Fukumori</surname><given-names>N.</given-names></name>
<name><surname>Yoshizawa</surname><given-names>M.</given-names></name>
<name><surname>Suzuki</surname><given-names>Y.</given-names></name>
<name><surname>Kitagawa</surname><given-names>S.</given-names></name>
<name><surname>Mori</surname><given-names>K.</given-names></name>
<name><surname>Ogino</surname><given-names>S.</given-names></name>
<name><surname>Yasuda</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Peyote identification based on differences in morphology, mescaline content, and TRNL/TRNF sequence between <italic toggle="yes">Lophophora williamsii</italic> and <italic toggle="yes">L. diffuse</italic></article-title><source>J. Nat. Med.</source><year>2010</year><volume>65</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s11418-010-0469-7</pub-id><pub-id pub-id-type="pmid">20890669</pub-id>
</element-citation></ref><ref id="B186-pharmacy-13-00007"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watkins</surname><given-names>J.</given-names></name>
</person-group><article-title>Elucidation of the mescaline biosynthetic pathway in peyote (<italic toggle="yes">Lophophora williamsii</italic>)</article-title><source>Plant J.</source><year>2023</year><volume>116</volume><fpage>635</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1111/tpj.16447</pub-id><pub-id pub-id-type="pmid">37675639</pub-id>
</element-citation></ref><ref id="B187-pharmacy-13-00007"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirschner</surname><given-names>G.</given-names></name>
</person-group><article-title>Breaking bad buttons: Mescaline biosynthesis in peyote</article-title><source>Plant J.</source><year>2023</year><volume>116</volume><fpage>633</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1111/tpj.16503</pub-id><pub-id pub-id-type="pmid">37861456</pub-id>
</element-citation></ref><ref id="B188-pharmacy-13-00007"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gambelunghe</surname><given-names>C.</given-names></name>
<name><surname>Marsili</surname><given-names>R.</given-names></name>
<name><surname>Aroni</surname><given-names>K.</given-names></name>
<name><surname>Bacci</surname><given-names>M.</given-names></name>
<name><surname>Rossi</surname><given-names>R.</given-names></name>
</person-group><article-title>GC-MS and GC-MS/MS in PCI mode determination of mescaline in peyote tea and in biological matrices</article-title><source>J. Forensic Sci.</source><year>2012</year><volume>58</volume><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/j.1556-4029.2012.02249.x</pub-id><pub-id pub-id-type="pmid">22900815</pub-id>
</element-citation></ref><ref id="B189-pharmacy-13-00007"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ermakova</surname><given-names>A.</given-names></name>
<name><surname>Whiting</surname><given-names>C.</given-names></name>
<name><surname>Trout</surname><given-names>K.</given-names></name>
<name><surname>Clubbe</surname><given-names>C.</given-names></name>
<name><surname>Terry</surname><given-names>M.</given-names></name>
</person-group><article-title>Densities, plant sizes, and spatial distributions of six wild populations of <italic toggle="yes">Lophophora williamsii</italic> (Cactaceae) in Texas, U.S.A</article-title><source>J. Bot. Res. Inst. Tex.</source><year>2021</year><volume>15</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.17348/jbrit.v15.i1.1057</pub-id></element-citation></ref><ref id="B190-pharmacy-13-00007"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varlet</surname><given-names>V.</given-names></name>
</person-group><article-title>Drug vaping: From the dangers of misuse to new therapeutic devices</article-title><source>Toxics</source><year>2016</year><volume>4</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/toxics4040029</pub-id><pub-id pub-id-type="pmid">29051432</pub-id>
</element-citation></ref><ref id="B191-pharmacy-13-00007"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Sonsin-Oliveira</surname><given-names>J.</given-names></name>
<name><surname>Santos</surname><given-names>T.</given-names></name>
<name><surname>Silva</surname><given-names>M.</given-names></name>
<name><surname>Fagg</surname><given-names>C.</given-names></name>
<name><surname>Sebastiani</surname><given-names>R.</given-names></name>
</person-group><article-title>Lectotypification of <italic toggle="yes">Banisteriopsis caapi</italic> and <italic toggle="yes">B. quitensis</italic> (Malpighiaceae), names associated with an important ingredient of ayahuasca</article-title><source>Taxon</source><year>2020</year><volume>70</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1002/tax.12407</pub-id></element-citation></ref><ref id="B192-pharmacy-13-00007"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>B.</given-names></name>
<name><surname>Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Sonsin-Oliveira</surname><given-names>J.</given-names></name>
<name><surname>Fagg</surname><given-names>C.</given-names></name>
<name><surname>Barbosa</surname><given-names>J.</given-names></name>
<name><surname>Caldas</surname><given-names>E.</given-names></name>
</person-group><article-title>Biodiversity of &#x003b2;-carboline profile of Banisteriopsis caapi and ayahuasca, a plant and a brew with neuropharmacological potential</article-title><source>Plants</source><year>2020</year><volume>9</volume><elocation-id>870</elocation-id><pub-id pub-id-type="doi">10.3390/plants9070870</pub-id><pub-id pub-id-type="pmid">32660098</pub-id>
</element-citation></ref><ref id="B193-pharmacy-13-00007"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ara&#x000fa;jo</surname><given-names>D.</given-names></name>
<name><surname>Ribeiro</surname><given-names>S.</given-names></name>
<name><surname>Cecchi</surname><given-names>G.</given-names></name>
<name><surname>Carvalho</surname><given-names>F.</given-names></name>
<name><surname>Sanchez</surname><given-names>T.</given-names></name>
<name><surname>Pinto</surname><given-names>J.</given-names></name>
<name><surname>de Martinis</surname><given-names>B.S.</given-names></name>
<name><surname>Crippa</surname><given-names>J.A.</given-names></name>
<name><surname>Hallak</surname><given-names>J.E.</given-names></name>
<name><surname>Santos</surname><given-names>A.C.</given-names></name>
<etal/>
</person-group><article-title>Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion</article-title><source>Hum. Brain Mapp.</source><year>2011</year><volume>33</volume><fpage>2550</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1002/hbm.21381</pub-id><pub-id pub-id-type="pmid">21922603</pub-id>
</element-citation></ref><ref id="B194-pharmacy-13-00007"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tupper</surname><given-names>K.W.</given-names></name>
</person-group><article-title>The globalization of ayahuasca: Harm reduction or benefit maximization?</article-title><source>Int. J. Drug Policy</source><year>2008</year><volume>19</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2006.11.001</pub-id><pub-id pub-id-type="pmid">18638702</pub-id>
</element-citation></ref><ref id="B195-pharmacy-13-00007"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000f6;ckler</surname><given-names>N.</given-names></name>
<name><surname>Jofr&#x000e9;</surname><given-names>G.</given-names></name>
<name><surname>Papadopoulos</surname><given-names>C.</given-names></name>
<name><surname>Soppa</surname><given-names>U.</given-names></name>
<name><surname>Tejedor</surname><given-names>F.</given-names></name>
<name><surname>Becker</surname><given-names>W.</given-names></name>
</person-group><article-title>Harmine inhibits explicitly protein kinase DYRK1A and interferes with neurite formation</article-title><source>FEBS J.</source><year>2009</year><volume>276</volume><fpage>6324</fpage><lpage>6337</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07346.x</pub-id><pub-id pub-id-type="pmid">19796173</pub-id>
</element-citation></ref><ref id="B196-pharmacy-13-00007"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morales-Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Revenga</surname><given-names>M.</given-names></name>
<name><surname>Alonso-Gil</surname><given-names>S.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Franco</surname><given-names>M.</given-names></name>
<name><surname>Feilding</surname><given-names>A.</given-names></name>
<name><surname>P&#x000e9;rez-Castillo</surname><given-names>A.</given-names></name>
<name><surname>Riba</surname><given-names>J.</given-names></name>
</person-group><article-title>The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen ayahuasca, stimulate adult neurogenesis in vitro</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>5309</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05407-9</pub-id><pub-id pub-id-type="pmid">28706205</pub-id>
</element-citation></ref><ref id="B197-pharmacy-13-00007"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Estrella-Parra</surname><given-names>E.</given-names></name>
<name><surname>Almanza-Perez</surname><given-names>J.</given-names></name>
<name><surname>Alarc&#x000f3;n-Aguilar</surname><given-names>F.</given-names></name>
</person-group><article-title>Ayahuasca: Uses, phytochemical, and biological activities</article-title><source>Nat. Prod. Bioprospecting</source><year>2019</year><volume>9</volume><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1007/s13659-019-0210-5</pub-id><pub-id pub-id-type="pmid">31134518</pub-id>
</element-citation></ref><ref id="B198-pharmacy-13-00007"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Samoylenko</surname><given-names>V.</given-names></name>
<name><surname>Tekwani</surname><given-names>B.</given-names></name>
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Miller</surname><given-names>L.</given-names></name>
<name><surname>Chaurasiya</surname><given-names>N.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Tripathi</surname><given-names>L.M.</given-names></name>
<name><surname>Khan</surname><given-names>S.I.</given-names></name>
<name><surname>Joshi</surname><given-names>V.C.</given-names></name>
<etal/>
</person-group><article-title>Composition, standardization, and chemical profiling of Banisteriopsis caapi, a plant for treating neurodegenerative disorders relevant to Parkinson&#x02019;s disease</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>128</volume><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.02.013</pub-id><pub-id pub-id-type="pmid">20219660</pub-id>
</element-citation></ref><ref id="B199-pharmacy-13-00007"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carbonaro</surname><given-names>T.</given-names></name>
<name><surname>Gatch</surname><given-names>M.</given-names></name>
</person-group><article-title>Neuropharmacology of N, N-dimethyltryptamine</article-title><source>Brain Res. Bull.</source><year>2016</year><volume>126</volume><fpage>74</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.04.016</pub-id><pub-id pub-id-type="pmid">27126737</pub-id>
</element-citation></ref><ref id="B200-pharmacy-13-00007"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uthaug</surname><given-names>M.</given-names></name>
<name><surname>Oorsouw</surname><given-names>K.</given-names></name>
<name><surname>Kuypers</surname><given-names>K.</given-names></name>
<name><surname>Boxtel</surname><given-names>M.</given-names></name>
<name><surname>Broers</surname><given-names>N.</given-names></name>
<name><surname>Mason</surname><given-names>N.</given-names></name>
<name><surname>Toennes</surname><given-names>S.W.</given-names></name>
<name><surname>Riba</surname><given-names>J.</given-names></name>
<name><surname>Ramaekers</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution</article-title><source>Psychopharmacology</source><year>2018</year><volume>235</volume><fpage>2979</fpage><lpage>2989</lpage><pub-id pub-id-type="doi">10.1007/s00213-018-4988-3</pub-id><pub-id pub-id-type="pmid">30105399</pub-id>
</element-citation></ref><ref id="B201-pharmacy-13-00007"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Correa-Netto</surname><given-names>N.</given-names></name>
<name><surname>Coelho</surname><given-names>L.</given-names></name>
<name><surname>Galfano</surname><given-names>G.</given-names></name>
<name><surname>Nishide</surname><given-names>F.</given-names></name>
<name><surname>Tamura</surname><given-names>F.</given-names></name>
<name><surname>Shimizu</surname><given-names>M.</given-names></name>
<name><surname>Santos</surname><given-names>J.G.</given-names><suffix>Jr.</suffix></name>
<name><surname>Linardi</surname><given-names>A.</given-names></name>
</person-group><article-title>Chronic intermittent exposure to ayahuasca during aging does not affect memory in mice</article-title><source>Braz. J. Med. Biol. Res.</source><year>2017</year><volume>50</volume><elocation-id>e6037</elocation-id><pub-id pub-id-type="pmid">28591380</pub-id>
</element-citation></ref><ref id="B202-pharmacy-13-00007"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kummrow</surname><given-names>F.</given-names></name>
<name><surname>Maselli</surname><given-names>B.</given-names></name>
<name><surname>Lanaro</surname><given-names>R.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Umbuzeiro</surname><given-names>G.</given-names></name>
<name><surname>Linardi</surname><given-names>A.</given-names></name>
</person-group><article-title>Mutagenicity of ayahuasca and their constituents to the salmonella/microsome assay</article-title><source>Environ. Mol. Mutagen.</source><year>2018</year><volume>60</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1002/em.22263</pub-id><pub-id pub-id-type="pmid">30488498</pub-id>
</element-citation></ref><ref id="B203-pharmacy-13-00007"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>B.</given-names></name>
<name><surname>Moreira</surname><given-names>D.</given-names></name>
<name><surname>Borges</surname><given-names>T.</given-names></name>
<name><surname>Caldas</surname><given-names>E.</given-names></name>
</person-group><article-title>Components of Banisteriopsis caapi, a plant used in the preparation of the psychoactive ayahuasca, induce anti-inflammatory effects in microglial cells</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>2500</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27082500</pub-id><pub-id pub-id-type="pmid">35458698</pub-id>
</element-citation></ref><ref id="B204-pharmacy-13-00007"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaire</surname><given-names>B.</given-names></name>
<name><surname>Subedi</surname><given-names>L.</given-names></name>
</person-group><article-title>A review on the pharmacological and toxicological aspects of <italic toggle="yes">Datura stramonium</italic> L</article-title><source>J. Integr. Med.</source><year>2013</year><volume>11</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.3736/jintegrmed2013016</pub-id><pub-id pub-id-type="pmid">23506688</pub-id>
</element-citation></ref><ref id="B205-pharmacy-13-00007"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Snafi</surname><given-names>A.</given-names></name>
</person-group><article-title>Medical importance of Datura fastuosa (syn: Datura metal) and Datura stramonium&#x02014;A review</article-title><source>IOSR J. Pharm. (IOSRPHR)</source><year>2017</year><volume>7</volume><fpage>43</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.9790/3013-0702014358</pub-id></element-citation></ref><ref id="B206-pharmacy-13-00007"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pk</surname><given-names>D.</given-names></name>
<name><surname>Op</surname><given-names>S.</given-names></name>
</person-group><article-title>Acute renal failure: A complication of Datura poisoning</article-title><source>J. Kidney</source><year>2017</year><volume>3</volume><fpage>1000147</fpage><pub-id pub-id-type="doi">10.4172/2472-1220.1000147</pub-id></element-citation></ref><ref id="B207-pharmacy-13-00007"><label>207.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>U.S. Department of Justice, National Drug Intelligence Center</collab>
</person-group><source>Jimsonweed (Datura Stramonium)</source><publisher-name>U.S. Department of Justice</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>1998</year></element-citation></ref><ref id="B208-pharmacy-13-00007"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ademikanra</surname><given-names>K.</given-names></name>
</person-group><article-title>Evaluation of in-vivo antioxidant and toxicological potential of Datura stramonium methanolic seed extracts in male Wistar rats</article-title><source>SFJ</source><year>2021</year><volume>26</volume><fpage>67</fpage><lpage>83</lpage></element-citation></ref><ref id="B209-pharmacy-13-00007"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Didou</surname><given-names>L.</given-names></name>
<name><surname>Azzaoui</surname><given-names>F.</given-names></name>
<name><surname>Ahami</surname><given-names>A.</given-names></name>
<name><surname>Ed-Day</surname><given-names>S.</given-names></name>
<name><surname>Kacimi</surname><given-names>F.</given-names></name>
<name><surname>Boulbaroud</surname><given-names>S.</given-names></name>
</person-group><article-title>Rosmarinus officinalis L. leaf extract improves anxiety impairment induced by tropane alkaloids extracted from Datura stramonium</article-title><source>E3S Web Conf.</source><year>2021</year><volume>319</volume><fpage>01059</fpage><pub-id pub-id-type="doi">10.1051/e3sconf/202131901059</pub-id></element-citation></ref><ref id="B210-pharmacy-13-00007"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vearrier</surname><given-names>D.</given-names></name>
<name><surname>Greenberg</surname><given-names>M.</given-names></name>
</person-group><article-title>Anticholinergic delirium following Datura stramonium ingestion: Implications for the internet age</article-title><source>J. Emergencies Trauma Shock</source><year>2010</year><volume>3</volume><fpage>303</fpage><pub-id pub-id-type="doi">10.4103/0974-2700.66565</pub-id></element-citation></ref><ref id="B211-pharmacy-13-00007"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diker</surname><given-names>D.</given-names></name>
<name><surname>Markovitz</surname><given-names>D.</given-names></name>
<name><surname>Rothman</surname><given-names>M.</given-names></name>
<name><surname>Sendovski</surname><given-names>U.</given-names></name>
</person-group><article-title>Coma as a presenting sign of Datura stramonium seed tea poisoning</article-title><source>Eur. J. Intern. Med.</source><year>2007</year><volume>18</volume><fpage>336</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2006.09.035</pub-id><pub-id pub-id-type="pmid">17574113</pub-id>
</element-citation></ref><ref id="B212-pharmacy-13-00007"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beynon</surname><given-names>S.</given-names></name>
<name><surname>Chaturvedi</surname><given-names>S.</given-names></name>
</person-group><article-title><italic toggle="yes">Datura</italic> intoxication in an adolescent male: A challenge in the Internet era</article-title><source>J. Paediatr. Child Health</source><year>2017</year><volume>54</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/jpc.13726</pub-id><pub-id pub-id-type="pmid">28948668</pub-id>
</element-citation></ref><ref id="B213-pharmacy-13-00007"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arefi</surname><given-names>M.</given-names></name>
<name><surname>Barzegari</surname><given-names>N.</given-names></name>
<name><surname>Asgari</surname><given-names>M.</given-names></name>
<name><surname>Soltani</surname><given-names>S.</given-names></name>
<name><surname>Farhidnia</surname><given-names>N.</given-names></name>
<name><surname>Fallah</surname><given-names>F.</given-names></name>
</person-group><article-title><italic toggle="yes">Datura</italic> poisoning, clinical and laboratory findings. Report of five cases</article-title><source>Rom. J. Leg. Med.</source><year>2016</year><volume>24</volume><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.4323/rjlm.2016.308</pub-id></element-citation></ref><ref id="B214-pharmacy-13-00007"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogunmoyole</surname><given-names>T.</given-names></name>
<name><surname>Adeyeye</surname><given-names>R.</given-names></name>
<name><surname>Olatilu</surname><given-names>B.</given-names></name>
<name><surname>Akande</surname><given-names>O.</given-names></name>
<name><surname>Agunbiade</surname><given-names>O.</given-names></name>
</person-group><article-title>Multiple organ toxicity of <italic toggle="yes">Datura stramonium</italic> seed extracts</article-title><source>Toxicol. Rep.</source><year>2019</year><volume>6</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2019.09.011</pub-id><pub-id pub-id-type="pmid">31673500</pub-id>
</element-citation></ref><ref id="B215-pharmacy-13-00007"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>D.</given-names></name>
<name><surname>Brown</surname><given-names>K.</given-names></name>
<name><surname>McMenemy</surname><given-names>M.</given-names></name>
<name><surname>Dennany</surname><given-names>L.</given-names></name>
<name><surname>Baker</surname><given-names>M.</given-names></name>
<name><surname>Allan</surname><given-names>P.</given-names></name>
<name><surname>Cartwright</surname><given-names>C.</given-names></name>
<name><surname>Bernard</surname><given-names>J.</given-names></name>
<name><surname>Sturt</surname><given-names>F.</given-names></name>
<name><surname>Kotoula</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Datura</italic> quids at Pinwheel Cave, California, provide unambiguous confirmation of the ingestion of hallucinogens at a rock art site</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>31026</fpage><lpage>31037</lpage><pub-id pub-id-type="doi">10.1073/pnas.2014529117</pub-id><pub-id pub-id-type="pmid">33229522</pub-id>
</element-citation></ref><ref id="B216-pharmacy-13-00007"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krenzelok</surname><given-names>E.</given-names></name>
</person-group><article-title>Aspects of <italic toggle="yes">Datura</italic> poisoning and treatment</article-title><source>Clin. Toxicol.</source><year>2010</year><volume>48</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.3109/15563651003630672</pub-id><pub-id pub-id-type="pmid">20229618</pub-id>
</element-citation></ref><ref id="B217-pharmacy-13-00007"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>S.</given-names></name>
<name><surname>Perttula</surname><given-names>T.</given-names></name>
<name><surname>Gaikwad</surname><given-names>N.</given-names></name>
</person-group><article-title>Production matters</article-title><source>Adv. Archaeol. Pract.</source><year>2021</year><volume>10</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1017/aap.2021.15</pub-id></element-citation></ref><ref id="B218-pharmacy-13-00007"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shebani</surname><given-names>A.</given-names></name>
<name><surname>Hnish</surname><given-names>M.</given-names></name>
<name><surname>Elmelliti</surname><given-names>H.</given-names></name>
<name><surname>Abdeen</surname><given-names>M.</given-names></name>
<name><surname>Ganaw</surname><given-names>A.</given-names></name>
</person-group><article-title>Acute poisoning with <italic toggle="yes">Datura stramonium</italic> plant seeds in Qatar</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e20152</fpage><pub-id pub-id-type="doi">10.7759/cureus.20152</pub-id><pub-id pub-id-type="pmid">35003983</pub-id>
</element-citation></ref><ref id="B219-pharmacy-13-00007"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rakotomavo</surname><given-names>F.</given-names></name>
<name><surname>Andriamasy</surname><given-names>C.</given-names></name>
<name><surname>Ndrantoniaina</surname><given-names>R.</given-names></name>
<name><surname>Raveloson</surname><given-names>N.</given-names></name>
</person-group><article-title><italic toggle="yes">Datura stramonium</italic> intoxication in two children</article-title><source>Pediatr. Int.</source><year>2014</year><volume>56</volume><fpage>e14</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1111/ped.12363</pub-id><pub-id pub-id-type="pmid">24894939</pub-id>
</element-citation></ref><ref id="B220-pharmacy-13-00007"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereda-Miranda</surname><given-names>R.</given-names></name>
<name><surname>Mata</surname><given-names>R.</given-names></name>
<name><surname>Anaya</surname><given-names>A.</given-names></name>
<name><surname>Wickramaratne</surname><given-names>D.</given-names></name>
<name><surname>Pezzuto</surname><given-names>J.</given-names></name>
<name><surname>Kinghorn</surname><given-names>A.</given-names></name>
</person-group><article-title>Tricolorin A, major phytogrowth inhibitor from <italic toggle="yes">Ipomoea tricolor</italic></article-title><source>J. Nat. Prod.</source><year>1993</year><volume>56</volume><fpage>571</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1021/np50094a018</pub-id><pub-id pub-id-type="pmid">8496705</pub-id>
</element-citation></ref><ref id="B221-pharmacy-13-00007"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>M.</given-names></name>
<name><surname>Dhaliwal</surname><given-names>I.</given-names></name>
<name><surname>Rana</surname><given-names>K.</given-names></name>
<name><surname>Delta</surname><given-names>A.K.</given-names></name>
<name><surname>Kaushik</surname><given-names>P.</given-names></name>
</person-group><article-title>Phytochemistry, Pharmacology, and Toxicology of <italic toggle="yes">Datura</italic> Species-A Review</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><elocation-id>1291</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10081291</pub-id><pub-id pub-id-type="pmid">34439539</pub-id>
</element-citation></ref><ref id="B222-pharmacy-13-00007"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fasakin</surname><given-names>O.W.</given-names></name>
<name><surname>Oboh</surname><given-names>G.</given-names></name>
<name><surname>Ademosun</surname><given-names>A.O.</given-names></name>
</person-group><article-title>The prevalence, mechanism of action, and toxicity of Nigerian psychoactive plants</article-title><source>Comp. Clin. Pathol.</source><year>2022</year><volume>31</volume><fpage>853</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1007/s00580-022-03374-w</pub-id><pub-id pub-id-type="pmid">35789743</pub-id>
</element-citation></ref><ref id="B223-pharmacy-13-00007"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meira</surname><given-names>M.</given-names></name>
<name><surname>Silva</surname><given-names>E.</given-names></name>
<name><surname>David</surname><given-names>J.</given-names></name>
<name><surname>David</surname><given-names>J.</given-names></name>
</person-group><article-title>Review of the genus <italic toggle="yes">Ipomoea</italic>: Traditional uses, chemistry, and biological activities</article-title><source>Rev. Bras. De Farmacogn.</source><year>2012</year><volume>22</volume><fpage>682</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1590/S0102-695X2012005000025</pub-id></element-citation></ref><ref id="B224-pharmacy-13-00007"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selim</surname><given-names>N.</given-names></name>
<name><surname>Hawary</surname><given-names>S.</given-names></name>
<name><surname>Aly</surname><given-names>H.</given-names></name>
<name><surname>Matlob</surname><given-names>A.</given-names></name>
<name><surname>Elhenawy</surname><given-names>M.</given-names></name>
<name><surname>Deabes</surname><given-names>D.</given-names></name>
<name><surname>Ebrahim</surname><given-names>H.</given-names></name>
</person-group><article-title>Comparative phytochemical and biological studies of lipoidal matter of <italic toggle="yes">Ipomoea tricolor</italic> (Cav.) and <italic toggle="yes">Ipomoea fistulosa</italic> (Mart. ex Choisy) growing in Egypt</article-title><source>Egypt. J. Chem.</source><year>2021</year><volume>64</volume><fpage>1845</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.21608/ejchem.2021.61245.3316</pub-id></element-citation></ref><ref id="B225-pharmacy-13-00007"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ameamsri</surname><given-names>U.</given-names></name>
<name><surname>Tanee</surname><given-names>T.</given-names></name>
<name><surname>Chaveerach</surname><given-names>A.</given-names></name>
<name><surname>Peigneur</surname><given-names>S.</given-names></name>
<name><surname>Tytgat</surname><given-names>J.</given-names></name>
<name><surname>Sudmoon</surname><given-names>R.</given-names></name>
</person-group><article-title>Anti-inflammatory and detoxification activities of some <italic toggle="yes">Ipomoea</italic> species determined by ion channel inhibition and their phytochemical constituents</article-title><source>ScienceAsia</source><year>2021</year><volume>47</volume><fpage>321</fpage><pub-id pub-id-type="doi">10.2306/scienceasia1513-1874.2021.042</pub-id></element-citation></ref><ref id="B226-pharmacy-13-00007"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le&#x000f3;n-Rivera</surname><given-names>I.</given-names></name>
<name><surname>Mir&#x000f3;n-L&#x000f3;pez</surname><given-names>G.</given-names></name>
<name><surname>Molina-Salinas</surname><given-names>G.</given-names></name>
<name><surname>Herrera-Ruiz</surname><given-names>M.</given-names></name>
<name><surname>Estrada-Soto</surname><given-names>S.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>M.</given-names></name>
<name><surname>Alonso-Cortes</surname><given-names>D.</given-names></name>
<name><surname>Navarrete-V&#x000e1;zquez</surname><given-names>G.</given-names></name>
<name><surname>R&#x000ed;os</surname><given-names>M.Y.</given-names></name>
<name><surname>Said-Fern&#x000e1;ndez</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Tyrianthinic acids from <italic toggle="yes">Ipomoea tyrianthina</italic> and their antimycobacterial activity, cytotoxicity, and effects on the central nervous system</article-title><source>J. Nat. Prod.</source><year>2008</year><volume>71</volume><fpage>1686</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1021/np800266a</pub-id><pub-id pub-id-type="pmid">18826278</pub-id>
</element-citation></ref><ref id="B227-pharmacy-13-00007"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parnmen</surname><given-names>S.</given-names></name>
<name><surname>Nooron</surname><given-names>N.</given-names></name>
<name><surname>Sikaphan</surname><given-names>S.</given-names></name>
<name><surname>Pringsulaka</surname><given-names>O.</given-names></name>
<name><surname>Rangsiruji</surname><given-names>A.</given-names></name>
</person-group><article-title>Potential toxicity of wild <italic toggle="yes">Ipomoea</italic> ingested by schoolchildren in remote northeastern Thailand</article-title><source>J. Assoc. Med. Sci.</source><year>2023</year><volume>56</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.12982/JAMS.2023.008</pub-id></element-citation></ref><ref id="B228-pharmacy-13-00007"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>A.</given-names></name>
<name><surname>O&#x02019;Hern</surname><given-names>P.</given-names></name>
<name><surname>Elkins</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Evaluation of two new methods for DNA extraction of &#x0201c;legal high&#x0201d; plant species</article-title><source>J. Forensic Sci.</source><year>2020</year><volume>65</volume><fpage>1704</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1111/1556-4029.14478</pub-id><pub-id pub-id-type="pmid">32542747</pub-id>
</element-citation></ref><ref id="B229-pharmacy-13-00007"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Maeso</surname><given-names>J.</given-names></name>
<name><surname>Weisstaub</surname><given-names>N.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Chan</surname><given-names>P.</given-names></name>
<name><surname>Ivic</surname><given-names>L.</given-names></name>
<name><surname>Ang</surname><given-names>R.</given-names></name>
<name><surname>Lira</surname><given-names>A.</given-names></name>
<name><surname>Bradley-Moore</surname><given-names>M.</given-names></name>
<name><surname>Ge</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Hallucinogens recruit specific cortical 5-HT&#x02082;A receptor-mediated signaling pathways to affect behavior</article-title><source>Neuron</source><year>2007</year><volume>53</volume><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.008</pub-id><pub-id pub-id-type="pmid">17270739</pub-id>
</element-citation></ref><ref id="B230-pharmacy-13-00007"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arunotayanun</surname><given-names>W.</given-names></name>
<name><surname>Gibbons</surname><given-names>S.</given-names></name>
</person-group><article-title>Natural product &#x02018;legal highs&#x02019;</article-title><source>Nat. Prod. Rep.</source><year>2012</year><volume>29</volume><fpage>1304</fpage><pub-id pub-id-type="doi">10.1039/c2np20068f</pub-id><pub-id pub-id-type="pmid">22930322</pub-id>
</element-citation></ref><ref id="B231-pharmacy-13-00007"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmid</surname><given-names>C.</given-names></name>
<name><surname>Bohn</surname><given-names>L.</given-names></name>
</person-group><article-title>Serotonin, but not dimethyltryptamine, activates the serotonin 2A receptor via a &#x003b2;-arrestin2/src/Akt signaling complex in vivo</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>13513</fpage><lpage>13524</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1665-10.2010</pub-id><pub-id pub-id-type="pmid">20926677</pub-id>
</element-citation></ref><ref id="B232-pharmacy-13-00007"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halberstadt</surname><given-names>A.</given-names></name>
<name><surname>Geyer</surname><given-names>M.</given-names></name>
</person-group><article-title>Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens</article-title><source>Neuropharmacology</source><year>2011</year><volume>61</volume><fpage>364</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.01.017</pub-id><pub-id pub-id-type="pmid">21256140</pub-id>
</element-citation></ref><ref id="B233-pharmacy-13-00007"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passie</surname><given-names>T.</given-names></name>
<name><surname>Halpern</surname><given-names>J.H.</given-names></name>
<name><surname>Stichtenoth</surname><given-names>D.O.</given-names></name>
<name><surname>Emrich</surname><given-names>H.M.</given-names></name>
<name><surname>Hintzen</surname><given-names>A.</given-names></name>
</person-group><article-title>The pharmacology of lysergic acid diethylamide: A review</article-title><source>CNS Neurosci. Ther.</source><year>2008</year><volume>14</volume><fpage>295</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2008.00059.x</pub-id><pub-id pub-id-type="pmid">19040555</pub-id>
</element-citation></ref><ref id="B234-pharmacy-13-00007"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halberstadt</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent advances in the neuropsychopharmacology of serotonergic hallucinogens</article-title><source>Behav. Brain Res.</source><year>2015</year><volume>277</volume><fpage>99</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2014.07.016</pub-id><pub-id pub-id-type="pmid">25036425</pub-id>
</element-citation></ref><ref id="B235-pharmacy-13-00007"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nowak</surname><given-names>J.</given-names></name>
<name><surname>Wo&#x0017a;niakiewicz</surname><given-names>M.</given-names></name>
<name><surname>Klepacki</surname><given-names>P.</given-names></name>
<name><surname>Sowa</surname><given-names>A.</given-names></name>
<name><surname>Ko&#x0015b;cielniak</surname><given-names>P.</given-names></name>
</person-group><article-title>Identification and determination of ergot alkaloids in morning glory cultivars</article-title><source>Anal. Bioanal. Chem.</source><year>2016</year><volume>408</volume><fpage>3093</fpage><lpage>3102</lpage><pub-id pub-id-type="doi">10.1007/s00216-016-9322-5</pub-id><pub-id pub-id-type="pmid">26873205</pub-id>
</element-citation></ref><ref id="B236-pharmacy-13-00007"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>J.</given-names></name>
<name><surname>Mercx</surname><given-names>S.</given-names></name>
<name><surname>Boutry</surname><given-names>M.</given-names></name>
<name><surname>Chaumont</surname><given-names>F.</given-names></name>
</person-group><article-title>Evolutionary and predictive functional insights into the aquaporin gene family in the allotetraploid plant <italic toggle="yes">Nicotiana tabacum</italic></article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4743</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21134743</pub-id><pub-id pub-id-type="pmid">32635213</pub-id>
</element-citation></ref><ref id="B237-pharmacy-13-00007"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olatunji</surname><given-names>B.</given-names></name>
<name><surname>Arowosegbe</surname><given-names>S.</given-names></name>
<name><surname>Adeleke</surname><given-names>O.</given-names></name>
<name><surname>Obawumi</surname><given-names>D.</given-names></name>
<name><surname>Asowata-Ayodele</surname><given-names>A.</given-names></name>
</person-group><article-title>Nicotine content and dietary composition of some cultivated species of <italic toggle="yes">Solanaceae</italic> family</article-title><source>Ann. Sci. Technol.</source><year>2022</year><volume>7</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.2478/ast-2022-0008</pub-id></element-citation></ref><ref id="B238-pharmacy-13-00007"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardavas</surname><given-names>C.I.</given-names></name>
</person-group><article-title>European Tobacco Products Directive (TPD): Current impact and future steps</article-title><source>Tob. Control</source><year>2022</year><volume>31</volume><fpage>198</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1136/tobaccocontrol-2021-056548</pub-id><pub-id pub-id-type="pmid">35241588</pub-id>
</element-citation></ref><ref id="B239-pharmacy-13-00007"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>B.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Panter</surname><given-names>K.</given-names></name>
<name><surname>Brown</surname><given-names>D.</given-names></name>
</person-group><article-title>Piperidine alkaloids: Human and food animal teratogens</article-title><source>Food Chem. Toxicol.</source><year>2012</year><volume>50</volume><fpage>2049</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2012.03.049</pub-id><pub-id pub-id-type="pmid">22449544</pub-id>
</element-citation></ref><ref id="B240-pharmacy-13-00007"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sierro</surname><given-names>N.</given-names></name>
<name><surname>Battey</surname><given-names>J.</given-names></name>
<name><surname>Ouadi</surname><given-names>S.</given-names></name>
<name><surname>Bovet</surname><given-names>L.</given-names></name>
<name><surname>Goepfert</surname><given-names>S.</given-names></name>
<name><surname>Bakaher</surname><given-names>N.</given-names></name>
<name><surname>Peitsch</surname><given-names>M.C.</given-names></name>
<name><surname>Ivanov</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Reference genomes and transcriptomes of <italic toggle="yes">Nicotiana sylvestris</italic> and <italic toggle="yes">Nicotiana tomentosiformis</italic></article-title><source>Genome Biol.</source><year>2013</year><volume>14</volume><elocation-id>R60</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-6-r60</pub-id><pub-id pub-id-type="pmid">23773524</pub-id>
</element-citation></ref><ref id="B241-pharmacy-13-00007"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nwaji</surname><given-names>A.</given-names></name>
<name><surname>Inwang</surname><given-names>U.</given-names></name>
<name><surname>Nwoke</surname><given-names>F.</given-names></name>
<name><surname>Ante</surname><given-names>I.</given-names></name>
</person-group><article-title>Changes in serum electrolytes, urea, and creatinine in <italic toggle="yes">Nicotiana tabacum</italic>-treated rats</article-title><source>Niger. J. Physiol. Sci.</source><year>2022</year><volume>37</volume><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.54548/njps.v37i1.19</pub-id><pub-id pub-id-type="pmid">35947840</pub-id>
</element-citation></ref><ref id="B242-pharmacy-13-00007"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>K.</given-names></name>
<name><surname>Cai</surname><given-names>B.</given-names></name>
<name><surname>Xiang</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Rao</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>W.</given-names></name>
<name><surname>Lei</surname><given-names>B.</given-names></name>
</person-group><article-title>Low-temperature derivatization followed by vortex-assisted liquid-liquid microextraction for the analysis of polyamines in <italic toggle="yes">Nicotiana tabacum</italic></article-title><source>J. Sep. Sci.</source><year>2016</year><volume>39</volume><fpage>2573</fpage><lpage>2583</lpage><pub-id pub-id-type="doi">10.1002/jssc.201600210</pub-id><pub-id pub-id-type="pmid">27145427</pub-id>
</element-citation></ref><ref id="B243-pharmacy-13-00007"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adler</surname><given-names>L.</given-names></name>
<name><surname>Wink</surname><given-names>M.</given-names></name>
<name><surname>Distl</surname><given-names>M.</given-names></name>
<name><surname>Lentz</surname><given-names>A.</given-names></name>
</person-group><article-title>Leaf herbivory and nutrients increase nectar alkaloids</article-title><source>Ecol. Lett.</source><year>2006</year><volume>9</volume><fpage>960</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1111/j.1461-0248.2006.00944.x</pub-id><pub-id pub-id-type="pmid">16913940</pub-id>
</element-citation></ref><ref id="B244-pharmacy-13-00007"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sierro</surname><given-names>N.</given-names></name>
<name><surname>Battey</surname><given-names>J.</given-names></name>
<name><surname>Bovet</surname><given-names>L.</given-names></name>
<name><surname>Liedschulte</surname><given-names>V.</given-names></name>
<name><surname>Ouadi</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Broye</surname><given-names>H.</given-names></name>
<name><surname>Laparra</surname><given-names>H.</given-names></name>
<name><surname>Vuarnoz</surname><given-names>A.</given-names></name>
<name><surname>Lang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>The impact of genome evolution on the allotetraploid <italic toggle="yes">Nicotiana rustica</italic>&#x02014;An intriguing story of enhanced alkaloid production</article-title><source>BMC Genom.</source><year>2018</year><volume>19</volume><elocation-id>855</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-018-5241-5</pub-id><pub-id pub-id-type="pmid">30497378</pub-id>
</element-citation></ref><ref id="B245-pharmacy-13-00007"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Finch</surname><given-names>P.</given-names></name>
<name><surname>Drummond</surname><given-names>P.</given-names></name>
</person-group><article-title>Topical treatment in pain medicine: From ancient remedies to modern usage</article-title><source>Pain Manag.</source><year>2015</year><volume>5</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2217/pmt.15.23</pub-id><pub-id pub-id-type="pmid">26196538</pub-id>
</element-citation></ref><ref id="B246-pharmacy-13-00007"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llanes</surname><given-names>L.</given-names></name>
<name><surname>Biazotto</surname><given-names>N.</given-names></name>
<name><surname>Cenci</surname><given-names>A.</given-names></name>
<name><surname>Teixeira</surname><given-names>K.</given-names></name>
<name><surname>Fran&#x000e7;a</surname><given-names>I.</given-names></name>
<name><surname>Meier</surname><given-names>L.</given-names></name>
<name><surname>de Oliveira</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Witches, potions, and metabolites: An overview from a medicinal perspective</article-title><source>RSC Med. Chem.</source><year>2022</year><volume>13</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1039/D2MD00025C</pub-id><pub-id pub-id-type="pmid">35647543</pub-id>
</element-citation></ref><ref id="B247-pharmacy-13-00007"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chidiac</surname><given-names>E.</given-names></name>
<name><surname>Kaddoum</surname><given-names>R.</given-names></name>
<name><surname>Fuleihan</surname><given-names>S.</given-names></name>
</person-group><article-title>Mandragora</article-title><source>Anesth. Analg.</source><year>2012</year><volume>115</volume><fpage>1437</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1213/ANE.0b013e318259ee4d</pub-id><pub-id pub-id-type="pmid">22584550</pub-id>
</element-citation></ref><ref id="B248-pharmacy-13-00007"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gr&#x000fc;ndemann</surname><given-names>C.</given-names></name>
<name><surname>Diegel</surname><given-names>C.</given-names></name>
<name><surname>Sauer</surname><given-names>B.</given-names></name>
<name><surname>Garcia-K&#x000e4;ufer</surname><given-names>M.</given-names></name>
<name><surname>Huber</surname><given-names>R.</given-names></name>
</person-group><article-title>Immunomodulatory effects of preparations from anthroposophical medicine for parenteral use</article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>303</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0757-6</pub-id><pub-id pub-id-type="pmid">26329810</pub-id>
</element-citation></ref><ref id="B249-pharmacy-13-00007"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xia</surname><given-names>G.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Qiu</surname><given-names>F.</given-names></name>
</person-group><article-title>Natural withanolides, an update</article-title><source>Nat. Prod. Rep.</source><year>2022</year><volume>39</volume><fpage>784</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1039/D1NP00055A</pub-id><pub-id pub-id-type="pmid">34816854</pub-id>
</element-citation></ref><ref id="B250-pharmacy-13-00007"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monadi</surname><given-names>T.</given-names></name>
<name><surname>Azadbakht</surname><given-names>M.</given-names></name>
<name><surname>Ahmadi</surname><given-names>A.</given-names></name>
<name><surname>Chabra</surname><given-names>A.</given-names></name>
</person-group><article-title>A comprehensive review on the ethnopharmacology, phytochemistry, pharmacology, and toxicology of the <italic toggle="yes">Mandragora</italic> genus; from folk medicine to modern medicine</article-title><source>Curr. Pharm. Des.</source><year>2021</year><volume>27</volume><fpage>3609</fpage><lpage>3637</lpage><pub-id pub-id-type="doi">10.2174/1381612827666210203143445</pub-id><pub-id pub-id-type="pmid">33535944</pub-id>
</element-citation></ref><ref id="B251-pharmacy-13-00007"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Don-Lawson</surname><given-names>C.</given-names></name>
<name><surname>Oforibika</surname><given-names>G.</given-names></name>
<name><surname>Okah</surname><given-names>R.</given-names></name>
</person-group><article-title>Hepatic impact of <italic toggle="yes">Mandragora officinarum</italic> leaf extract on Wistar albino rats</article-title><source>Am. J. Anal. Chem.</source><year>2022</year><volume>13</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.4236/ajac.2022.1312035</pub-id></element-citation></ref><ref id="B252-pharmacy-13-00007"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frasca</surname><given-names>T.</given-names></name>
</person-group><article-title>Mandrake toxicity: A case of mistaken identity</article-title><source>Arch. Intern. Med.</source><year>1997</year><volume>157</volume><fpage>2007</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1001/archinte.1997.00440380117012</pub-id><pub-id pub-id-type="pmid">9308513</pub-id>
</element-citation></ref><ref id="B253-pharmacy-13-00007"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manthey</surname><given-names>J.</given-names></name>
<name><surname>Jacobsen</surname><given-names>B.</given-names></name>
<name><surname>Hayer</surname><given-names>T.</given-names></name>
<name><surname>Kalke</surname><given-names>J.</given-names></name>
<name><surname>L&#x000f3;pez-Pelayo</surname><given-names>H.</given-names></name>
<name><surname>Pons-Cabrera</surname><given-names>M.T.</given-names></name>
<name><surname>Verthein</surname><given-names>U.</given-names></name>
<name><surname>Rosenkranz</surname><given-names>M.</given-names></name>
</person-group><article-title>The impact of legal cannabis availability on cannabis use and health outcomes: A systematic review</article-title><source>Int. J. Drug Policy</source><year>2023</year><volume>116</volume><fpage>104039</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2023.104039</pub-id><pub-id pub-id-type="pmid">37126997</pub-id>
</element-citation></ref><ref id="B254-pharmacy-13-00007"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahamad</surname><given-names>S.</given-names></name>
<name><surname>Hammond</surname><given-names>D.</given-names></name>
</person-group><article-title>Retail price and availability of illicit cannabis in Canada</article-title><source>Addict. Behav.</source><year>2019</year><volume>90</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2018.12.001</pub-id><pub-id pub-id-type="pmid">30530299</pub-id>
</element-citation></ref><ref id="B255-pharmacy-13-00007"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahamad</surname><given-names>S.</given-names></name>
<name><surname>Wadsworth</surname><given-names>E.</given-names></name>
<name><surname>Rynard</surname><given-names>V.</given-names></name>
<name><surname>Goodman</surname><given-names>S.</given-names></name>
<name><surname>Hammond</surname><given-names>D.</given-names></name>
</person-group><article-title>Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalization</article-title><source>Drug Alcohol Rev.</source><year>2020</year><volume>39</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1111/dar.13069</pub-id><pub-id pub-id-type="pmid">32291811</pub-id>
</element-citation></ref><ref id="B256-pharmacy-13-00007"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levy</surname><given-names>N.S.</given-names></name>
<name><surname>Mauro</surname><given-names>P.M.</given-names></name>
<name><surname>Mauro</surname><given-names>C.M.</given-names></name>
<name><surname>Segura</surname><given-names>L.E.</given-names></name>
<name><surname>Martins</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Joint perceptions of the risk and availability of cannabis in the United States, 2002&#x02013;2018</article-title><source>Drug Alcohol Depend.</source><year>2021</year><volume>226</volume><fpage>108873</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108873</pub-id><pub-id pub-id-type="pmid">34275699</pub-id>
</element-citation></ref><ref id="B257-pharmacy-13-00007"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Decorte</surname><given-names>T.</given-names></name>
<name><surname>Pardal</surname><given-names>M.</given-names></name>
<name><surname>Queirolo</surname><given-names>R.</given-names></name>
<name><surname>Boidi</surname><given-names>M.F.</given-names></name>
<name><surname>S&#x000e1;nchez Avil&#x000e9;s</surname><given-names>C.</given-names></name>
<name><surname>Par&#x000e9;s Franquero</surname><given-names>&#x000d2;.</given-names></name>
</person-group><article-title>Regulating Cannabis Social Clubs: A comparative analysis of legal and self-regulatory practices in Spain, Belgium, and Uruguay</article-title><source>Int. J. Drug Policy</source><year>2017</year><volume>43</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2016.12.020</pub-id><pub-id pub-id-type="pmid">28189980</pub-id>
</element-citation></ref><ref id="B258-pharmacy-13-00007"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickinson</surname><given-names>T.</given-names></name>
<name><surname>Jacques</surname><given-names>S.</given-names></name>
</person-group><article-title>Drug control policy, normalization, and symbolic boundaries in Amsterdam&#x02019;s coffee shops</article-title><source>Br. J. Criminol.</source><year>2021</year><volume>61</volume><fpage>22</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/bjc/azaa059</pub-id></element-citation></ref><ref id="B259-pharmacy-13-00007"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>A.Y.</given-names></name>
<name><surname>Gottfredson</surname><given-names>N.C.</given-names></name>
<name><surname>Ribisl</surname><given-names>K.M.</given-names></name>
<name><surname>Baggett</surname><given-names>C.D.</given-names></name>
<name><surname>Delamater</surname><given-names>P.L.</given-names></name>
<name><surname>Golden</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Associations of County Tobacco Retailer Availability With U.S. Adult Smoking Behaviors, 2014&#x02013;2015</article-title><source>Am. J. Prev. Med.</source><year>2021</year><volume>61</volume><fpage>e139</fpage><lpage>e147</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2021.03.015</pub-id><pub-id pub-id-type="pmid">34134883</pub-id>
</element-citation></ref><ref id="B260-pharmacy-13-00007"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valiente</surname><given-names>R.</given-names></name>
<name><surname>Sureda</surname><given-names>X.</given-names></name>
<name><surname>Bilal</surname><given-names>U.</given-names></name>
<name><surname>Navas-Acien</surname><given-names>A.</given-names></name>
<name><surname>Pearce</surname><given-names>J.</given-names></name>
<name><surname>Franco</surname><given-names>M.</given-names></name>
<name><surname>Escobar</surname><given-names>F.</given-names></name>
</person-group><article-title>Regulating the local availability of tobacco retailing in Madrid, Spain: A GIS study to evaluate compliance</article-title><source>Tob. Control</source><year>2019</year><volume>28</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1136/tobaccocontrol-2018-054269</pub-id><pub-id pub-id-type="pmid">29991639</pub-id>
</element-citation></ref><ref id="B261-pharmacy-13-00007"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kingsley</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Robertson</surname><given-names>J.</given-names></name>
<name><surname>Henley</surname><given-names>P.</given-names></name>
<name><surname>Ursprung</surname><given-names>W.W.S.</given-names></name>
</person-group><article-title>Impact of flavored tobacco restriction policies on flavored product availability in Massachusetts</article-title><source>Tob. Control</source><year>2020</year><volume>29</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">30777880</pub-id>
</element-citation></ref><ref id="B262-pharmacy-13-00007"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skolnick</surname><given-names>P.</given-names></name>
</person-group><article-title>The opioid epidemic: Crisis and solutions</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2018</year><volume>58</volume><fpage>143</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010617-052534</pub-id><pub-id pub-id-type="pmid">28968188</pub-id>
</element-citation></ref><ref id="B263-pharmacy-13-00007"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esquibel</surname><given-names>A.Y.</given-names></name>
<name><surname>Borkan</surname><given-names>J.</given-names></name>
</person-group><article-title>Doctors and patients in pain: Conflict and collaboration in opioid prescription in primary care</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>2575</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.09.018</pub-id><pub-id pub-id-type="pmid">25261714</pub-id>
</element-citation></ref><ref id="B264-pharmacy-13-00007"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manchikanti</surname><given-names>L.</given-names></name>
<name><surname>Kaye</surname><given-names>A.M.</given-names></name>
<name><surname>Knezevic</surname><given-names>N.N.</given-names></name>
<name><surname>McAnally</surname><given-names>H.</given-names></name>
<name><surname>Slavin</surname><given-names>K.</given-names></name>
<name><surname>Trescot</surname><given-names>A.M.</given-names></name>
<name><surname>Blank</surname><given-names>S.</given-names></name>
<name><surname>Pampati</surname><given-names>V.</given-names></name>
<name><surname>Abdi</surname><given-names>S.</given-names></name>
<name><surname>Grider</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines</article-title><source>Pain Physician</source><year>2017</year><volume>20</volume><fpage>S3</fpage><lpage>S92</lpage><pub-id pub-id-type="doi">10.36076/ppj.2017.s92</pub-id><pub-id pub-id-type="pmid">28226332</pub-id>
</element-citation></ref><ref id="B265-pharmacy-13-00007"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaprutko</surname><given-names>T.</given-names></name>
<name><surname>Koligat</surname><given-names>D.</given-names></name>
<name><surname>Michalak</surname><given-names>M.</given-names></name>
<name><surname>Wieczorek</surname><given-names>M.</given-names></name>
<name><surname>J&#x000f3;ziak</surname><given-names>M.</given-names></name>
<name><surname>Ratajczak</surname><given-names>M.</given-names></name>
<name><surname>Szyd&#x00142;owska</surname><given-names>K.</given-names></name>
<name><surname>Miazek</surname><given-names>J.</given-names></name>
<name><surname>Kus</surname><given-names>K.</given-names></name>
<name><surname>Nowakowska</surname><given-names>E.</given-names></name>
</person-group><article-title>Misuse of OTC drugs in Poland</article-title><source>Health Policy</source><year>2016</year><volume>120</volume><fpage>875</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1016/j.healthpol.2016.06.008</pub-id><pub-id pub-id-type="pmid">27344198</pub-id>
</element-citation></ref><ref id="B266-pharmacy-13-00007"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hockenhull</surname><given-names>J.</given-names></name>
<name><surname>Wood</surname><given-names>D.M.</given-names></name>
<name><surname>Fonseca</surname><given-names>F.</given-names></name>
<name><surname>Guareschi</surname><given-names>M.</given-names></name>
<name><surname>Scherbaum</surname><given-names>N.</given-names></name>
<name><surname>Iwanicki</surname><given-names>J.L.</given-names></name>
<name><surname>Dart</surname><given-names>R.C.</given-names></name>
<name><surname>Dargan</surname><given-names>P.I.</given-names></name>
</person-group><article-title>The association between the availability of over-the-counter codeine and the prevalence of non-medical use</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2022</year><volume>78</volume><fpage>1011</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1007/s00228-021-03158-1</pub-id><pub-id pub-id-type="pmid">35244726</pub-id>
</element-citation></ref><ref id="B267-pharmacy-13-00007"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>S.</given-names></name>
<name><surname>Cameron</surname><given-names>J.</given-names></name>
<name><surname>Pahoki</surname><given-names>S.</given-names></name>
</person-group><article-title>Opportunities and challenges: Over-the-counter codeine supply from the codeine consumer&#x02019;s perspective</article-title><source>Int. J. Pharm. Pract.</source><year>2013</year><volume>21</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7174.2012.00247.x</pub-id><pub-id pub-id-type="pmid">23419000</pub-id>
</element-citation></ref><ref id="B268-pharmacy-13-00007"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kudlacek</surname><given-names>O.</given-names></name>
<name><surname>Hofmaier</surname><given-names>T.</given-names></name>
<name><surname>Luf</surname><given-names>A.</given-names></name>
<name><surname>Mayer</surname><given-names>F.P.</given-names></name>
<name><surname>Stockner</surname><given-names>T.</given-names></name>
<name><surname>Nagy</surname><given-names>C.</given-names></name>
<name><surname>Holy</surname><given-names>M.</given-names></name>
<name><surname>Freissmuth</surname><given-names>M.</given-names></name>
<name><surname>Schmid</surname><given-names>R.</given-names></name>
<name><surname>Sitte</surname><given-names>H.H.</given-names></name>
<etal/>
</person-group><article-title>Cocaine adulteration</article-title><source>J. Chem. Neuroanat.</source><year>2017</year><volume>83&#x02013;84</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2017.06.001</pub-id><pub-id pub-id-type="pmid">28619473</pub-id>
</element-citation></ref><ref id="B269-pharmacy-13-00007"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mejia</surname><given-names>D.</given-names></name>
<name><surname>Restrepo</surname><given-names>P.</given-names></name>
</person-group><article-title>The economics of the war on illegal drug production and trafficking</article-title><source>J. Econ. Behav. Organ.</source><year>2016</year><volume>126</volume><fpage>255</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jebo.2015.11.003</pub-id></element-citation></ref><ref id="B270-pharmacy-13-00007"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boivin</surname><given-names>R.</given-names></name>
</person-group><article-title>Risks, prices, and positions: A social network analysis of illegal drug trafficking in the world-economy</article-title><source>Int. J. Drug Policy</source><year>2014</year><volume>25</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2013.12.004</pub-id><pub-id pub-id-type="pmid">24418633</pub-id>
</element-citation></ref><ref id="B271-pharmacy-13-00007"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondo</surname><given-names>T.</given-names></name>
<name><surname>Nakano</surname><given-names>Y.</given-names></name>
<name><surname>Adachi</surname><given-names>S.</given-names></name>
<name><surname>Murohara</surname><given-names>T.</given-names></name>
</person-group><article-title>Effects of Tobacco Smoking on Cardiovascular Disease</article-title><source>Circ. J.</source><year>2019</year><volume>83</volume><fpage>2289</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-19-0323</pub-id><pub-id pub-id-type="pmid">31462607</pub-id>
</element-citation></ref><ref id="B272-pharmacy-13-00007"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quaranta</surname><given-names>A.</given-names></name>
<name><surname>D&#x02019;Isidoro</surname><given-names>O.</given-names></name>
<name><surname>Piattelli</surname><given-names>A.</given-names></name>
<name><surname>Hui</surname><given-names>W.L.</given-names></name>
<name><surname>Perrotti</surname><given-names>V.</given-names></name>
</person-group><article-title>Illegal drugs and periodontal conditions</article-title><source>Periodontology 2000</source><year>2022</year><volume>90</volume><fpage>62</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/prd.12450</pub-id><pub-id pub-id-type="pmid">36183328</pub-id>
</element-citation></ref><ref id="B273-pharmacy-13-00007"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jett</surname><given-names>J.</given-names></name>
<name><surname>Stone</surname><given-names>E.</given-names></name>
<name><surname>Warren</surname><given-names>G.</given-names></name>
<name><surname>Cummings</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Cannabis Use, Lung Cancer, and Related Issues</article-title><source>J. Thorac. Oncol.</source><year>2018</year><volume>13</volume><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2017.12.013</pub-id><pub-id pub-id-type="pmid">29374567</pub-id>
</element-citation></ref><ref id="B274-pharmacy-13-00007"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vearrier</surname><given-names>D.</given-names></name>
<name><surname>Grundmann</surname><given-names>O.</given-names></name>
</person-group><article-title>Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids</article-title><source>J. Clin. Pharmacol.</source><year>2021</year><volume>61</volume><issue>(Suppl. S2)</issue><fpage>S70</fpage><lpage>S88</lpage><pub-id pub-id-type="doi">10.1002/jcph.1923</pub-id><pub-id pub-id-type="pmid">34396552</pub-id>
</element-citation></ref><ref id="B275-pharmacy-13-00007"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.T.</given-names></name>
<name><surname>Park</surname><given-names>T.</given-names></name>
</person-group><article-title>Acute and Chronic Effects of Cocaine on Cardiovascular Health</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>584</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20030584</pub-id><pub-id pub-id-type="pmid">30700023</pub-id>
</element-citation></ref><ref id="B276-pharmacy-13-00007"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ukah</surname><given-names>U.V.</given-names></name>
<name><surname>Potter</surname><given-names>B.J.</given-names></name>
<name><surname>Paradis</surname><given-names>G.</given-names></name>
<name><surname>Low</surname><given-names>N.</given-names></name>
<name><surname>Ayoub</surname><given-names>A.</given-names></name>
<name><surname>Auger</surname><given-names>N.</given-names></name>
</person-group><article-title>Cocaine and the Long-Term Risk of Cardiovascular Disease in Women</article-title><source>Am. J. Med.</source><year>2022</year><volume>135</volume><fpage>993</fpage><lpage>1000.e1</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2022.04.002</pub-id><pub-id pub-id-type="pmid">35472377</pub-id>
</element-citation></ref><ref id="B277-pharmacy-13-00007"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hecht</surname><given-names>S.S.</given-names></name>
<name><surname>Hatsukami</surname><given-names>D.K.</given-names></name>
</person-group><article-title>Smokeless tobacco and cigarette smoking: Chemical mechanisms and cancer prevention</article-title><source>Nat. Rev. Cancer</source><year>2022</year><volume>22</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00423-4</pub-id><pub-id pub-id-type="pmid">34980891</pub-id>
</element-citation></ref><ref id="B278-pharmacy-13-00007"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drummer</surname><given-names>O.H.</given-names></name>
<name><surname>Gerostamoulos</surname><given-names>D.</given-names></name>
<name><surname>Woodford</surname><given-names>N.W.</given-names></name>
</person-group><article-title>Cannabis as a cause of death: A review</article-title><source>Forensic Sci. Int.</source><year>2019</year><volume>298</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2019.03.007</pub-id><pub-id pub-id-type="pmid">30925348</pub-id>
</element-citation></ref><ref id="B279-pharmacy-13-00007"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urits</surname><given-names>I.</given-names></name>
<name><surname>Charipova</surname><given-names>K.</given-names></name>
<name><surname>Gress</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Berger</surname><given-names>A.A.</given-names></name>
<name><surname>Cornett</surname><given-names>E.M.</given-names></name>
<name><surname>Kassem</surname><given-names>H.</given-names></name>
<name><surname>Ngo</surname><given-names>A.L.</given-names></name>
<name><surname>Kaye</surname><given-names>A.D.</given-names></name>
<name><surname>Viswanath</surname><given-names>O.</given-names></name>
</person-group><article-title>Adverse Effects of Recreational and Medical Cannabis</article-title><source>Psychopharmacol. Bull.</source><year>2021</year><volume>51</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">33897066</pub-id>
</element-citation></ref><ref id="B280-pharmacy-13-00007"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kesner</surname><given-names>A.J.</given-names></name>
<name><surname>Lovinger</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings</article-title><source>J. Neurochem.</source><year>2021</year><volume>157</volume><fpage>1674</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1111/jnc.15369</pub-id><pub-id pub-id-type="pmid">33891706</pub-id>
</element-citation></ref><ref id="B281-pharmacy-13-00007"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zehra</surname><given-names>A.</given-names></name>
<name><surname>Burns</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>C.K.</given-names></name>
<name><surname>Manza</surname><given-names>P.</given-names></name>
<name><surname>Wiers</surname><given-names>C.E.</given-names></name>
<name><surname>Volkow</surname><given-names>N.D.</given-names></name>
<name><surname>Wang</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Cannabis Addiction and the Brain: A Review</article-title><source>J. Neuroimmune Pharmacol.</source><year>2018</year><volume>13</volume><fpage>438</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1007/s11481-018-9782-9</pub-id><pub-id pub-id-type="pmid">29556883</pub-id>
</element-citation></ref><ref id="B282-pharmacy-13-00007"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assi</surname><given-names>S.</given-names></name>
<name><surname>Keenan</surname><given-names>A.</given-names></name>
<name><surname>Al Hamid</surname><given-names>A.</given-names></name>
</person-group><article-title>Exploring e-psychonauts&#x02019; perspectives towards cocaine effects and toxicity</article-title><source>Subst. Abus. Treat. Prev. Policy</source><year>2022</year><volume>17</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s13011-022-00455-5</pub-id><pub-id pub-id-type="pmid">35761409</pub-id>
</element-citation></ref><ref id="B283-pharmacy-13-00007"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-G&#x000f3;mez</surname><given-names>L.</given-names></name>
<name><surname>Robles-Hern&#x000e1;ndez</surname><given-names>R.</given-names></name>
<name><surname>Thiri&#x000f3;n-Romero</surname><given-names>I.</given-names></name>
<name><surname>Osio-Ech&#x000e1;nove</surname><given-names>J.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Llamazares</surname><given-names>S.</given-names></name>
<name><surname>Baler</surname><given-names>R.</given-names></name>
<name><surname>P&#x000e9;rez-Padilla</surname><given-names>R.</given-names></name>
</person-group><article-title>Addiction to Tobacco Smoking and Vaping</article-title><source>Rev. De Investig. Cl&#x000ed;nica</source><year>2023</year><volume>75</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.24875/RIC.23000117</pub-id><pub-id pub-id-type="pmid">37441760</pub-id>
</element-citation></ref><ref id="B284-pharmacy-13-00007"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sobczak</surname><given-names>M.</given-names></name>
<name><surname>Sa&#x00142;aga</surname><given-names>M.</given-names></name>
<name><surname>Storr</surname><given-names>M.A.</given-names></name>
<name><surname>Fichna</surname><given-names>J.</given-names></name>
</person-group><article-title>Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: Current concepts and future perspectives</article-title><source>J. Gastroenterol.</source><year>2014</year><volume>49</volume><fpage>24</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00535-013-0753-x</pub-id><pub-id pub-id-type="pmid">23397116</pub-id>
</element-citation></ref><ref id="B285-pharmacy-13-00007"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strzelak</surname><given-names>A.</given-names></name>
<name><surname>Ratajczak</surname><given-names>A.</given-names></name>
<name><surname>Adamiec</surname><given-names>A.</given-names></name>
<name><surname>Feleszko</surname><given-names>W.</given-names></name>
</person-group><article-title>Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>15</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph15051033</pub-id><pub-id pub-id-type="pmid">29883409</pub-id>
</element-citation></ref><ref id="B286-pharmacy-13-00007"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bortoletto</surname><given-names>P.</given-names></name>
<name><surname>Prabhu</surname><given-names>M.</given-names></name>
</person-group><article-title>Impact of Tobacco and Marijuana on Infertility and Early Reproductive Wastage</article-title><source>Clin. Obstet. Gynecol.</source><year>2022</year><volume>65</volume><fpage>360</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1097/GRF.0000000000000689</pub-id><pub-id pub-id-type="pmid">35125388</pub-id>
</element-citation></ref><ref id="B287-pharmacy-13-00007"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>A.</given-names></name>
<name><surname>Norman</surname><given-names>R.</given-names></name>
<name><surname>Freedman</surname><given-names>G.</given-names></name>
<name><surname>Baxter</surname><given-names>A.</given-names></name>
<name><surname>Pirkis</surname><given-names>J.</given-names></name>
<name><surname>Harris</surname><given-names>M.</given-names></name>
<name><surname>Page</surname><given-names>A.</given-names></name>
<name><surname>Carnahan</surname><given-names>E.</given-names></name>
<name><surname>Degenhardt</surname><given-names>L.</given-names></name>
<name><surname>Vos</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>The burden attributable to mental and substance use disorders as risk factors for suicide: Findings from the global burden of disease study 2010</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e91936</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0091936</pub-id><pub-id pub-id-type="pmid">24694747</pub-id>
</element-citation></ref><ref id="B288-pharmacy-13-00007"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ra&#x000ef;ch</surname><given-names>I.</given-names></name>
<name><surname>Lillo</surname><given-names>J.</given-names></name>
<name><surname>Rivas-Santisteban</surname><given-names>R.</given-names></name>
<name><surname>Rebassa</surname><given-names>J.B.</given-names></name>
<name><surname>Cap&#x000f3;</surname><given-names>T.</given-names></name>
<name><surname>Santandreu</surname><given-names>M.</given-names></name>
<name><surname>Cubeles-Juberias</surname><given-names>E.</given-names></name>
<name><surname>Reyes-Resina</surname><given-names>I.</given-names></name>
<name><surname>Navarro</surname><given-names>G.</given-names></name>
</person-group><article-title>Potential of CBD Acting on Cannabinoid Receptors CB<sub>1</sub> and CB<sub>2</sub> in Ischemic Stroke</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>6708</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25126708</pub-id><pub-id pub-id-type="pmid">38928415</pub-id>
</element-citation></ref><ref id="B289-pharmacy-13-00007"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lan</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Xue-fen</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Statistical methods and software for substance use and dependence genetic research</article-title><source>Curr. Genom.</source><year>2019</year><volume>20</volume><fpage>172</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.2174/1389202920666190617094930</pub-id></element-citation></ref><ref id="B290-pharmacy-13-00007"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rutherford</surname><given-names>H.</given-names></name>
<name><surname>Mayes</surname><given-names>L.</given-names></name>
</person-group><article-title>Parenting stress: A novel mechanism of addiction vulnerability</article-title><source>Neurobiol. Stress</source><year>2019</year><volume>11</volume><elocation-id>100172</elocation-id><pub-id pub-id-type="doi">10.1016/j.ynstr.2019.100172</pub-id><pub-id pub-id-type="pmid">31193862</pub-id>
</element-citation></ref><ref id="B291-pharmacy-13-00007"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliere</surname><given-names>S.</given-names></name>
<name><surname>Jolette-Riopel</surname><given-names>A.</given-names></name>
<name><surname>Potvin</surname><given-names>S.</given-names></name>
<name><surname>Jutras-Aswad</surname><given-names>D.</given-names></name>
</person-group><article-title>Modulation of the endocannabinoid system: Vulnerability factor and new treatment target for stimulant addiction</article-title><source>Front. Psychiatry</source><year>2013</year><volume>4</volume><elocation-id>109</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2013.00109</pub-id><pub-id pub-id-type="pmid">24069004</pub-id>
</element-citation></ref><ref id="B292-pharmacy-13-00007"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feingold</surname><given-names>D.</given-names></name>
<name><surname>Bitan</surname><given-names>D.D.</given-names></name>
</person-group><article-title>Addiction psychotherapy: Going beyond self-medication</article-title><source>Front. Psychiatry</source><year>2022</year><volume>13</volume><elocation-id>820660</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2022.820660</pub-id><pub-id pub-id-type="pmid">35222121</pub-id>
</element-citation></ref><ref id="B293-pharmacy-13-00007"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno</surname><given-names>C.</given-names></name>
<name><surname>Tandon</surname><given-names>R.</given-names></name>
</person-group><article-title>Should overeating and obesity be classified as an addictive disorder in DSM-5?</article-title><source>Curr. Pharm. Des.</source><year>2011</year><volume>17</volume><fpage>1128</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.2174/138161211795656701</pub-id><pub-id pub-id-type="pmid">21492085</pub-id>
</element-citation></ref><ref id="B294-pharmacy-13-00007"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Hodgins</surname><given-names>D.</given-names></name>
</person-group><article-title>Component model of addiction treatment: A pragmatic transdiagnostic treatment model of behavioral and substance addictions</article-title><source>Front. Psychiatry</source><year>2018</year><volume>9</volume><elocation-id>406</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2018.00406</pub-id><pub-id pub-id-type="pmid">30233427</pub-id>
</element-citation></ref><ref id="B295-pharmacy-13-00007"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Badiani</surname><given-names>A.</given-names></name>
<name><surname>Belin</surname><given-names>D.</given-names></name>
<name><surname>Epstein</surname><given-names>D.</given-names></name>
<name><surname>Calu</surname><given-names>D.</given-names></name>
<name><surname>Shaham</surname><given-names>Y.</given-names></name>
</person-group><article-title>Opiate versus psychostimulant addiction: The differences do matter</article-title><source>Nat. Rev. Neurosci.</source><year>2011</year><volume>12</volume><fpage>685</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/nrn3104</pub-id><pub-id pub-id-type="pmid">21971065</pub-id>
</element-citation></ref><ref id="B296-pharmacy-13-00007"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Tian</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular and functional imaging of internet addiction</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><elocation-id>378675</elocation-id><pub-id pub-id-type="doi">10.1155/2015/378675</pub-id><pub-id pub-id-type="pmid">25879023</pub-id>
</element-citation></ref><ref id="B297-pharmacy-13-00007"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinha</surname><given-names>R.</given-names></name>
</person-group><article-title>The clinical neurobiology of drug craving</article-title><source>Curr. Opin. Neurobiol.</source><year>2013</year><volume>23</volume><fpage>649</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2013.05.001</pub-id><pub-id pub-id-type="pmid">23764204</pub-id>
</element-citation></ref><ref id="B298-pharmacy-13-00007"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scarna</surname><given-names>H.</given-names></name>
</person-group><article-title>Genesis of the heroin-induced addictive process: Articulation between psychodynamic and neurobiological theories</article-title><source>Front. Psychiatry</source><year>2020</year><volume>11</volume><elocation-id>524764</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2020.524764</pub-id><pub-id pub-id-type="pmid">33362589</pub-id>
</element-citation></ref><ref id="B299-pharmacy-13-00007"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eme</surname><given-names>R.</given-names></name>
</person-group><article-title>The overlapping neurobiology of addiction and ADHD</article-title><source>Ment. Health Addict. Res.</source><year>2017</year><volume>2</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.15761/MHAR.1000129</pub-id></element-citation></ref><ref id="B300-pharmacy-13-00007"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dakwar</surname><given-names>E.</given-names></name>
<name><surname>Kleber</surname><given-names>H.</given-names></name>
</person-group><article-title>Minding the brain: The role of pharmacotherapy in substance-use disorder treatment</article-title><source>Dialogues Clin. Neurosci.</source><year>2017</year><volume>19</volume><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">29302226</pub-id>
</element-citation></ref><ref id="B301-pharmacy-13-00007"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>S.</given-names></name>
<name><surname>Malenka</surname><given-names>R.</given-names></name>
</person-group><article-title>Addiction and the brain: The neurobiology of compulsion and its persistence</article-title><source>Nat. Rev. Neurosci.</source><year>2001</year><volume>2</volume><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1038/35094560</pub-id><pub-id pub-id-type="pmid">11584307</pub-id>
</element-citation></ref><ref id="B302-pharmacy-13-00007"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Conway</surname><given-names>M.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>D.</given-names></name>
</person-group><article-title>Social media, big data, and mental health: Current advances and ethical implications</article-title><source>Curr. Opin. Psychol.</source><year>2016</year><volume>9</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.copsyc.2016.01.004</pub-id><pub-id pub-id-type="pmid">27042689</pub-id>
</element-citation></ref><ref id="B303-pharmacy-13-00007"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000fc;hler</surname><given-names>K.M.</given-names></name>
<name><surname>Gin&#x000e9;</surname><given-names>E.</given-names></name>
<name><surname>Echeverry-Alzate</surname><given-names>V.</given-names></name>
<name><surname>Calleja-Conde</surname><given-names>J.</given-names></name>
<name><surname>de Fonseca</surname><given-names>F.R.</given-names></name>
<name><surname>L&#x000f3;pez-Moreno</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Common single nucleotide variants underlying drug addiction: More than a decade of research</article-title><source>Addict. Biol.</source><year>2015</year><volume>20</volume><fpage>845</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1111/adb.12204</pub-id><pub-id pub-id-type="pmid">25603899</pub-id>
</element-citation></ref><ref id="B304-pharmacy-13-00007"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bierut</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Genetic vulnerability and susceptibility to substance dependence</article-title><source>Neuron</source><year>2011</year><volume>69</volume><fpage>618</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.015</pub-id><pub-id pub-id-type="pmid">21338875</pub-id>
</element-citation></ref><ref id="B305-pharmacy-13-00007"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urbanoski</surname><given-names>K.A.</given-names></name>
<name><surname>Kelly</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Understanding genetic risk for substance use and addiction: A guide for non-geneticists</article-title><source>Clin. Psychol. Rev.</source><year>2012</year><volume>32</volume><fpage>60</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2011.11.002</pub-id><pub-id pub-id-type="pmid">22155620</pub-id>
</element-citation></ref><ref id="B306-pharmacy-13-00007"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>D.A.</given-names></name>
<name><surname>Utrankar</surname><given-names>A.</given-names></name>
<name><surname>Reyes</surname><given-names>J.A.</given-names></name>
<name><surname>Simons</surname><given-names>D.D.</given-names></name>
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Epigenetics of drug abuse: Predisposition or response</article-title><source>Pharmacogenomics</source><year>2012</year><volume>13</volume><fpage>1149</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.2217/pgs.12.94</pub-id><pub-id pub-id-type="pmid">22909205</pub-id>
</element-citation></ref><ref id="B307-pharmacy-13-00007"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cecil</surname><given-names>C.A.</given-names></name>
<name><surname>Walton</surname><given-names>E.</given-names></name>
<name><surname>Smith</surname><given-names>R.G.</given-names></name>
<name><surname>Viding</surname><given-names>E.</given-names></name>
<name><surname>McCrory</surname><given-names>E.J.</given-names></name>
<name><surname>Relton</surname><given-names>C.L.</given-names></name>
<name><surname>Suderman</surname><given-names>M.</given-names></name>
<name><surname>Pingault</surname><given-names>J.B.</given-names></name>
<name><surname>McArdle</surname><given-names>W.</given-names></name>
<name><surname>Gaunt</surname><given-names>T.R.</given-names></name>
<etal/>
</person-group><article-title>DNA methylation and substance-use risk: A prospective, genome-wide study spanning gestation to adolescence</article-title><source>Transl. Psychiatry</source><year>2016</year><volume>6</volume><fpage>e976</fpage><pub-id pub-id-type="doi">10.1038/tp.2016.247</pub-id><pub-id pub-id-type="pmid">27922636</pub-id>
</element-citation></ref><ref id="B308-pharmacy-13-00007"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renthal</surname><given-names>W.</given-names></name>
<name><surname>Nestler</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Epigenetic mechanisms in drug addiction</article-title><source>Trends Mol. Med.</source><year>2008</year><volume>14</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2008.06.004</pub-id><pub-id pub-id-type="pmid">18635399</pub-id>
</element-citation></ref><ref id="B309-pharmacy-13-00007"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>Y.</given-names></name>
<name><surname>Nestler</surname><given-names>E.J.</given-names></name>
</person-group><article-title>The neural rejuvenation hypothesis of cocaine addiction</article-title><source>Trends Pharmacol. Sci.</source><year>2014</year><volume>35</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.05.005</pub-id><pub-id pub-id-type="pmid">24958329</pub-id>
</element-citation></ref><ref id="B310-pharmacy-13-00007"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Quizon</surname><given-names>P.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular mechanism: ERK signaling, drug addiction, and behavioral effects</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><year>2016</year><volume>137</volume><fpage>1</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">26809997</pub-id>
</element-citation></ref><ref id="B311-pharmacy-13-00007"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Moosa</surname><given-names>S.</given-names></name>
<name><surname>Dallapiazza</surname><given-names>R.</given-names></name>
<name><surname>Elias</surname><given-names>W.</given-names></name>
<name><surname>Lynch</surname><given-names>W.</given-names></name>
</person-group><article-title>Deep brain stimulation for the treatment of drug addiction</article-title><source>Neurosurg. Focus</source><year>2018</year><volume>45</volume><fpage>E11</fpage><pub-id pub-id-type="doi">10.3171/2018.5.FOCUS18163</pub-id><pub-id pub-id-type="pmid">30064320</pub-id>
</element-citation></ref><ref id="B312-pharmacy-13-00007"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaneda</surname><given-names>K.</given-names></name>
</person-group><article-title>Neuroplasticity in cholinergic neurons of the laterodorsal tegmental nucleus contributes to the development of cocaine addiction</article-title><source>Eur. J. Neurosci.</source><year>2018</year><volume>50</volume><fpage>2239</fpage><lpage>2246</lpage><pub-id pub-id-type="doi">10.1111/ejn.13962</pub-id><pub-id pub-id-type="pmid">29791036</pub-id>
</element-citation></ref><ref id="B313-pharmacy-13-00007"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torregrossa</surname><given-names>M.</given-names></name>
<name><surname>Kalivas</surname><given-names>P.</given-names></name>
</person-group><article-title>Microdialysis and the neurochemistry of addiction</article-title><source>Pharmacol. Biochem. Behav.</source><year>2008</year><volume>90</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2007.09.001</pub-id><pub-id pub-id-type="pmid">17928041</pub-id>
</element-citation></ref><ref id="B314-pharmacy-13-00007"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ross</surname><given-names>S.</given-names></name>
<name><surname>Peselow</surname><given-names>E.</given-names></name>
</person-group><article-title>The neurobiology of addictive disorders</article-title><source>Clin. Neuropharmacol.</source><year>2009</year><volume>32</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3181a9163c</pub-id><pub-id pub-id-type="pmid">19834992</pub-id>
</element-citation></ref><ref id="B315-pharmacy-13-00007"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chambers</surname><given-names>R.</given-names></name>
</person-group><article-title>Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders</article-title><source>Drug Alcohol Depend.</source><year>2013</year><volume>130</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2012.12.005</pub-id><pub-id pub-id-type="pmid">23279925</pub-id>
</element-citation></ref><ref id="B316-pharmacy-13-00007"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muskiewicz</surname><given-names>D.</given-names></name>
<name><surname>Uhl</surname><given-names>G.</given-names></name>
<name><surname>Hall</surname><given-names>F.</given-names></name>
</person-group><article-title>The role of cell adhesion molecule genes regulating neuroplasticity in addiction</article-title><source>Neural Plast.</source><year>2018</year><volume>2018</volume><fpage>9803764</fpage><pub-id pub-id-type="doi">10.1155/2018/9803764</pub-id><pub-id pub-id-type="pmid">29675039</pub-id>
</element-citation></ref><ref id="B317-pharmacy-13-00007"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Im</surname><given-names>H.</given-names></name>
<name><surname>Hollander</surname><given-names>J.</given-names></name>
<name><surname>Bali</surname><given-names>P.</given-names></name>
<name><surname>Kenny</surname><given-names>P.</given-names></name>
</person-group><article-title>MECP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212</article-title><source>Nat. Neurosci.</source><year>2010</year><volume>13</volume><fpage>1120</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1038/nn.2615</pub-id><pub-id pub-id-type="pmid">20711185</pub-id>
</element-citation></ref><ref id="B318-pharmacy-13-00007"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daughters</surname><given-names>S.</given-names></name>
<name><surname>Lejuez</surname><given-names>C.</given-names></name>
<name><surname>Bornovalova</surname><given-names>M.</given-names></name>
<name><surname>Kahler</surname><given-names>C.</given-names></name>
<name><surname>Strong</surname><given-names>D.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
</person-group><article-title>Distress tolerance as a predictor of early treatment dropout in a residential substance abuse treatment facility</article-title><source>J. Abnorm. Psychol.</source><year>2005</year><volume>114</volume><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.114.4.729</pub-id><pub-id pub-id-type="pmid">16351393</pub-id>
</element-citation></ref><ref id="B319-pharmacy-13-00007"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Turel</surname><given-names>O.</given-names></name>
<name><surname>Bechara</surname><given-names>A.</given-names></name>
</person-group><article-title>Brain anatomy alterations associated with social networking site (SNS) addiction</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>srep45064</elocation-id><pub-id pub-id-type="doi">10.1038/srep45064</pub-id><pub-id pub-id-type="pmid">28332625</pub-id>
</element-citation></ref><ref id="B320-pharmacy-13-00007"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnett</surname><given-names>A.</given-names></name>
<name><surname>Dilkes-Frayne</surname><given-names>E.</given-names></name>
<name><surname>Savic</surname><given-names>M.</given-names></name>
<name><surname>Carter</surname><given-names>A.</given-names></name>
</person-group><article-title>When the brain leaves the scanner and enters the clinic</article-title><source>Contemp. Drug Probl.</source><year>2018</year><volume>45</volume><fpage>227</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1177/0091450918774918</pub-id></element-citation></ref><ref id="B321-pharmacy-13-00007"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calder</surname><given-names>A.</given-names></name>
<name><surname>Hasler</surname><given-names>G.</given-names></name>
</person-group><article-title>Towards an understanding of psychedelic-induced neuroplasticity</article-title><source>Neuropsychopharmacology</source><year>2022</year><volume>48</volume><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/s41386-022-01389-z</pub-id><pub-id pub-id-type="pmid">36123427</pub-id>
</element-citation></ref><ref id="B322-pharmacy-13-00007"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edemann-Callesen</surname><given-names>H.</given-names></name>
<name><surname>Barak</surname><given-names>S.</given-names></name>
<name><surname>Hadar</surname><given-names>R.</given-names></name>
<name><surname>Winter</surname><given-names>C.</given-names></name>
</person-group><article-title>Choosing the optimal brain target for neuromodulation therapies as alcohol addiction progresses&#x02014;Insights from pre-clinical studies</article-title><source>Curr. Addict. Rep.</source><year>2020</year><volume>7</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1007/s40429-020-00316-w</pub-id></element-citation></ref><ref id="B323-pharmacy-13-00007"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>C.</given-names></name>
<name><surname>S&#x000e1;ez-Briones</surname><given-names>P.</given-names></name>
<name><surname>Barra</surname><given-names>R.</given-names></name>
<name><surname>Reyes</surname><given-names>A.</given-names></name>
<name><surname>Zepeda-Morales</surname><given-names>K.</given-names></name>
<name><surname>Constandil</surname><given-names>L.</given-names></name>
<name><surname>R&#x000ed;os</surname><given-names>M.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>P.</given-names></name>
<name><surname>Burgos</surname><given-names>H.</given-names></name>
<name><surname>Hern&#x000e1;ndez</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Prefrontal cortical control of activity in nucleus accumbens core is weakened by high-fat diet and prevented by co-treatment with n-acetylcysteine: Implications for the development of obesity</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>10089</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231710089</pub-id><pub-id pub-id-type="pmid">36077493</pub-id>
</element-citation></ref><ref id="B324-pharmacy-13-00007"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miguel</surname><given-names>E.</given-names></name>
<name><surname>Vekovischeva</surname><given-names>O.</given-names></name>
<name><surname>Kuokkanen</surname><given-names>K.</given-names></name>
<name><surname>Vesajoki</surname><given-names>M.</given-names></name>
<name><surname>Paasikoski</surname><given-names>N.</given-names></name>
<name><surname>Kaskinoro</surname><given-names>J.</given-names></name>
<name><surname>Myllym&#x000e4;ki</surname><given-names>M.</given-names></name>
<name><surname>Lainiola</surname><given-names>M.</given-names></name>
<name><surname>Janhunen</surname><given-names>S.K.</given-names></name>
<name><surname>Hyyti&#x000e4;</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>GABAB receptor-positive allosteric modulators with different efficacies affect neuroadaptation to and self-administration of alcohol and cocaine</article-title><source>Addict. Biol.</source><year>2018</year><volume>24</volume><fpage>1191</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1111/adb.12688</pub-id><pub-id pub-id-type="pmid">30421860</pub-id>
</element-citation></ref><ref id="B325-pharmacy-13-00007"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kenny</surname><given-names>P.</given-names></name>
</person-group><article-title>Epigenetics, microRNA, and addiction</article-title><source>Dialogues Clin. Neurosci.</source><year>2014</year><volume>16</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.31887/DCNS.2014.16.3/pkenny</pub-id><pub-id pub-id-type="pmid">25364284</pub-id>
</element-citation></ref><ref id="B326-pharmacy-13-00007"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ornstein</surname><given-names>P.</given-names></name>
</person-group><article-title>Cognitive deficits in chronic alcoholics</article-title><source>Psychol. Rep.</source><year>1977</year><volume>40</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.2466/pr0.1977.40.3.719</pub-id><pub-id pub-id-type="pmid">866512</pub-id>
</element-citation></ref><ref id="B327-pharmacy-13-00007"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>N.</given-names></name>
<name><surname>Tull</surname><given-names>M.</given-names></name>
<name><surname>Viana</surname><given-names>A.</given-names></name>
<name><surname>Anestis</surname><given-names>M.</given-names></name>
<name><surname>Gratz</surname><given-names>K.</given-names></name>
</person-group><article-title>Impulsive behaviors as an emotion regulation strategy: Examining associations between PTSD, emotion dysregulation, and impulsive behaviors among substance dependent inpatients</article-title><source>J. Anxiety Disord.</source><year>2012</year><volume>26</volume><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.janxdis.2012.01.007</pub-id><pub-id pub-id-type="pmid">22366447</pub-id>
</element-citation></ref><ref id="B328-pharmacy-13-00007"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>N.</given-names></name>
<name><surname>Sullivan</surname><given-names>T.</given-names></name>
<name><surname>Tull</surname><given-names>M.</given-names></name>
</person-group><article-title>Explicating the role of emotion dysregulation in risky behaviors: A review and synthesis of the literature with directions for future research and clinical practice</article-title><source>Curr. Opin. Psychol.</source><year>2015</year><volume>3</volume><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.copsyc.2015.01.013</pub-id><pub-id pub-id-type="pmid">25705711</pub-id>
</element-citation></ref><ref id="B329-pharmacy-13-00007"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>N.</given-names></name>
<name><surname>Tull</surname><given-names>M.</given-names></name>
<name><surname>Anestis</surname><given-names>M.</given-names></name>
<name><surname>Gratz</surname><given-names>K.</given-names></name>
</person-group><article-title>The relative and unique contributions of emotion dysregulation and impulsivity to posttraumatic stress disorder among substance dependent inpatients</article-title><source>Drug Alcohol Depend.</source><year>2013</year><volume>128</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2012.07.017</pub-id><pub-id pub-id-type="pmid">22917752</pub-id>
</element-citation></ref><ref id="B330-pharmacy-13-00007"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinn</surname><given-names>W.</given-names></name>
<name><surname>Gansler</surname><given-names>D.</given-names></name>
<name><surname>Moczynski</surname><given-names>N.</given-names></name>
<name><surname>Fulwiler</surname><given-names>C.</given-names></name>
</person-group><article-title>Brain dysfunction and community violence in patients with major mental illness</article-title><source>Crim. Justice Behav.</source><year>2008</year><volume>36</volume><fpage>117</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1177/0093854808327507</pub-id></element-citation></ref><ref id="B331-pharmacy-13-00007"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crow</surname><given-names>T.</given-names></name>
<name><surname>Cross</surname><given-names>D.</given-names></name>
<name><surname>Powers</surname><given-names>A.</given-names></name>
<name><surname>Bradley</surname><given-names>B.</given-names></name>
</person-group><article-title>Emotion dysregulation as a mediator between childhood emotional abuse and current depression in a low-income African-American sample</article-title><source>Child Abus. Negl.</source><year>2014</year><volume>38</volume><fpage>1590</fpage><lpage>1598</lpage><pub-id pub-id-type="doi">10.1016/j.chiabu.2014.05.015</pub-id><pub-id pub-id-type="pmid">25035171</pub-id>
</element-citation></ref><ref id="B332-pharmacy-13-00007"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vocci</surname><given-names>F.</given-names></name>
</person-group><article-title>Cognitive remediation in the treatment of stimulant abuse disorders: A research agenda</article-title><source>Exp. Clin. Psychopharmacol.</source><year>2008</year><volume>16</volume><fpage>484</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1037/a0014101</pub-id><pub-id pub-id-type="pmid">19086769</pub-id>
</element-citation></ref><ref id="B333-pharmacy-13-00007"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magill</surname><given-names>M.</given-names></name>
<name><surname>Ray</surname><given-names>L.</given-names></name>
<name><surname>Kiluk</surname><given-names>B.</given-names></name>
<name><surname>Hoadley</surname><given-names>A.</given-names></name>
<name><surname>Bernstein</surname><given-names>M.</given-names></name>
<name><surname>Tonigan</surname><given-names>J.</given-names></name>
<name><surname>Carroll</surname><given-names>K.</given-names></name>
</person-group><article-title>A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition</article-title><source>J. Consult. Clin. Psychol.</source><year>2019</year><volume>87</volume><fpage>1093</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1037/ccp0000447</pub-id><pub-id pub-id-type="pmid">31599606</pub-id>
</element-citation></ref><ref id="B334-pharmacy-13-00007"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Csillik</surname><given-names>A.</given-names></name>
<name><surname>Devulder</surname><given-names>L.</given-names></name>
<name><surname>Fenouillet</surname><given-names>F.</given-names></name>
<name><surname>Louville</surname><given-names>P.</given-names></name>
</person-group><article-title>A pilot study on the effectiveness of motivational interviewing groups in alcohol use disorders</article-title><source>J. Clin. Psychol.</source><year>2021</year><volume>77</volume><fpage>2746</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1002/jclp.23265</pub-id><pub-id pub-id-type="pmid">34687228</pub-id>
</element-citation></ref><ref id="B335-pharmacy-13-00007"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najavits</surname><given-names>L.</given-names></name>
<name><surname>Hien</surname><given-names>D.</given-names></name>
</person-group><article-title>Helping vulnerable populations: A comprehensive review of the treatment outcome literature on substance use disorder and PTSD</article-title><source>J. Clin. Psychol.</source><year>2013</year><volume>69</volume><fpage>433</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1002/jclp.21980</pub-id><pub-id pub-id-type="pmid">23592045</pub-id>
</element-citation></ref><ref id="B336-pharmacy-13-00007"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiers</surname><given-names>R.</given-names></name>
<name><surname>Gladwin</surname><given-names>T.</given-names></name>
<name><surname>Hofmann</surname><given-names>W.</given-names></name>
<name><surname>Ridderinkhof</surname><given-names>K.</given-names></name>
</person-group><article-title>Cognitive bias modification and cognitive control training in addiction and related psychopathology</article-title><source>Clin. Psychol. Sci.</source><year>2013</year><volume>1</volume><fpage>192</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1177/2167702612466547</pub-id></element-citation></ref><ref id="B337-pharmacy-13-00007"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>W.</given-names></name>
</person-group><article-title>Motivation for treatment: A review with particular emphasis on alcoholism</article-title><source>Psychol. Bull.</source><year>1985</year><volume>98</volume><fpage>84</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1037/0033-2909.98.1.84</pub-id><pub-id pub-id-type="pmid">3898175</pub-id>
</element-citation></ref><ref id="B338-pharmacy-13-00007"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luquiens</surname><given-names>A.</given-names></name>
<name><surname>Aubin</surname><given-names>H.</given-names></name>
</person-group><article-title>Patient preferences and perspectives regarding reducing alcohol consumption: Role of nalmefene</article-title><source>Patient Prefer. Adherence</source><year>2014</year><volume>8</volume><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">25302021</pub-id>
</element-citation></ref><ref id="B339-pharmacy-13-00007"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stoffel</surname><given-names>V.</given-names></name>
<name><surname>Moyers</surname><given-names>P.</given-names></name>
</person-group><article-title>An evidence-based and occupational perspective of interventions for persons with substance-use disorders</article-title><source>Am. J. Occup. Ther.</source><year>2004</year><volume>58</volume><fpage>570</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.5014/ajot.58.5.570</pub-id><pub-id pub-id-type="pmid">15481784</pub-id>
</element-citation></ref><ref id="B340-pharmacy-13-00007"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugarman</surname><given-names>D.</given-names></name>
<name><surname>Nich</surname><given-names>C.</given-names></name>
<name><surname>Carroll</surname><given-names>K.</given-names></name>
</person-group><article-title>Coping strategy use following computerized cognitive-behavioral therapy for substance use disorders</article-title><source>Psychol. Addict. Behav.</source><year>2010</year><volume>24</volume><fpage>689</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1037/a0021584</pub-id><pub-id pub-id-type="pmid">21198228</pub-id>
</element-citation></ref><ref id="B341-pharmacy-13-00007"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tariah</surname><given-names>H.</given-names></name>
<name><surname>Hamed</surname><given-names>R.</given-names></name>
<name><surname>Al-Omari</surname><given-names>H.</given-names></name>
</person-group><article-title>Jordanian client perspectives of substance abuse: Implications for occupational therapists</article-title><source>Int. J. Ther. Rehabil.</source><year>2015</year><volume>22</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.12968/ijtr.2015.22.12.566</pub-id></element-citation></ref><ref id="B342-pharmacy-13-00007"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Penberthy</surname><given-names>K.</given-names></name>
</person-group><article-title>Stage of change and coping skills acquisition: Ideas for individualized treatment approaches</article-title><source>J. Addict. Res. Ther.</source><year>2016</year><volume>7</volume><fpage>e135</fpage><pub-id pub-id-type="doi">10.4172/2155-6105.1000e135</pub-id></element-citation></ref><ref id="B343-pharmacy-13-00007"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hogue</surname><given-names>A.</given-names></name>
<name><surname>Henderson</surname><given-names>C.E.</given-names></name>
<name><surname>Ozechowski</surname><given-names>T.J.</given-names></name>
<name><surname>Robbins</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Systemic interventions in substance-abuse treatment: Past, present, and future</article-title><source>J. Fam. Psychother.</source><year>2011</year><volume>22</volume><fpage>177</fpage><lpage>192</lpage></element-citation></ref><ref id="B344-pharmacy-13-00007"><label>344.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Ozechowski</surname><given-names>T.J.</given-names></name>
<name><surname>Hogue</surname><given-names>A.</given-names></name>
</person-group><article-title>Systemic treatments for substance use disorders</article-title><source>The Wiley-Blackwell Handbook of Family Psychology</source><person-group person-group-type="editor">
<name><surname>Bray</surname><given-names>J.H.</given-names></name>
<name><surname>Stanton</surname><given-names>M.</given-names></name>
</person-group><publisher-name>Wiley-Blackwell</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2010</year><fpage>637</fpage><lpage>649</lpage></element-citation></ref><ref id="B345-pharmacy-13-00007"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klostermann</surname><given-names>K.</given-names></name>
<name><surname>O&#x02019;Farrell</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Treating substance abuse: Partner and family approaches</article-title><source>Soc. Work Public Health</source><year>2013</year><volume>28</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1080/19371918.2013.759014</pub-id><pub-id pub-id-type="pmid">23731417</pub-id>
</element-citation></ref><ref id="B346-pharmacy-13-00007"><label>346.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kimball</surname><given-names>T.</given-names></name>
<name><surname>Shumway</surname><given-names>S.</given-names></name>
<name><surname>Bradshaw</surname><given-names>S.</given-names></name>
<name><surname>Soloski</surname><given-names>K.L.</given-names></name>
<name><surname>Wampler</surname><given-names>K.</given-names></name>
<name><surname>Rastogi</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>R.</given-names></name>
</person-group><article-title>A systemic understanding of addiction formation and the recovery process</article-title><source>Multicultural Couple Therapy: Theory and Practice</source><person-group person-group-type="editor">
<name><surname>Rastogi</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>R.</given-names></name>
</person-group><publisher-name>Routledge</publisher-name><publisher-loc>London, UK</publisher-loc><year>2020</year><fpage>325</fpage><lpage>355</lpage></element-citation></ref><ref id="B347-pharmacy-13-00007"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horigian</surname><given-names>V.E.</given-names></name>
<name><surname>Anderson</surname><given-names>A.R.</given-names></name>
<name><surname>Szapocznik</surname><given-names>J.</given-names></name>
</person-group><article-title>Family-Based Treatments for Adolescent Substance Use</article-title><source>Child Adolesc. Psychiatr. Clin. N. Am.</source><year>2016</year><volume>25</volume><fpage>603</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.chc.2016.06.001</pub-id><pub-id pub-id-type="pmid">27613341</pub-id>
</element-citation></ref><ref id="B348-pharmacy-13-00007"><label>348.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Patton</surname><given-names>R.</given-names></name>
<name><surname>Goerke</surname><given-names>J.E.</given-names></name>
<name><surname>Katafiasz</surname><given-names>H.</given-names></name>
</person-group><article-title>Systemic approaches to adolescent substance abuse</article-title><source>The Handbook of Systemic Family Therapy: Systemic Family Therapy with Children and Adolescents</source><person-group person-group-type="editor">
<name><surname>Wampler</surname><given-names>K.S.</given-names></name>
<name><surname>McWey</surname><given-names>L.M.</given-names></name>
</person-group><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2020</year><comment>Chapter 12</comment></element-citation></ref><ref id="B349-pharmacy-13-00007"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bant</surname><given-names>D.</given-names></name>
</person-group><article-title>A cross-sectional study to assess the prevalence, pattern, trend, and impact of substance abuse among medical students</article-title><source>Indian J. Public Health Res. Dev.</source><year>2022</year><volume>13</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.37506/ijphrd.v13i3.18172</pub-id></element-citation></ref><ref id="B350-pharmacy-13-00007"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Momtazi</surname><given-names>S.</given-names></name>
<name><surname>Rawson</surname><given-names>R.</given-names></name>
</person-group><article-title>Substance abuse among Iranian high school students</article-title><source>Curr. Opin. Psychiatry</source><year>2010</year><volume>23</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1097/YCO.0b013e328338630d</pub-id><pub-id pub-id-type="pmid">20308905</pub-id>
</element-citation></ref><ref id="B351-pharmacy-13-00007"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>S.</given-names></name>
</person-group><article-title>Pharmacological means of reducing human drug dependence: A selective and narrative clinical literature review</article-title><source>Br. J. Clin. Pharmacol.</source><year>2014</year><volume>77</volume><fpage>242</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/bcp.12163</pub-id><pub-id pub-id-type="pmid">23701272</pub-id>
</element-citation></ref><ref id="B352-pharmacy-13-00007"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baca</surname><given-names>C.</given-names></name>
<name><surname>Yahne</surname><given-names>C.</given-names></name>
</person-group><article-title>Smoking cessation during substance abuse treatment: What you need to know</article-title><source>J. Subst. Abus. Treat.</source><year>2009</year><volume>36</volume><fpage>205</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2008.06.003</pub-id><pub-id pub-id-type="pmid">18715746</pub-id>
</element-citation></ref><ref id="B353-pharmacy-13-00007"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weisner</surname><given-names>C.</given-names></name>
<name><surname>Mertens</surname><given-names>J.</given-names></name>
<name><surname>Parthasarathy</surname><given-names>S.</given-names></name>
<name><surname>Moore</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Integrating primary medical care with addiction treatment</article-title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>1715</fpage><pub-id pub-id-type="doi">10.1001/jama.286.14.1715</pub-id><pub-id pub-id-type="pmid">11594896</pub-id>
</element-citation></ref><ref id="B354-pharmacy-13-00007"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ivanov</surname><given-names>I.</given-names></name>
<name><surname>Schulz</surname><given-names>K.</given-names></name>
<name><surname>Palmero</surname><given-names>R.</given-names></name>
<name><surname>Newcorn</surname><given-names>J.</given-names></name>
</person-group><article-title>Neurorobiology and evidence-based biological treatments for substance abuse disorders</article-title><source>CNS Spectr.</source><year>2006</year><volume>11</volume><fpage>864</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1017/S1092852900015017</pub-id><pub-id pub-id-type="pmid">17075558</pub-id>
</element-citation></ref><ref id="B355-pharmacy-13-00007"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yeung</surname><given-names>J.</given-names></name>
</person-group><article-title>Faith-based intervention, change of religiosity, and abstinence of substance addicts</article-title><source>Braz. J. Psychiatry</source><year>2022</year><volume>44</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1590/1516-4446-2020-1576</pub-id><pub-id pub-id-type="pmid">34190824</pub-id>
</element-citation></ref><ref id="B356-pharmacy-13-00007"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weaver</surname><given-names>M.</given-names></name>
<name><surname>Jarvis</surname><given-names>M.</given-names></name>
<name><surname>Schnoll</surname><given-names>S.</given-names></name>
</person-group><article-title>Role of the primary care physician in problems of substance abuse</article-title><source>Arch. Intern. Med.</source><year>1999</year><volume>159</volume><fpage>913</fpage><pub-id pub-id-type="doi">10.1001/archinte.159.9.913</pub-id><pub-id pub-id-type="pmid">10326934</pub-id>
</element-citation></ref><ref id="B357-pharmacy-13-00007"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
<name><surname>Davidson</surname><given-names>L.</given-names></name>
</person-group><article-title>Health care equality and parity for treatment of addictive disease</article-title><source>J. Psychoact. Drugs</source><year>2010</year><volume>42</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1080/02791072.2010.10400684</pub-id><pub-id pub-id-type="pmid">20648907</pub-id>
</element-citation></ref><ref id="B358-pharmacy-13-00007"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moulahoum</surname><given-names>H.</given-names></name>
<name><surname>Zihnioglu</surname><given-names>F.</given-names></name>
<name><surname>Timur</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel technologies in the detection, treatment, and prevention of substance use disorders</article-title><source>J. Food Drug Anal.</source><year>2019</year><volume>27</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.jfda.2018.09.003</pub-id><pub-id pub-id-type="pmid">30648574</pub-id>
</element-citation></ref><ref id="B359-pharmacy-13-00007"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caponnetto</surname><given-names>P.</given-names></name>
<name><surname>Auditore</surname><given-names>R.</given-names></name>
<name><surname>Russo</surname><given-names>C.</given-names></name>
<name><surname>Alamo</surname><given-names>A.</given-names></name>
<name><surname>Campagna</surname><given-names>D.</given-names></name>
<name><surname>Demma</surname><given-names>S.</given-names></name>
<name><surname>Polosa</surname><given-names>R.</given-names></name>
</person-group><article-title>&#x0201c;Dangerous relationships&#x0201d;: Asthma and substance abuse</article-title><source>J. Addict. Dis.</source><year>2013</year><volume>32</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1080/10550887.2013.795469</pub-id><pub-id pub-id-type="pmid">23815423</pub-id>
</element-citation></ref><ref id="B360-pharmacy-13-00007"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHugh</surname><given-names>C.</given-names></name>
<name><surname>Park</surname><given-names>R.</given-names></name>
<name><surname>S&#x000f6;nksen</surname><given-names>P.</given-names></name>
<name><surname>Holt</surname><given-names>R.</given-names></name>
</person-group><article-title>Challenges in detecting the abuse of growth hormone in sport</article-title><source>Clin. Chem.</source><year>2005</year><volume>51</volume><fpage>1587</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2005.047845</pub-id><pub-id pub-id-type="pmid">16020502</pub-id>
</element-citation></ref><ref id="B361-pharmacy-13-00007"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fingerhood</surname><given-names>M.</given-names></name>
</person-group><article-title>Substance abuse in older people</article-title><source>J. Am. Geriatr. Soc.</source><year>2000</year><volume>48</volume><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2000.tb06900.x</pub-id><pub-id pub-id-type="pmid">10968307</pub-id>
</element-citation></ref><ref id="B362-pharmacy-13-00007"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ragab</surname><given-names>A.</given-names></name>
<name><surname>Al-Mazroua</surname><given-names>M.</given-names></name>
<name><surname>El-Harouny</surname><given-names>M.</given-names></name>
<name><surname>Afify</surname><given-names>M.</given-names></name>
<name><surname>Omran</surname><given-names>M.</given-names></name>
<name><surname>Katbai</surname><given-names>C.</given-names></name>
<name><surname>Al Qurnay</surname><given-names>M.A.</given-names></name>
<name><surname>Al Saeed</surname><given-names>I.</given-names></name>
<name><surname>Al Zweide</surname><given-names>F.</given-names></name>
</person-group><article-title>Validity of substances of abuse detection in hair by biochips array technology</article-title><source>J. Alcohol. Drug Depend.</source><year>2018</year><volume>6</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.4172/2329-6488.1000299</pub-id></element-citation></ref><ref id="B363-pharmacy-13-00007"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razlansari</surname><given-names>M.</given-names></name>
<name><surname>Ulucan-Karnak</surname><given-names>F.</given-names></name>
<name><surname>Kahrizi</surname><given-names>M.</given-names></name>
<name><surname>Mirinejad</surname><given-names>S.</given-names></name>
<name><surname>Sargazi</surname><given-names>S.</given-names></name>
<name><surname>Mishra</surname><given-names>S.</given-names></name>
<name><surname>Rahdar</surname><given-names>A.</given-names></name>
<name><surname>D&#x000ed;ez-Pascual</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Nanobiosensors for detection of opioids: A review of latest advancements</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2022</year><volume>179</volume><fpage>79</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2022.08.017</pub-id><pub-id pub-id-type="pmid">36067954</pub-id>
</element-citation></ref><ref id="B364-pharmacy-13-00007"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bremer</surname><given-names>P.T.</given-names></name>
<name><surname>Janda</surname><given-names>K.D.</given-names></name>
<name><surname>Barker</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Conjugate Vaccine Immunotherapy for Substance Use Disorder</article-title><source>Pharmacol. Rev.</source><year>2017</year><volume>69</volume><fpage>298</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1124/pr.117.013904</pub-id><pub-id pub-id-type="pmid">28634286</pub-id>
</element-citation></ref><ref id="B365-pharmacy-13-00007"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benowitz</surname><given-names>N.L.</given-names></name>
<name><surname>Bernert</surname><given-names>J.T.</given-names></name>
<name><surname>Foulds</surname><given-names>J.</given-names></name>
<name><surname>Hecht</surname><given-names>S.S.</given-names></name>
<name><surname>Jacob</surname><given-names>P.</given-names></name>
<name><surname>Jarvis</surname><given-names>M.J.</given-names></name>
<name><surname>Joseph</surname><given-names>A.</given-names></name>
<name><surname>Oncken</surname><given-names>C.</given-names></name>
<name><surname>Piper</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Biochemical Verification of Tobacco Use and Abstinence: 2019 Update</article-title><source>Nicotine Tob. Res.</source><year>2020</year><volume>22</volume><fpage>1086</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntz132</pub-id><pub-id pub-id-type="pmid">31570931</pub-id>
</element-citation></ref><ref id="B366-pharmacy-13-00007"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soomro</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Development of Biosensors for Drug Detection Applications</article-title><source>Nanobiosensors</source><year>2020</year><fpage>203</fpage><lpage>222</lpage></element-citation></ref><ref id="B367-pharmacy-13-00007"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verov&#x00161;ek</surname><given-names>T.</given-names></name>
<name><surname>Krizman-Matasic</surname><given-names>I.</given-names></name>
<name><surname>Heath</surname><given-names>D.</given-names></name>
<name><surname>Heath</surname><given-names>E.</given-names></name>
</person-group><article-title>Investigation of drugs of abuse in educational institutions using wastewater analysis</article-title><source>Sci. Total Environ.</source><year>2021</year><volume>799</volume><fpage>150013</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2021.150013</pub-id><pub-id pub-id-type="pmid">34602307</pub-id>
</element-citation></ref><ref id="B368-pharmacy-13-00007"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solin</surname><given-names>K.</given-names></name>
<name><surname>Vuoriluoto</surname><given-names>M.</given-names></name>
<name><surname>Khakalo</surname><given-names>A.</given-names></name>
<name><surname>Tammelin</surname><given-names>T.</given-names></name>
</person-group><article-title>Cannabis detection with solid sensors and paper-based immunoassays by conjugating antibodies to nanocellulose</article-title><source>Carbohydr. Polym.</source><year>2023</year><volume>304</volume><fpage>120517</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2022.120517</pub-id><pub-id pub-id-type="pmid">36641163</pub-id>
</element-citation></ref><ref id="B369-pharmacy-13-00007"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nissim</surname><given-names>R.</given-names></name>
<name><surname>Compton</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Absorptive stripping voltammetry for cannabis detection</article-title><source>Chem. Cent. J.</source><year>2015</year><volume>9</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s13065-015-0117-0</pub-id><pub-id pub-id-type="pmid">26155306</pub-id>
</element-citation></ref><ref id="B370-pharmacy-13-00007"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobri</surname><given-names>S.C.D.</given-names></name>
<name><surname>Moslehi</surname><given-names>A.H.</given-names></name>
<name><surname>Davies</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Are oral fluid testing devices effective for the roadside detection of recent cannabis use? A systematic review</article-title><source>Public Health</source><year>2019</year><volume>171</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.puhe.2019.03.006</pub-id><pub-id pub-id-type="pmid">31102828</pub-id>
</element-citation></ref><ref id="B371-pharmacy-13-00007"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Owusu-Bempah</surname><given-names>A.</given-names></name>
</person-group><article-title>Cannabis Impaired Driving: An Evaluation of Current Modes of Detection</article-title><source>Can. J. Criminol. Crim. Justice</source><year>2014</year><volume>56</volume><fpage>219</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.3138/CJCCJ.2014.ES05</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmacy-13-00007-f001"><label>Figure 1</label><caption><p>Mechanism of action for plants used today for recreational and narcotic purposes: <italic toggle="yes">Cannabis sativa</italic> (<uri xlink:href="https://www.countynewscenter.com/new-cannabis-program-to-address-inequity-in-unincorporated-area/">https://www.countynewscenter.com/new-cannabis-program-to-address-inequity-in-unincorporated-area/</uri>, accessed on 4 January 2025), <italic toggle="yes">Erythroxylum coca</italic> (<uri xlink:href="https://www.fieldmuseum.org/collection/erythroxylum">https://www.fieldmuseum.org/collection/erythroxylum</uri>, accessed on 4 January 2025), <italic toggle="yes">Papaver somniferum</italic> (<uri xlink:href="https://ro.wikipedia.org/wiki/Mac_de_gr%C4%83din%C4%83">https://ro.wikipedia.org/wiki/Mac_de_gr%C4%83din%C4%83</uri>, accessed on 24 November 2024), <italic toggle="yes">Mitragyna speciosa</italic> (<uri xlink:href="https://en.wikipedia.org/wiki/Mitragyna_speciosa">https://en.wikipedia.org/wiki/Mitragyna_speciosa</uri>, accessed on 4 January 2025), <italic toggle="yes">Catha edulis</italic> (<uri xlink:href="https://www.inaturalist.org/taxa/190367-Catha-edulis">https://www.inaturalist.org/taxa/190367-Catha-edulis</uri>, accessed on 4 January 2025), <italic toggle="yes">Salvia divinorum</italic> (<uri xlink:href="https://www.iceers.org/salvia-divinorum-basic-info/">https://www.iceers.org/salvia-divinorum-basic-info/</uri>, accessed on 24 November 2024), <italic toggle="yes">Lophophora williamsii</italic> (<uri xlink:href="https://llifle.com/Encyclopedia/CACTI/Family/Cactaceae/1117/Lophophora_williamsii">https://llifle.com/Encyclopedia/CACTI/Family/Cactaceae/1117/Lophophora_williamsii</uri>, accessed on 4 January 2025), <italic toggle="yes">Banisteriopsis caapi</italic> (<uri xlink:href="https://ntbg.org/database/plants/detail/banisteriopsis-caapi">https://ntbg.org/database/plants/detail/banisteriopsis-caapi</uri>, accessed on 24 November 2024), <italic toggle="yes">Datura stramonium</italic> (<uri xlink:href="https://www.infoflora.ch/de/flora/datura-stramonium.html">https://www.infoflora.ch/de/flora/datura-stramonium.html</uri>, accessed on 4 January 2025), <italic toggle="yes">Ipomoea</italic> sp. (<uri xlink:href="https://www.britannica.com/plant/Ipomoea">https://www.britannica.com/plant/Ipomoea</uri>, accessed on 24 November 2024), <italic toggle="yes">Nicotiana tabacum</italic> (<uri xlink:href="https://www.nzpcn.org.nz/flora/species/nicotiana-tabacum/">https://www.nzpcn.org.nz/flora/species/nicotiana-tabacum/</uri>, accessed on 4 January 2025), and <italic toggle="yes">Mandragora officinarum</italic> (<uri xlink:href="https://www.britannica.com/plant/Mandragora-officinarum">https://www.britannica.com/plant/Mandragora-officinarum</uri>, accessed on 24 November 2024).</p></caption><graphic xlink:href="pharmacy-13-00007-g001" position="float"/></fig><table-wrap position="float" id="pharmacy-13-00007-t001"><object-id pub-id-type="pii">pharmacy-13-00007-t001_Table 1</object-id><label>Table 1</label><caption><p>The most commonly used plants for recreational and narcotic purposes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Latin Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Used Part(s) of the Plant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phytocompound(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cannabis sativa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flowering tops, leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;9-tetrahydrocannabinol (THC), cannabidiol (CBD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pharmacy-13-00007" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Erythroxylum coca</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coca plant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythroxylaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cocaine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-pharmacy-13-00007" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Papaver somniferum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opium poppy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Papaveraceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dried latex from seed pods</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morphine, codeine, thebaine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-pharmacy-13-00007" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Mitragyna speciosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kratom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rubiaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitragynine, 7-hydroxy mitragynine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmacy-13-00007" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Catha edulis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Khat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Celastraceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves stems</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cathinone, cathine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-pharmacy-13-00007" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salvia divinorum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Holy sage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lamiaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salvinorin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-pharmacy-13-00007" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lophophora williamsii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peyote</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cactaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dried top of the cactus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mescaline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-pharmacy-13-00007" ref-type="bibr">179</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Banisteriopsis caapi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soul vine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malpighiaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stems, bark, leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harmine, harmaline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B192-pharmacy-13-00007" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Datura stramonium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Devil&#x02019;s trumpet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solanaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves, seeds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scopolamine, atropine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-pharmacy-13-00007" ref-type="bibr">207</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Ipomoea</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morning glory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Convolvulaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Seeds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ergine (lysergic acid amide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B229-pharmacy-13-00007" ref-type="bibr">229</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Nicotiana tabacum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solanaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leaves</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nicotine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B242-pharmacy-13-00007" ref-type="bibr">242</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Mandragora officinarum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mandrake</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solanaceae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roots</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atropine, scopolamine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B247-pharmacy-13-00007" ref-type="bibr">247</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmacy-13-00007-t002"><object-id pub-id-type="pii">pharmacy-13-00007-t002_Table 2</object-id><label>Table 2</label><caption><p>Adverse reactions profile and receptor targets of frequently abused substances.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Substance Abuse</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adverse Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Receptors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Opioids</td><td align="center" valign="middle" rowspan="1" colspan="1">Constipation</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>,<xref rid="B275-pharmacy-13-00007" ref-type="bibr">275</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Respiratory depression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>,<xref rid="B275-pharmacy-13-00007" ref-type="bibr">275</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sedation</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003bc;, &#x003b4;, &#x003ba;</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>,<xref rid="B275-pharmacy-13-00007" ref-type="bibr">275</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Addiction</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyperalgesia</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hallucinations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmacy-13-00007" ref-type="bibr">69</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cocaine</td><td align="center" valign="middle" rowspan="1" colspan="1">Mydriasis</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Heart diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">D2, D3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>,<xref rid="B279-pharmacy-13-00007" ref-type="bibr">279</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tremors</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;1-adrenergic</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>,<xref rid="B279-pharmacy-13-00007" ref-type="bibr">279</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hostile conduct</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b2;2-adrenergic</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Insomnia</td><td align="center" valign="middle" rowspan="1" colspan="1">5-HT</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disorientation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tobacco</td><td align="center" valign="middle" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B257-pharmacy-13-00007" ref-type="bibr">257</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B257-pharmacy-13-00007" ref-type="bibr">257</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B257-pharmacy-13-00007" ref-type="bibr">257</xref>,<xref rid="B270-pharmacy-13-00007" ref-type="bibr">270</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="middle" rowspan="1" colspan="1">nACH</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B270-pharmacy-13-00007" ref-type="bibr">270</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B280-pharmacy-13-00007" ref-type="bibr">280</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B280-pharmacy-13-00007" ref-type="bibr">280</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infertility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B281-pharmacy-13-00007" ref-type="bibr">281</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cannabis</td><td align="center" valign="middle" rowspan="1" colspan="1">Cardiovascular events</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B263-pharmacy-13-00007" ref-type="bibr">263</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Wheezing breath</td><td align="center" valign="middle" rowspan="1" colspan="1">CB1, CB2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B259-pharmacy-13-00007" ref-type="bibr">259</xref>,<xref rid="B273-pharmacy-13-00007" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Emphysema</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B2-pharmacy-13-00007" ref-type="bibr">2</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Infertility</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B272-pharmacy-13-00007" ref-type="bibr">272</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Psychoactive effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B274-pharmacy-13-00007" ref-type="bibr">274</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>